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4Abstract
Cisplatin (cDDP) is a potent chemotherapeutic agent used in the management of a range of
tumours, however its clinical efficacy is limited by tumour cell chemoresistance. Whilst the
major target of the drug is considered to be nuclear DNA, cDDP has been shown to interact
with other organelles, notably the ER and mitochondria, although the importance of these
interactions is not fully understood. The contribution of such extranuclear effects is here
addressed through comparative studies of two lung adenocarcinoma cell lines with differing
sensitivity towards cDDP. Exposure to cDDP induced proliferative arrest and caspase-
dependent apoptosis in A549-WT cells, without requirement for caspase-8, calpains, ROS or
Ca2+. Two-fold resistance towards cDDP-induced apoptosis was measured in A549-CR cells,
generated through long term exposure to the drug. A549-CR cells showed marked inhibition
of Ca2+ signalling from the ER due to a 50% reduction of IP3R function. However, cDDP
treatment did not alter cytosolic Ca2+ levels nor deplete the ER Ca2+ store. Further, neither
chelation of intracellular Ca2+ nor pharmacological inhibition of IP3R Ca2+ channel opening
inhibited cDDP-induced A549-WT cell death, thus under the present experimental conditions
Ca2+ flux through the IP3R does not modulate cDDP sensitivity. Basal and maximal cellular
O2 consumption in A549-WT cells significantly increased following cDDP treatment, but
was unaltered in A549-CR cells. Sequencing of mtDNA identified a novel point mutation in
A549-CR mtDNA causing a 50% reduction of complex I activity. Mutations of mtDNA and
reduced respiratory chain activity might inhibit apoptosis. The abundance of complex I was
increased by 50%, potentially an example of pro-survival mitochondrial-nucleus
compensatory retrograde signalling. Thus, key differences in mitochondrial function and
response to cDDP which may alter A549 cell sensitivity to cDDP have been identified for
further investigation.
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1.1 Cancer
1.1.1 What is Cancer?
The term 'cancer' refers to a collection of clinically diverse diseases affecting multicellular
organisms which may manifest in a multiplicity of phenotypes. Such diseases are caused by
the accumulation of a number of genetic alterations within a cell, leading to altered patterns
of gene expression. Ultimately these changes give rise to an imbalance of cell proliferation
over cell death processes, producing a proliferating mass of cells, or tumour. Should these
cells acquire the capability to invade local tissue(s) and metastasise to, or colonise, remote
sites within the host organism to establish secondary sites of growth, the tumour is termed
malignant, whilst those which remain localised to the initial site of tumour growth are
categorised as benign (Ruddon, 2007a). In comparison to the benign form, malignant tumours
contain cells less differentiated than the tissue from which they arose and frequently,
although not invariably, show a faster rate of growth. Left untreated such neoplasms are of
significant detriment, and may lead to the death of the host. Cancer remains the leading cause
of death in humans, responsible for approximately 7.4 million deaths in 2004, a figure
predicted to rise to 12 million by 2030 (World Health Organisation, 2009). Coupled with the
increasing cost of new anti-cancer therapies, the rise in cases of cancer represents a serious
social and economic burden for both patients and health care providers (Bosanquet & Sikora,
2006).
Cancer incidence increases dramatically with age (DePinho, 2000), reflecting the requirement
of cancerous cells to accrue multiple genetic changes. The number of mutational events
required varies depending upon the cell type and genes involved, from as little as one or two
in the case of chronic myeloid leukaemia and retinoblastoma respectively (Paget & London,
2006), to more than six for solid tumours such as colon cancer (Ruddon, 2007b). The nature
of these genetic changes may be broadly classified into two areas as those affecting
oncogenes and those affecting tumour suppressor genes. Oncogenes are genes in which an
increase in the activity of the gene product promotes cellular transformation to the cancer cell
phenotype; the non-mutated form of such genes, proto-oncogenes, often encode proteins
involved in proliferation, growth and signalling. Activation of oncogenes may occur either by
increased expression of the gene product through gene amplification or mutation of
regulatory sequences, as is the case for the myc oncogene in Burkitt's lymphoma, or through
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producing a product with dysregulated activity, exemplified by constitutive activation of the
Ras GTPase in numerous cancers (R. J. B. King & Robins, 2006a; Ruddon, 2007c). Tumour
suppressor genes often encode regulatory proteins which act to restrain cellular growth and
proliferation and promote differentiation, in which a loss of function contributes to
tumourigenicity by allowing these processes to proceed unchecked. This loss of function may
occur through mutation of both normal alleles or of a single allele leading to
haploinsufficiency, or through inactivation by increased inhibitory modifications, such as
phosphorylation or binding of inhibitory proteins. The retinoblastoma and p53 tumour
suppressor proteins variably demonstrate such alterations in multiple tumour contexts (R. J.
B. King & Robins, 2006a; Ruddon, 2007c)(Ruddon, 2007c)(Ruddon, 2007c)(Ruddon,
2007c)(Ruddon, 2007c)(Ruddon, 2007c). Most commonly cancers result from synergistic
mutations in oncogenes, driving a proliferative transformation, and in tumour suppressors,
allowing these changes to occur in an unrestrained manner (R. J. B. King & Robins, 2006a).
The sources of mutations leading to cancer are varied, and reflect a complex interplay of
genetic and environmental risk factors balanced by processes repairing and removing
damaged cells. Spontaneous mutation of DNA during the cell cycle may contribute to, but
alone cannot explain, the incidence of human cancers (Ruddon, 2007c). The ability to
effectively repair damage once it has occurred is key to preventing carcinogenesis, thus
individuals carrying heritable deficiencies in DNA repair associated pathways experience
earlier and more frequent cancer onset (Paget & London, 2006; Su & Lenardo, 2010).
Exposure to conditions which directly or indirectly alter the structure of DNA and/ or its
constituent bases, including a wide range of chemical carcinogens and both UV and ionising
radiation, may drastically increase cancer risk. It is notable however that these mutations
need not directly affect the structure or sequence of a given protein. Changes in the level of
gene expression by mutations altering transcriptional activity, mRNA and protein half-life,
transcription of regulatory miRNA and heritable epigenetic modifications including DNA
methylation and histone acetylation may aid cellular transformation (Esteller, 2008;
Lujambio et al., 2007; Ruddon, 2007b). Viral infection may also drive carcinogenesis through
direct provision of a viral-oncogene (v-onc), disruption of key regulatory or protein coding
sequences by viral genome insertion into the host cell DNA or indirectly by interfering with
the function of endogenous cellular proteins (R. J. B. King & Robins, 2006a; Ruddon,
2007c).
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Overall, cancer is a multifaceted disease with both genetic and environmental components.
The increasing longevity and changing lifestyles of individuals within many populations
makes cancer a growing problem in both the developed and developing world.
1.1.2 Strategies for Cancer Treatment
The goal of cancer treatment varies depending upon the type and stage of cancer at the time
of presentation, the location of the tumour(s) and both the physical condition and wishes of
the patient. For early stage and localised cancers, radical treatment attempts to be fully
curative. Cases in which tumours are highly advanced and/ or have metastasised often require
a palliative approach, aiming to prolong the period of time in which symptoms may be
controlled and quality of life for the patient maintained. In both cases three major routes of
treatment exist; surgery, radiotherapy and chemotherapy. Often the best results are achieved
through the combined use of two or more of these strategies (Watson, Barrett, Spence, &
Twelves, 2006).
Surgical intervention with a curative intent aims to completely remove the tumour along with
a surrounding border of histologically normal tissue and nearby structures such as lymph
nodes into which tumour cell invasion may have occurred (Stephens & Aigner, 2009).
Surgery may be applied to a range of cancers, including those of the lung and breast. Whilst
surgical resection is potentially curative, it is not possible for all tumour types, such as those
occurring deeply within the brain or spine, and carries a risk of disfigurement or loss of
function of the affected area.
Radiotherapy uses irradiation of tumour cells with directed beams of high-intensity x-rays or
γ-radiation to induce DNA damage. Such treatment is effective only in cells actively 
progressing through the cell cycle, thus requires multiple administrations attempting to
destroy previously quiescent cells, and is most effective when tumour burden is low and a
greater proportion of cells are actively dividing (R. J. B. King & Robins, 2006b). Combined
with improved imaging techniques to precisely locate neoplasms, radiotherapy may be used
to treat deep-seated tumours and those not suitable for surgery, but carries risks for
surrounding healthy tissue which also receives doses of radiation.
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Chemotherapy attempts to kill cells using cytotoxic drugs to inhibit processes vital to cellular
function or by engaging cell death pathways (Kaufmann & Vaux, 2003). Some cancers may
be cured in this manner, but more commonly chemotherapy is used in combination with other
modes of treatment, either before (neoadjuvant chemotherapy) or after (adjuvant
chemotherapy) surgery and radiotherapy (R. J. B. King & Robins, 2006b). Chemotherapy
may also be used in a palliative context. However, unlike surgery and radiotherapy,
chemotherapy may achieve systemic delivery, thus is used to combat metastases, particularly
in patients where such secondary growths are thought likely but are not yet clinically
apparent. Such systemic delivery may be associated with notable adverse side effects such as
alopecia, cardiotoxicity, myelosuppression, nausea and renal toxicity, depending upon the
drug in question (Watson et al., 2006).
Most frequently several drugs with different activities are used in combination, the dose and
treatment regime subject to the particular combination. Using combination therapy allows for
lower effective concentrations of each drug to be administered, and whilst a given cell in the
heterogeneous tumour cell population may acquire resistance to one compound, it is likely to
remain susceptible to the others. Antimetabolites such as methotrexate and 5-fluorouracil are
drugs which inhibit the synthesis of nucleic acid either through enzyme inhibition or direct
incorporation. Cisplatin (cDDP) and cyclophosphamide exemplify a class of drugs known as
alkylating (or alkylating-like) agents, which form direct adducts with the existing bases of
nucleic acids, interfering with replication and cell division (R. J. B. King & Robins, 2006b;
Stephens & Aigner, 2009). Vinca alkyloids and taxanes act upon the cellular microtubule
network, whilst others inhibit enzymes including targeting of topioisomerase II by etoposide
or of a cancer specific Bcr/Abl fusion kinase by Gleevec (Ruddon, 2007b). Specific cancers
may show hormone dependent proliferation, thus ablating circulating hormone levels can be
used to inhibit cancer growth, as is the case for breast and prostate cancers derived from sex
hormone-sensitive progenitor cells (Stephens & Aigner, 2009).
1.1.3 Lung Cancer and the A549 Cell Line
Lung cancer is the most common form of the disease in males and, after cancers of the breast,
cervix and colon, the fourth most frequent in females (Ferlay J, Shin HR, Bray F, Forman D,
Mathers C, 2010); globally approximately 1.61 million new diagnoses of lung cancer were
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made in 2008, 39750 of these in the United Kingdom (Cancer Research UK, 2010). Cancers
of the lung account for the greatest number of cancer-related deaths worldwide, responsible
for more than 1.3 million deaths annually (Cancer Research UK, 2010; World Health
Organisation, 2009), and are predicted to remain the leading cause of cancer deaths in
Western countries (Jemal, Siegel, Xu, & Ward, 2010). Such high mortality rates are due in
part to the late stage at which diagnosis is made (Wistuba & Gazdar, 2006), evidenced by a
five year survival rate of less than 10% for patients diagnosed in England between 2001 and
2006 (Cancer Research UK, 2010).
By far the most common cause of lung cancer is long term exposure to tobacco smoke, and
the epidemiology linking the uptake of cigarette smoking with increased deaths from lung
cancer is well established (Doll, Peto, Boreham, & Sutherland, 2004, 2005). The relative risk
of lung cancer is increased in regular tobacco smokers up to 22 times in comparison to non-
smokers (Doll et al., 2004; Ruddon, 2007b), however it is estimated that 90% of this
smoking-related risk may be avoided by cessation of smoking before middle age (Jha, 2009).
Other contributing factors include exposure to natural radon gas, industrial carcinogens such
as asbestos and air pollution and particulate matter (Cancer Research UK, 2010). Lung cancer
is classified into four major histological types: squamous cell carcinomas, arising from
epithelial cell layers; adenocarcinomas, arising from glandular epithelium; large-cell
carcinomas, a heterogenous group of undifferentiated tumours; and small-cell carcinomas, a
highly metastatic form (Stephens & Aigner, 2009). Clinically, treatment for the first three of
these histological types is similar, thus they are together classed non-small cell lung cancer
(NSCLC). Treatment for lung cancer may involve surgical resection, chemotherapy and
radiotherapy, depending upon tumour type and progression, however the late stage disease
with which many patients present leads ultimately to a poor prognosis.
The A549 cell line was established from a lung tumour explant derived from basal epithelial
cells, thus falls into the squamous cell carcinoma subdivision of NSCLC (American Type
Culture Collection (ATTC), 2010; Giard, Aaronson, & Todaro, 1973; Lieber, Smith, Szakal,
Nelson-Rees, & Todaro, 1976). The cell line is well characterised, and commonly used as an
in vitro model for both lung cancer and cDDP treatment (Beleford, Rattan, Chien, &
Shridhar, 2010; Dasgupta et al., 2006; Guo et al., 2010).
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1.2 Cell Death and Cellular Ca2+ Signalling
1.2.1 Apoptosis
Apoptosis is the most studied form of cell death, and is best defined through a set of
morphological criteria (Galluzzi et al., 2007; Kroemer et al., 2009). Originally described by
Kerr et al. in 1972 with regard to hepatocytes (Kerr, Wyllie, & Currie, 1972), the apoptotic
morphology consists of pyknosis (reduced cellular volume) accompanied by a 'rounding up'
of the cell, blebbing of the plasma membrane, chromatin condensation, nuclear fragmentation
(karyorrhexis) and disintegration of the cell into 'apoptotic bodies', small membrane bound
structures which often contain intact cellular organelles (Galluzzi et al., 2007; Kroemer et al.,
2009). Plasma membrane integrity is maintained until the final stages of this process. In vivo
the resulting apoptotic bodies are subsequently engulfed by neighbouring phagocytes, usually
without an immune response. That apoptosis lacks a tight biochemical definition belies the
fact that it is a broad process encompassing a number of distinct signalling pathways, yet
certain biochemical observations may still be used in conjunction with morphology as an aid
in identifying apoptotic cell death (Kroemer et al., 2009).
The best characterised signalling cascades leading to apoptosis are the receptor-mediated (or
'extrinsic') pathway and the mitochondrial (or 'intrinsic') pathway, although other routes are
known to exist (Rao et al., 2002). Both pathways converge upon a class of cysteine-
dependent aspartate specific proteases known as caspases (I. Chowdhury, Tharakan, & Bhat,
2008; Kroemer, Galluzzi, & Brenner, 2007), the activation of which seems to be required for
full manifestation of apoptotic morphology. However, many caspases may also fulfil roles in
normal physiology aside from cell death (Feinstein-Rotkopf & Arama, 2009; Lamkanfi,
Festjens, Declercq, Vanden Berghe, & Vandenabeele, 2007), whilst caspase inhibition does
not always prevent cell death signalled through apoptotic pathways, thus caspase activation
may not alone be considered a marker of apoptosis (Galluzzi et al., 2007; Kroemer et al.,
2009).
All caspases are synthesised as zymogens (inactive pro-enzymes) which may be divided
according to substrate specificity and structural considerations (Chowdhury et al., 2008; Pop
& Salvesen, 2009). The executioner caspases contain a short pro-domain, and are responsible
for the cleavage of many proteins which lead directly or indirectly to destruction of cellular
architecture, including disassembly of the cytoskeleton, nucleus and Golgi (Fischer, Jänicke,
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& Schulze-Osthoff, 2003; Timmer & Salvesen, 2007). Activation of these executioners
occurs through cleavage mediated by a second subset of caspases, the long pro-domain
initiator caspases, themselves activated by recruitment to multi-protein complexes and
autoproteolysis (Pop & Salvesen, 2009). Apoptosis is thus initiated by a minimally two step
proteolytic cascade, the heterogeneity of the apoptotic response due to differences in the
particular enzymes which become activated and the manner in which they are recruited.
Signalling through the receptor-mediated apoptotic pathway begins at the plasma membrane.
Initiation classically occurs through ligand binding to the extracellular face of receptors
belonging to the tumour necrosis factor receptor (TNFR) superfamily, such as CD95
(Fas/APO-1), TNFR1 and TRAIL receptors 1 and 2 (Debatin & Krammer, 2004). Ligand
binding causes receptor clustering and recruitment of the adaptor molecule ‘Fas-associated
death domain containing protein’ (FADD), which may in turn recruit and oligomerise
initiator caspases -8 and -10 (Kroemer et al., 2007; Walczak & Krammer, 2000). Collectively
termed the death-inducing signalling complex (DISC), these multimers of receptors, adaptor
proteins and initiator caspases stimulate apoptosis through cleavage of executioner caspases -
3, -6 and -7. The receptor mediated pathway may conversely be engaged by a group of
plasma membrane receptors upon the absence of ligand. The so-called ‘dependence
receptors’, typified by 'deleted in colorectal cancer' (DDC), require constitutive ligand
binding for cell survival, whilst ligand withdrawal induces apoptosis through direct activation
of caspases (Goldschneider & Mehlen, 2010).
The mitochondrial pathway of apoptosis may be initiated by a variety of stimuli, including
DNA damage, ER stress, growth factor deprivation and viral infection (Youle & Strasser,
2008). Mitochondrial outer membrane permeabilisation (MOMP) driving the release of
cytochrome c along with other pro-apoptotic factors from the mitochondrial inter-membrane
space into the cytosol is the defining event in this pathway, and is considered to be the ‘point
of no return’ in the cell death program. This permeabilisation is regulated by members of the
B-cell lymphoma-2 (BCL-2) family (see Section 1.2.2). Once released, cytochrome c and the
nucleotide dATP interact with monomeric apoptotic protease activating factor-1 (APAF-1),
promoting its oligomerisation. This large protein complex, the apoptosome, acts as an
activation platform for the initiator caspase of the pathway, caspase-9. Caspase-9 is thus
activated and may mediate cleavage of executioner caspases -3, -6 and -7. Other factors
released from the inter-membrane space after MOMP include SMAC/ DIABLO and OMI/
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HTRA2, antagonists of X-linked inhibitor of apoptosis (XIAP), an endogenous caspase
inhibitor, and apoptosis inducing factor (AIF) and endonuclease G, which may contribute to
genomic fragmentation (Tait & Green, 2010).
1.2.2 The BCL-2 Family in Apoptosis
During the mitochondrial pathway of apoptosis the integrity of the mitochondrial outer
membrane is regulated by interactions between members of the BCL-2 family of proteins
(Chipuk, Moldoveanu, Llambi, Parsons, & Green, 2010; Tait & Green, 2010; Youle &
Strasser, 2008). BCL-2 family members show opposing activities during apoptosis, and are
therefore functionally divided into anti-apoptotic and pro-apoptotic groups, the latter of
which may be further subdivided into pro-apoptotic effectors and BH3-only proteins. Anti-
apoptotic proteins maintain mitochondrial outer membrane integrity through direct inhibition
of the pro-apoptotic effectors (Chipuk et al., 2010). Members of this group include BCL-2,
BCL-xL and MCL-1 proteins, and characteristically contain four BCL-2 homology (BH)
domains (BH 1-4). Pro-apoptotic effector proteins BCL-2-associated x protein (BAX) and
BCL-2 antagonist killer 1 (BAK) contain three BH domains (BH 1-3) and are responsible for
the release of apoptogenic factors from the inter-membrane space. Apoptotic signalling
causes translocation of monomeric effector proteins from the cytosol to the mitochondrial
outer membrane where BAX and BAK form homo-oligomeric pores (Chipuk et al., 2010;
Tait & Green, 2010; Youle & Strasser, 2008). Whilst this oligomerisation event is known to
coincide with MOMP, the biochemical nature of these pores remains elusive (Tait & Green,
2010). BH 3-only proteins contain just one BH domain (BH 3), and are induced by specific
cellular stresses. They act to stimulate apoptosis through inhibitory interactions with anti-
apoptotic BCL-2 proteins and/ or synergistic interactions with BCL-2 effectors. BH 3-only
proteins tBID and BIM may directly promote effector polymerisation and MOMP (‘direct
activation’), whilst others such as BAD, BIK, NOXA and PUMA act to sequester anti-
apoptotic members or relieve inhibition of direct activator proteins (Tait & Green, 2010).
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1.2.3 Non-Apoptotic Modes of Cell Death
Macroautophagy, or simply ‘autophagy’, is a conserved catabolic process for the bulk
degradation of cellular organelles and turnover of long-lived proteins. Portions of the cytosol
are sequestered into double membrane bound autophagosome structures, which subsequently
fuse with lysosomes. The contents of the resulting autolysosome lumen are then subject to
degradation and/ or recycling. Such autophagy occurs under basal growth conditions, and is
well documented as a pro-survival stress response, particularly during nutrient and growth
factor deprivation (Duprez, Wirawan, Vanden Berghe, & Vandenabeele, 2009; Gozuacik &
Kimchi, 2007). A ‘Janus-like’ nature has been ascribed to this process however, and under
certain circumstances autophagy has been proposed to be causative in cell death (Gozuacik &
Kimchi, 2007; Shintani & Klionsky, 2004). Autophagic cell death, that is death occurring
with massive vacuolarisation of the cytosol but without chromatin condensation (Galluzzi et
al., 2007; Kroemer et al., 2009), might conceptually occur through destruction of a proportion
of the cytosol past a ‘point of no return’ and subsequent cellular atrophy, or by selective
degradation of organelles vital for viability. This causative role in cell death has been brought
into question however, and the model systems which show an indispensable requirement for
autophagy in cell death are limited, thus it may be more appropriate to term this pathway
‘death with autophagy’ (Berry & Baehrecke, 2007; Kroemer & Levine, 2008; Kroemer et al.,
2009). The multiple links between the apoptotic and autophagic machinery and shared
activating stimuli might be explained as a means of ensuring efficient clearance of apoptotic
bodies (Duprez et al., 2009; Kroemer & Levine, 2008).
Necrosis is generally defined as a gain in cellular volume leading to swelling of organelles
and loss of plasma membrane integrity, in the absence of apoptotic or autophagic
morphologies (Galluzzi et al., 2007; Kroemer et al., 2009). Membrane rupture occurs early
during this mode of cell death, and the release of intracellular contents may stimulate an
inflammatory immune response (Galluzzi et al., 2007; Kroemer et al., 2007). For these
reasons necrosis has traditionally been viewed as an accidental form of cell death, yet
observations of common signalling patterns in necrotic cells have challenged this idea.
Indeed, the term necroptosis has been spawned to differentiate ‘accidental’ and
‘programmed’ necrosis (Galluzzi et al., 2007; Tait & Green, 2008). Whilst it remains an open
question as to which organelles and mediators may be directly involved in executing
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necroptosis, the receptor interacting protein-1 (RIP-1), an adaptor protein in TNFR signalling,
appears to play a key role (Degterev et al., 2008; Tait & Green, 2008).
Mitotic catastrophe is cell death occurring during or following a dysfunctional or abnormal
mitosis, and requires deficiencies in cell cycle and DNA damage checkpoints as well as a
damaging stimulus (Kroemer et al., 2009; Vakifahmetoglu, Olsson, & Zhivotovsky, 2008).
Whilst this process can lead to formation of micronuclei or multinucleate cells, death may
occur with either apoptotic or necrotic phenotypes, and mitotic catastrophe itself may be
better considered as a route to these modalities (Vakifahmetoglu, Olsson, & Zhivotovsky,
2008). Failure to undergo mitotic catastrophe can lead to asymmetric segregation of
chromosomes to daughter cells, and contribute to tumourigenesis (Kroemer et al., 2007).
1.2.4 Intracellular Ca2+ Homeostasis and Signalling
The pivotal role played by Ca2+ as an intracellular signalling molecule is well documented in
processes as diverse as fertilisation, muscle contraction, secretion, metabolism and cell death
(Alberts, 2008a). The distribution of this almost ubiquitous signalling molecule is highly
compartmentalised, the concentration within each compartment reflecting a balance between
uptake and extrusion processes. At rest the concentration of free Ca2+ in the cytosol ([Ca2+]cyt)
is low (~0.1 μM in most cases) compared to the intracellular Ca2+ storage organelles and the
extracellular fluid, thus a concentration gradient exists to readily permit increases in [Ca2+]cyt.
Cellular Ca2+ signalling occurs through oscillatory rises in [Ca2+]cyt, integrating both the
amplitude and frequency of the resulting Ca2+ spikes (Alberts, 2008a; Berridge, Bootman, &
Roderick, 2003).
Ca2+ flux across the plasma membrane is vital in cellular Ca2+ homeostasis. In mammalian
cells two types of pump expel Ca2+ to maintain the low [Ca2+]cyt. Ca2+ is transported out of
the cell by isoforms of the plasma membrane Ca2+ ATPase via active transport, or by ion
exchangers which exploit the Na+ and K+ concentration gradients also existing across the
membrane. Re-entry of Ca2+ in the context of signalling may occur through cation channels
of varying selectivity, including the transient receptor potential channels, or through voltage
gated Ca2+ channels in response to plasma membrane depolarisation (Hancock, 2010; Marks,
Klingmüller, & Müller-Decker, 2009).
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The greatest concentration of Ca2+ within the cell is found in the lumen of the endoplasmic
reticulum (ER) (~300-500 μM). Maintenance of a high intra-lumenal ER Ca2+ concentration
([Ca2+]ER) is important both for the role of the ER as a major site of protein and lipid
biosynthesis, and as a store from which intracellular Ca2+ signalling may be initiated
(Hancock, 2010). The ER membrane contains a Ca2+ pump similar in function to that at the
plasma membrane, the sarcoplasmic/ endoplasmic reticulum Ca2+ ATPase (SERCA), capable
of active transport to sequester Ca2+ within the ER. This ATPase is responsible for generating
the Ca2+ gradient across the ER membrane, although its function is inhibited by high
[Ca2+]ER, and may form up to 90% of the membrane protein content of specialised muscle
sarcoplasmic reticulum (Brini & Carafoli, 2009; J. Hancock, 2010).
Release of ER Ca2+ occurs through two separate processes, that of poorly characterised basal
'leak' and stimulated Ca2+ release occurring via the inositol triphosphate receptor (IP3R) and
the ryanodine receptor (RYR). The IP3R exists in three isoforms (IP3R-1, IP3R-2 and IP3R-3)
which form homo- and hetero-tetramers ~1200 kDa in size. Each subunit contains six
transmembrane helices with a short cytosolic C-terminus involved in channel function and a
large cytosolic N-terminus responsible for ligand binding, regulatory modifications and
capable of multiple protein interactions (Devogelaere, Verbert, Parys, & Missiaen, 2008;
Hancock, 2010). Binding of the ligand inositol 1,4,5-triphosphate (IP3), generated during
cellular signal transduction, causes opening of the IP3R channel to allow Ca2+ efflux into the
cytosol. Ca2+ itself is a co-activator of the IP3R in a biphasic manner; low concentrations
stimulate channel opening (peaking ~0.2-0.3 μM) whilst high concentrations are inhibitory. 
Regulation of the receptor occurs through a complex interaction of protein binding and post-
translational modifications (Ando, Mizutani, Kiefer, & Tsuzurugi, 2006; Devogelaere et al.,
2008). The RYR is a second tetrameric channel in the ER membrane whose endogenous
ligand has not yet been fully identified. The channel exhibits similar biphasic modulation by
Ca2+ to the IP3R, and the combined Ca2+ sensitivity of these channels means a small release
of Ca2+ in one cellular locale may be propagated across the entire cell in the process of Ca2+-
induced Ca2+ release (CICR). Interestingly, the RYR contains two key cysteine residues
within its channel domain, indicating the receptor may be redox sensitive (Hancock, 2010).
Depletion of the ER Ca2+ store stimulates the opening of a set of plasma membrane store-
operated Ca2+ channels (SOCs), allowing Ca2+ influx into the cytosol to aid store refilling, a
process known as store-operated Ca2+ entry (SOCE) (Marks et al., 2009). SOCE is mediated
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by the integral ER membrane protein stromal interaction molecule-1 (STIM-1) which acts as
a Ca2+ sensor of the ER lumen. Decreases in store Ca2+ leads to clustering of STIM-1 in
juxtaposition with Orai plasma membrane Ca2+ channels, the opening of which raise [Ca2+]cyt
(Cahalan, 2009; Marks et al., 2009).
Mitochondria make important contributions to cellular Ca2+ signalling, and their capacity to
accumulate Ca2+ is capable of boosting oxidative metabolism, altering the spatiotemporal
properties of Ca2+ signals and inducing cell death (Duchen, Verkhratsky, & Muallem, 2008;
McCormack, Halestrap, & Denton, 1990; Szabadkai & Duchen, 2008). Ca2+ uptake occurs
through the relatively low affinity mitochondrial Ca2+ uniporter (MCU) whose molecular
identity has eluded researchers for decades, but the identification of which (or a component
thereof) has recently been made (Baughman et al., 2011; De Stefani, Raffaello, Teardo,
Szabò, & Rizzuto, 2011; Perocchi et al., 2010). Extrusion occurs through a Na+/ Ca2+ ion
exchanger. Ca2+ may also be stored and released from acidic compartments such as
lysosomes, gated by NAADP (Patel, 2004).
The A549 cell line has previously been demonstrated to express an L-type voltage gated Ca2+
channel and both P2X and P2Y purinergic receptors, which generate intracellular Ca2+
signals upon ATP or UTP stimulation, at the plasma membrane. All three isoforms of the
IP3R and the type-1 RYR are also present (H. Xue, Zhao, Suda, & Uchida, 2000).
1.2.5 Functional Coupling Between the ER and Mitochondria
Crosstalk between the ER and mitochondria plays an important role in cellular physiology
and pathology. The association of the ER and mitochondrial networks has long been
suggested by co-sedimentation studies and fluorescence microscopy (Montisano, Cascarano,
Pickett, & James, 1982; R Rizzuto, Pinton, Carrington, Fay, & Fogarty, 1998; Shore & Tata,
1977), and indeed electron micrographs have revealed these local contacts to represent areas
of tight physical coupling between the two membranes (Csordás et al., 2006). Although the
exact molecular nature of the tethers connecting the two organelle membranes has not been
fully determined, evidence suggests they are likely to be proteinacious complexes. Mitofusin-
2 (Mfn2), a dynamin-related GTPase involved in mitochondrial fusion, has been
demonstrated to localise to both the outer mitochondrial membrane and the ER membrane,
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and Mfn2 ablation in mouse embryonic fibroblasts (MEFs) caused mitochondrial
fragmentation and a decrease in the number of ER-mitochondria contact sites. Whilst
recombinant expression of Mfn2 targeted to the outer mitochondrial membrane restored
elongation of the mitochondrial network in Mfn2 deficient MEFs, additional Mfn2 expression
at the ER membrane was required to re-establish inter-organelle contacts (de Brito &
Scorrano, 2008). The IP3R and voltage dependant anion channel (VDAC), a major protein
component of the mitochondrial outer membrane, have also been shown to form a direct
physical complex, an interaction mediated by the molecular chaperone glucose-regulated
protein 75 (Grp75) (Szabadkai et al., 2006). This tight coupling of organelles has functional
consequences, notably so in Ca2+ homeostasis, where, after release from the ER, the
formation of so called high Ca2+ ‘microdomains’ allow rapid mitochondrial accumulation of
Ca2+ to concentrations far above global cytosolic levels (R Rizzuto, Brini, Murgia, & Pozzan,
1993). Contacts between the ER and mitochondria have also long been recognised as
important in the process of phospholipid biosynthesis, since many synthetic enzymes
catalysing these pathways may be found at either the ER or mitochondrial membranes.
Phosphatidylcholine, for example, is synthesised in sequential stages by enzymes present in
the ER membrane and mitochondrial intermembrane space (Lebiedzinska, Szabadkai, Jones,
Duszynski, & Wieckowski, 2009). Complexes mediating ER-mitochondria contacts may also
directly impact upon cell fate. Disruption of complexes containing the multifunctional ER
sorting protein phoshofurin acidic cluster sorting protein-2 (PACS2) caused dynamin-related
protein-1 (Drp-1) dependent fragmentation of the mitochondrial network, whilst PACS2 was
shown to translocate pro-apoptotic BH3-only protein t-Bid to the outer mitochondrial
membrane in response to apoptotic stimuli, promoting oligomerisation of pro-apoptotic
effector BCL-2 proteins and cell death (Simmen et al., 2005).
1.2.6 Ca2+ Mediated Cell Death Pathways
Ca2+ signalling plays a central role in both the life and death of the cell. Dysregulation of
previously tightly controlled Ca2+ homeostasis (see Section 1.2.4) may generate prolonged
rises in intracellular Ca2+ unlike the oscillations characteristic of intracellular signalling, and
promote cell death.
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In many cases apoptotic Ca2+ signals are initiated by release of Ca2+ from the ER. Indeed, the
BCL-2 proteins, which so crucially regulate the integrity of the mitochondrial outer
membrane (see Section 1.2.2), also control Ca2+ retention in the ER store (Rong &
Distelhorst, 2008). Anti-apoptotic BCL-2 inhibits Ca2+ release from the ER by inhibiting
IP3R function. This effect may be due to direct binding, since BCL-2 is able to inhibit IP3R
opening in an in vitro membrane-reconstituted system (R. Chen et al., 2004), or by promoting
inhibitory phosphorylation of the receptor. BCL-2 also causes a decrease in [Ca2+]ER, thereby
lowering its apoptogenic potential, possibly by increasing basal Ca2+ leak from the IP3R (R
Rizzuto et al., 2003; Rong & Distelhorst, 2008). BCL-2 also inhibits Ca2+ transfer along the
ER-mitochondrial axis, the importance of which is outlined below. Conversely, pro-apoptotic
BAX and BAK promote redistribution of Ca2+ from the ER to mitochondria, and the BH3-
only protein tBid increases mitochondrial Ca2+ uptake (Csordás, Madesh, Antonsson, &
Hajnóczky, 2002; Rong & Distelhorst, 2008). ER Ca2+ release is also enhanced during the
apoptotic cascade. Cytochrome c released from mitochondria in the mitochondrial pathway of
apoptosis may bind directly to the IP3R to potentiate Ca2+ release, whilst the IP3R is also a
caspase-3 substrate, the cleavage of which increases Ca2+ release (Boehning et al., 2003;
Rong & Distelhorst, 2008). Pro-apoptotic Ca2+ transfer from the ER to mitochondria may
also occur during prolonged periods of ER-stress (Chami et al., 2008).
Cytochrome c resides in the cristae of mitochondria, where it fulfils a vital function in
ferrying electrons between complexes III and IV of the respiratory chain. During apoptosis a
widening of cristae junctions, termed cristae remodelling, and fragmentation of the
mitochondrial network promoted by Drp-1 has been proposed to aid cytochrome c egress into
the cytosol in a process which may be mediated by Ca2+ (Cereghetti & Scorrano, 2006;
Scorrano et al., 2002). The pro-apoptotic BH3-only protein BCL-2 interacting killer (BIK)
localises to the ER (Chinnadurai, Vijayalingam, & Rashmi, 2008). Under conditions of
cellular stress BIK activation promotes the release of Ca2+ from the ER store to mitochondria
and leads to Drp-1 regulated cristae remodelling (Mathai, Germain, & Shore, 2005). Cristae
remodelling by Drp-1 may both induce BAX/ BAK-dependent cytochrome c release via the
intrinsic pathway of apoptosis and cooperatively sensitise cells to death induced by the action
of other pro-apoptotic molecules such as NOXA (Germain, Mathai, McBride, & Shore,
2005).
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The calpain family of proteases provide a direct link between Ca2+ and apoptosis. Calpains
are expressed in both tissue specific and ubiquitous isoforms, which may be activated
proteolytically by increased Ca2+ in the micromolar (μ-calpain/ calpain I) to millimolar (m-
calpain/ calpain II) range, and are localised to multiple subcellular organelles (Kar et al.,
2010; R Rizzuto et al., 2003). Calpains have been shown to cleave many proteins involved in
apoptosis, including p53, BAX, Bid, XIAP and initiator caspase-12, thus may engage the cell
death pathway at multiple entry points (G. Gao & Dou, 2000; Kobayashi et al., 2002;
Kubbutat & Vousden, 1997; Mandic et al., 2002; Orrenius, Zhivotovsky, & Nicotera, 2003;
Wood et al., 1998). Processing by calpains has also been shown to be important in releasing
AIF from mitochondria after MOMP. Whilst it appears AIF is not required for most forms of
apoptosis, calpain-mediated AIF cleavage does seem to play a role in staurosporine-induced
cell death in a NSCLC cell line (Gallego et al., 2004; Norberg et al., 2008; Norberg, Orrenius,
& Zhivotovsky, 2010).
Ca2+-sensitive protein kinases and phospholipases have been assigned both pro-apoptotic and
anti-apoptotic roles. Notably, the phosholipase calcineurin may exert pro-apoptotic effects by
removing inhibitory phosphate groups from the BH3-only protein BAD (Orrenius et al.,
2003; R Rizzuto et al., 2003).
Intracellular rises in Ca2+ may also activate the necrotic pathway of cell death. Phospholipase
A2 activation through increased [Ca2+]cyt destabilises the cellular membrane system by
liberating arachidonic acid, aiding necrotic membrane rupture (Declercq, Van Herreweghe,
Vanden Berghe, & Vandenabeele, 2010). The most prominent route leading to necrosis
however occurs through mitochondrial permeability transition (mPT). mPT is the abrupt
permeabilisation of the inner mitochondrial membrane caused by the opening of a large non-
selective pore with a maximum conductance of approximately 1.5 kDa, the mitochondrial
permeability transition pore (mPTP) (Halestrap, 2009; Kroemer et al., 2007; Lemasters,
Theruvath, Zhong, & Nieminen, 2009). The strongest inducer of opening of this pore is
mitochondrial Ca2+ overload, again highlighting the importance of Ca2+ communication along
the ER-mitochondrial axis, although the concentration of Ca2+ at which opening occurs is
highly dependent upon both cell type and prevailing local conditions within the
mitochondrion. Oxidative stress, increased inorganic phosphate concentration and depletion
of adenine nucleotides are also strong inducers, whilst high mitochondrial transmembrane
potential (ΔΨ) inhibits mPT (Halestrap, 2009). Pore opening may be transient (‘flickering’) 
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or permanent, and leads to dissipation of ΔΨ, switching of ATP synthase into reverse mode, 
equilibration of solutes across the inner mitochondrial membrane and osmotic swelling of
mitochondria accompanied by subsequent rupture of the outer membrane (Halestrap, 2009;
Kroemer et al., 2007). Since these changes cause depletion of ATP required for caspase
activity, mPT is considered a necrotic mechanism, although it has been shown to promote cyt
c release through swelling-induced rupture of the outer mitochondrial membrane. The
molecular components of the pore have been hotly debated. Cyclophilin D (Cyp D), a matrix
peptidyl-prolyl cis-trans isomerase, remains the only confirmed component, and Cyp D
knock-out massively reduces the ability of Ca2+ to induce mPT. The adenine nucleotide
transporter (ANT) is generally considered to play a regulatory role, whilst VDAC isoforms
and the benzodiazepine receptor have largely been discounted (Halestrap, 2009; Kroemer et
al., 2007). It has also been suggested the mPTP may in fact be a pathological accumulation of
misfolded inner-membrane proteins (Lemasters et al., 2009).
In summary, pathological intracellular Ca2+ signals may lead to both apoptosis and necrosis
through a variety of mechanisms.
1.2.7 Cell Death and Cancer
The ability to remove cells through programmed cell death pathways is vital for multicellular
organisms. An estimated 60 billion new cells are produced by the adult human body each
day, with an approximately equal number required to die to counterbalance this increase
(Cotter, 2009). The comparative infrequency with which errors occur and remain unfixed is
of great testament to the fidelity of both processes. When such errors do occur however,
cancer may result. The idea that inhibition of cell death may contribute to tumour formation
was initially proposed nearly 40 years ago, and is now considered a defining feature of cancer
cells (Hanahan & Weinberg, 2000; Kerr et al., 1972; Luo, Solimini, & Elledge, 2009). In
discovering that BCL-2 mutations could drive carcinogenesis not by increasing proliferation
as an oncogene but by protecting cells from normal cell death pathways, the first molecular
link with the apoptotic machinery was made. Immortalised mouse cell lines harbouring
mutant BCL-2 form tumours when injected into mice only after the acquisition of secondary
mutation(s), demonstrating the synergy between increased proliferation and apoptosis
resistance in tumourigenesis (Cotter, 2009; Paget & London, 2006; Vaux, Cory, & Adams,
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1988). Indeed, overactivation of some oncogenes such as Myc cause a concomitant increase
in both cellular proliferation and apoptosis, a type of cellular 'safety valve', whilst the
resulting hyperplasia becomes neoplasia only when deficiencies in the death pathway are
acquired (Cotter, 2009; Evan et al., 1992). Dysregulation of cell death not only contributes to
tumour initiation, but may also negatively impact upon chemotherapy treatments, many of
which aim to engage apoptotic signalling (Kaufmann & Vaux, 2003; Yip & Reed, 2008;
Zhivotovsky & Orrenius, 2010).
Resistance to cell death may be caused by the overactivation of an anti-apoptotic protein or
by invalidation of an apoptotic activator or effector (Deng et al., 2007). The importance of
BCL-2 overexpression in increasing cell survival has already been discussed. It should be
noted however that this overexpression often occurs alongside overexpression of pro-
apoptotic proteins such as BAX and caspases, indicating the integrated activity of the
apoptotic machinery as a whole, rather than the absolute levels of individual proteins, is the
important factor in tipping the balance of life and death (Zhivotovsky & Orrenius, 2010).
Inactivation of BAX has been observed in human cancers, and loss of caspases may promote
oncogenic transformation (Yip & Reed, 2008; Zhivotovsky & Orrenius, 2010). Tumour
suppressor protein p53 is mutated in over half of human cancers. A transcription factor
involved in cell cycle arrest after DNA damage, p53 may upregulate many pro-apoptotic
genes such as PUMA, BAX and NOXA, and act in a transcription-independent manner to
activate BAX (Wolyniec, Haupt, & Haupt, 2010). Loss of p53 may, amongst other effects,
induce resistance to cell death.
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1.3 Cellular Metabolism and Cancer
1.3.1 Cellular Energy Metabolism – Glycolysis to the TCA Cycle, a Brief Overview
Metabolism is the total set of reactions occurring within a cell to support its viability and
function. Animal cells contain many thousands of these enzymatically catalysed reactions
working in anabolic and catabolic pathways, which may both converge upon and diverge
from common substrates and intermediates. The ATP demands of human cells are met by two
well characterised pathways, glycolysis and the tricarboxylic acid (TCA) cycle followed by
oxidative phosphorylation, both of which shall be briefly discussed.
Glycolysis is a catabolic pathway occurring in the cytosol, and consists of ten enzyme
catalysed reactions which result in the stepwise oxidation of one molecule of glucose into two
molecules of pyruvate. Key enzymes and substrates of the glycolytic pathway are outlined in
Figure 1. Glucose enters the cell through facilitated diffusion via different isoforms of the
GLUT glucose transporter, expression of which is tissue and cell specific (Thorens &
Mueckler, 2009). During the first three steps of the pathway glucose undergoes two
phosphorylation events to generate fructose-1,6-bisphosphate, thus the early stages utilise two
molecules of ATP. The resulting hexose is cleaved, producing two phosphoryl-containing
triose sugars, which undergo oxidation and phosphorylation, each reducing one molecule of
the co-factor nicotinamide adenine dinucleotide from the oxidised form (NAD+) to the
reduced form (NADH) in the process. NADH may be used as an electron-donor by the
mitochondrial electron transport chain (ETC, see Section 1.3.2). The final steps of the
pathway produce pyruvate through isomerisation reactions and hydrolysis of both phosphoryl
bonds; the Gibbs free energy release associated with this hydrolysis is used to synthesise two
molecules of ATP (Alberts, 2008b; Stryer, Berg, & Tymoczko, 2002; D. Voet & Voet,
2004a). Glycolysis therefore is biochemical pathway producing ATP, in which input of one
glucose molecule results in the net output of two molecules of pyruvate, two molecules of
ATP and two molecules of NADH. Alternatively, after the initial phosphorylation reaction of
glycolysis, glucose (as glucose-6-phosphate) may be diverted for use in the pentose-
phosphate pathway. The major products of this pathway are reduced nicotinamide adenine
dinucleotide phosphate (NADPH), a co-factor used in the reductive biosynthesis of molecules
such as lipids and endogenous antioxidants, and ribose-5-phosphate, a precursor of nucleotide
biosynthesis (D. Voet & Voet, 2004a).
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NADH produced during glycolysis must be oxidised to avoid depleting cellular NAD+, and to
allow glycolysis to continue. To this end, cellular energy metabolism may follow one of two
routes. Under anaerobic conditions, as may be encountered in skeletal muscle during
vigorous exercise, pyruvate is reduced to lactate using NADH by the enzyme lactate
dehydrogenase, regenerating NAD+ for use in glycolysis. Under aerobic conditions NADH is
re-oxidised by the mitochondrial respiratory chain, accompanied by further ATP production.
In this case pyruvate is imported into the mitochondrial matrix, where it undergoes oxidative
decarboxylation to produce acetyl-CoA for entry into the TCA cycle. The TCA cycle (also
known as the Krebs cycle or citric acid cycle) is a set of eight enzymatic reactions occurring
in the mitochondrial matrix, leading to the oxidation of the acetyl group of acetyl-CoA. One
complete ‘revolution’ of the cycle generates three molecules of NADH, one molecule of
reduced flavin adenine dinucleotide (FADH2), two molecules of CO2 and one molecule of
GTP (Alberts, 2008b; Stryer et al., 2002; D. Voet & Voet, 2004a). Numerous metabolic
pathways converge upon the TCA cycle. β-Oxidation of fatty acids provides another source 
of acetyl-CoA, whilst catabolism of amino acids may yield intermediates of the TCA cycle.
Replenishing of the citric acid cycle in this way is termed anaplerosis. TCA cycle
intermediates may also enter into other interconnected pathways in cataplerotic reactions,
including gluconeogenesis and biosynthesis of lipids and amino acids (D. Voet & Voet,
2004a).
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Figure 1: Key enzymes and substrates of the glycolytic pathway. For each molecule of
glucose passing through the ten enzyme catalysed reactions of glycolysis, the usage of two
molecules of ATP during the initial steps of the pathway results in net production of two
molecules of pyruvate, two molecules of ATP and two molecules of the cellular redox
intermediate NADH. In turn, pyruvate may be imported into the mitochondrial matrix as a
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substrate for the TCA cycle, or may be reduced to lactate by cytosolic lactate dehydrogenase,
oxidising NADH without the requirement of molecular oxygen. The two initial
phosphorylation reactions of glycolysis, catalysed by hexokinase and phosphofructokinase-1
respectively, represent key rate limiting steps regulating the flux of substrate through the
pathway. Following the initial phosphorylation of glucose, glucose-6-phosphate may be
diverted away from glycolysis and cellular energy production into the biosynthetic pentose
phosphate pathway.
1.3.2 Chemiosmotic Theory and Oxidative Phosphorylation
Under aerobic conditions the bulk of cellular ATP generation in many cells occurs through
oxidative phosphorylation in mitochondria. The chemiosmotic theory, proposed by Peter
Mitchell in 1961 (Mitchell, 1961), explains the underlying concept of oxidative
phosphorylation, in which the electrochemical proton gradient established by the ETC across
the inner mitochondrial membrane is directly harnessed to drive ATP synthesis.
The ETC consists of four multi-protein respiratory complexes of increasing redox potential
(complexes I, II, III and IV), the soluble haem protein cytochrome c and the lipid soluble co-
factor ubiquinone (Alberts, 2008b; Nicholls & Ferguson, 2002; D. Voet & Voet, 2004b).
Transfer of electrons between redox centres within the ETC components is associated with
the release of Gibbs free energy, used at complexes I, III and IV to pump protons from the
mitochondrial matrix into the inter-membrane space. Thus transfer of electrons along the
ETC is coupled to proton transport across the inner mitochondrial membrane, and is the
source of the proton electrochemical gradient (Nicholls & Ferguson, 2002; D. Voet & Voet,
2004b). The major sources of electrons for the ETC are the reduced pyrimidine and
flavoprotein co-factors, NADH and FADH2 respectively, generated by glycolysis and the
TCA cycle. By transferring electrons from the soluble dehydrogenases of these pathways to
the membrane bound ETC, NADH and FADH2 act as ‘high-energy’ intermediates to couple
energy released by metabolic oxidation of organic molecules to ATP synthesis (Nicholls &
Ferguson, 2002). After transport through complex IV, electrons are passed to molecular
oxygen, the final electron acceptor, which is reduced using four electrons and recombined
with protons to produce water (Alberts, 2008b). Figure 2 summarises this process. Electrons
may be inappropriately transferred to oxygen from complexes other than complex IV,
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producing reactive oxygen species (ROS), oxygen free radicals which may react with and
damage cellular components.
The action of the ETC in generating a proton electrochemical gradient means translocation of
protons back into the mitochondrial matrix is thermodynamically favoured, and acts as a
‘store’ of energy; this is the proton-motive force. Since the inner mitochondrial membrane is
impermeable to protons, this movement may only occur through specific proton pores and
channels such as ATP synthase, which may couple this energetically favoured process with a
second process requiring energy input (Nicholls & Ferguson, 2002; D. Voet & Voet, 2004b).
The ATP synthase consists of two major multi-subunit functional domains. Fo is a membrane
bound complex which forms a proton channel. F1 is a soluble ATPase associated with Fo on
the matrix side of the inner membrane, capable of operating in reverse to synthesise ATP
from ADP and inorganic phosphate. Proton flow through Fo causes rotary conformational
changes in F1, promoting phosphorylation of ADP (D. Voet & Voet, 2004b).
Oxidative phosphorylation driven by the oxidation of co-factors reduced by the passage of
one molecule of glucose through glycolysis and the TCA cycle produces a theoretical
maximum of between 30 and 36 ATP molecules. Oxidative phosphorylation is therefore a
high energy yield process in comparison to the net production of two molecules of ATP by
glycolysis coupled to lactate production (D. Voet & Voet, 2004b).
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Figure 2: The TCA cycle and oxidative phosphorylation. During aerobic respiration,
pyruvate produced by glycolysis undergoes oxidative decarboxylation upon import into the
mitochondrial matrix, generating acetyl-CoA for entry into the TCA cycle. Passage of acetyl-
CoA through the eight enzymatic reactions of the TCA cycle results in oxidation of the acetyl
group and production of the ‘high energy intermediate’ redox carrier molecules NADH and
FADH which, along with NADH generated by glycolysis, may be oxidised by the
mitochondrial electron transport chain (ETC) during oxidative phosphorylation. The ETC
couples the transfer of electrons from NADH and FADH to molecular oxygen with
concomitant pumping of H+ across the inner mitochondrial membrane. Following oxidation
of NADH at complex I and FADH at complex II, electrons are passed from the respective
complexes to the membrane soluble cofactor ubiquinone (Ubq), which in turn ferries
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electrons to complex III. Electrons are subsequently transferred between complex III and
complex IV by membrane associated cytochrome c (Cyt c), and finally used along with H+
from the intermembrane space in reduction of oxygen to H2O. The Gibb’s free energy release
associated with passage of electrons through complexes I, III and IV is utilised to pump into
the intermembrane space against its electrochemical gradient, generating the mitochondrial
transmembrane potential (ΔΨ). Translocation of H+ back along this electrochemical gradient
drives phosphorylation of ADP by ATP synthase.
1.3.3 Metabolic Adaptation in Cancer Cells
By necessity, rapidly proliferating cells must match their proliferative rates with increased
production of ATP and biochemical components such as amino acids and lipids required for
cell growth and division. During cellular transformation, cancer cells undergo metabolic
reprogramming in which intracellular metabolism is altered to cope both with rapid division
and the unique challenges of the tumour microenvironment (DeBerardinis, Lum,
Hatzivassiliou, & Thompson, 2008; Kroemer & Pouyssegur, 2008; Tennant, Durán,
Boulahbel, & Gottlieb, 2009). Amongst the most prominent of these changes is an increased
use of glycolysis for ATP production, even under adequate oxygen tension ('aerobic
glycolysis'), and a relative decrease in oxidative phosphorylation, a phenomenon known as
the Warburg effect (Kroemer & Pouyssegur, 2008; Warburg, 1956; Zhivotovsky & Orrenius,
2009). At first sight the use of glycolysis, a pathway with a relatively poor ATP yield per
molecule of glucose, to meet cellular energy demands is counter-intuitive. However, a vast
increase in glycolytic flux ensures ample provision of ATP and a rate of production which
may outstrip oxidative phosphorylation. As an additional benefit, pools of glycolytic
intermediates are syphoned off for use in biosynthetic pathways (DeBerardinis et al., 2008;
Kroemer & Pouyssegur, 2008; Shlomi, Benyamini, Gottlieb, Sharan, & Ruppin, 2011;
Vander Heiden, Cantley, & Thompson, 2009).
Increased glycolytic flux calls for a greater provision of substrate for the pathway. Tumours
do indeed exhibit greatly increased glucose uptake, a property exploited in medical imaging
of tumours and metastases by 18fluorodeoxyglucose-positron emission topography (FDG-
PET). This augmentation of glucose uptake is achieved through a variety of mechanisms. The
insufficient vasculature of many tumours means cancer cells, especially those in the central
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tumour region, experience low oxygen tension. Such conditions lead to the stabilisation of
hypoxia-inducible factor (HIF) transcription factor subunits, usually targeted for degradation
under normoxia. HIF target genes promote glycolysis over oxidative phosphorylation,
limiting oxygen usage under hypoxic conditions. In terms of substrate provision, HIF induces
greater expression of the Glut I glucose transporter (Kroemer & Pouyssegur, 2008).
Phosphatidylinositol-3-kinases (PI3Ks) are a key class of enzymes activated by growth factor
signalling. Lipid phosphorylation by PI3K can produce phosphatidylinositol-3-phosphate
(PI3P) and directly lead to activation of Akt protein kinase, an enzyme capable of enhancing
cell growth and survival. Mutations causing increased activity of the PI3K/ Akt pathway are
common in human cancer, and proliferation independent of growth factors is a hallmark of
cancer cells (Hanahan & Weinberg, 2000; Shaw & Cantley, 2006). Akt activation may
stimulate Glut I expression and Glut IV translocation to the plasma membrane.
The first step in glycolysis, phosphorylation of glucose to glucose-6-phosphate by hexokinase
(Figure 1), is also the first rate-limiting step. Hexokinase has been shown to associate with
VDAC-1 on the mitochondrial outer membrane, enhancing its activity by allowing direct
access to mitochondrially-derived ATP. This association is promoted by Akt activity, and
occurs much more frequently in tumour cells to increase glucose entry into glycolysis
(Kroemer & Pouyssegur, 2008; Pastorino & Hoek, 2008). VDAC-1 may also act as a direct
activator of BAX, whilst formation of the VDAC-1/ hexokinase complex appears to inhibit
this pro-apoptotic interaction, protecting against MOMP (Gottlob et al., 2001; Kroemer &
Pouyssegur, 2008; Pastorino, Shulga, & Hoek, 2002). Glucose-6-phosphate may either
continue into glycolysis or be diverted into the pentose-phosphate pathway (see Section
1.3.3). Increased glucose phosphorylation allows for greater activity of this pathway for
biosynthesis of nucleotide precursors, antioxidants and lipids.
Phosphofructokinase-1 (PFK-1) catalyses the second phosphorylation event of glycolysis
(Figure 1), and is the major rate-limiting step. The enzyme may be allosterically activated by
binding of fructose-2,6-bisphosphate, a regulatory molecule formed from its substrate by the
bifunctional enzyme 6-phosphfructo-2-kinase/ fructose-2,6-bisphosphatase (PFK-2/ F2,6BP)
(D. Voet & Voet, 2004c). Akt activation promotes the PFK-2 activity, and thus boosts
glycolysis. Regulation by p53 also occurs through transcriptional activation of TP53-induced
glycolysis regulator (TIGAR). TIGAR inhibits PFK-1 by degrading fructose-2,6-
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bisphosphate, thus loss of p53 function promotes glycolysis by relieving PFK-1 inhibition (R.
G. Jones & Thompson, 2009; Vousden & Ryan, 2009).
More than 90% of pyruvate produced by glycolytic cancers is reduced to lactate (R. G. Jones
& Thompson, 2009). Lactate dehydrogenase, the enzyme responsible for this reduction
(Figure 1), may be upregulated by aberrant c-myc and HIF signalling, whilst HIF may
additionally inhibit pyruvate dehydrogenase, decreasing production of acetyl-CoA from
pyruvate, thereby favouring aerobic glycolysis (Kroemer & Pouyssegur, 2008; Shim et al.,
1997; Tennant et al., 2009). Active transport of this lactate out of the cell causes a decrease in
the pH of tissue surrounding the tumour, which may suppress the host immune response and
promote an invasive phenotype (Kroemer & Pouyssegur, 2008; Shim et al., 1997). Such a
high rate of lactate production and export might reflect an excess production of pyruvate over
the capacity for entry into the TCA cycle (DeBerardinis et al., 2008), but may also provide
some protection from apoptosis. Evidence suggests ROS may play a key role both in
activating BAX and BAK, and in efficient caspase activation by promoting cytochrome c
release (Borutaite & Brown, 2007; Tomiyama et al., 2006). By inhibiting mitochondrial
oxidative activity and bolstering antioxidant defences cancer cells may therefore gain a
survival advantage. It seems that activity of the respiratory chain is required for apoptosis
under certain circumstances, and mitochondrial DNA (mtDNA) mutations affecting
respiratory complex function have been found to associate with some types of cancer
(Chatterjee, Mambo, & Sidransky, 2006; Kwong, Henning, Starkov, & Manfredi, 2007). Loss
of p53 may also inhibit oxidative phosphorylation by repressing the expression of synthesis
of cytochrome oxidase 2 (SCO2), a respiratory chain assembly factor (Kroemer &
Pouyssegur, 2008; Vousden & Ryan, 2009).
The function of the TCA cycle is also altered to take on more of a biosynthetic role. The
intermediates of the cycle may be used in anaplerosis as precursors for amino acid and lipid
synthesis. It is notable that some oncogenes, particularly c-myc, may cause upregulation of
enzymes involved in glutamine import and catabolism (Wise et al., 2008). This allows for
glutamine metabolism to yield significant amounts of α-ketoglutarate, replenishing cycle
intermediates lost through de novo synthesis of lipids. Interestingly, mutations in the enzymes
fumarate hydrolase and succinate dehydrogenase can lead to accumulation of TCA cycle
intermediates, a pseudohypoxic state which causes HIF activation and the accompanying shift
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towards glycolysis (Frezza & Gottlieb, 2009; A. King & Gottlieb, 2009; Sudarshan, Pinto,
Neckers, & Linehan, 2007).
Metabolism in tumour cells is thus altered to support cell division and survival, representing
an attractive target for cancer therapy (Michelakis, Webster, & Mackey, 2008; Rodríguez-
Enríquez, Marín-Hernández, Gallardo-Pérez, Carreño-Fuentes, & Moreno-Sánchez, 2009;
Tennant, Durán, & Gottlieb, 2010).
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1.4 Cis-Diamminedichloroplatinum II
1.4.1 Chemistry and Biochemistry of cDDP
The serendipitous discovery of the anti-proliferative effects of cis-diamminedichloroplatinum
II (cDDP), more commonly known as cisplatin, by Rosenberg and co-workers in 1965
remains a landmark in cancer treatment (Rosenberg, Van Camp, & Krigas, 1965). Within
eight years of this finding the anti-tumour properties of the drug had been demonstrated and
clinical trials begun. Curative as a single agent in testicular cancer, cDDP is widely used as a
first-line treatment for lung, head and neck and ovarian tumours (O’Dwyer, Stevenson, &
Johnson, 1999; Watson et al., 2006). However, whilst undoubtedly potent, cDDP treatment is
limited in the clinic by two major factors; chemoresistance (see Section 1.4.2) and adverse
side effects. The latter of these considerations is characterised by pronounced toxicity in the
kidney and inner ear, peripheral neuropathy and severe nausea, with limited
myelosuppression (O’Dwyer et al., 1999). Nephrotoxicity may be largely overcome by
aggressive pre-hydration and diuresis systems, whilst ototoxicity is both cumulative and
irreversible, thus requires careful monitoring of patients. Likewise, neural damage is
monitored throughout the course of treatment, whilst anti-emetics and the use of 'rescue
agents' to prevent off-target effects serve to limit other unfavourable consequences.
At the molecular level cDDP consists of two amine and two chloride groups in cis-
configuration, bound into a square planar complex by a single atom of platinum. Four
decades of research have yielded more than 3000 platinum drug derivatives, replacing these
side groups with increasingly complex structures in an effort to reduce toxicity and improve
efficacy, yet just three are registered as marketable drugs, and only two (carboplatin and
oxaliplatin) find common use (Jung & Lippard, 2007; O’Dwyer et al., 1999). Administered
by intravenous injection, the process by which cDDP enters cells remains unclear.
Considering the neutral charge of the molecule and that rate of uptake is not inhibited by
structurally similar molecules but is limited only by cDDP concentration, a model of passive
diffusion across the membrane has traditionally been favoured (Jung & Lippard, 2007;
Kelland, 2007). Recent evidence has demonstrated facilitated diffusion through copper
transporters may also occur (Holzer et al., 2004; Ishida, Lee, Thiele, & Herskowitz, 2002;
Kelland, 2007; Safaei, 2006).
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After entry into the cytoplasm, the relatively low intracellular concentration of chloride (~4-
20 mM compared to ~100 mM in the extracellular fluid) promotes hydrolysis of one chloride
group of cDDP (Figure 3). Mono-aquated cDDP is a highly reactive electrophile, the
formation of which is rate-limiting in intracellular reactions (Knox, Friedlos, Lydall, &
Roberts, 1986; Siddik, 2003). The major target is considered to be nuclear DNA, where
cDDP may covalently bond with the N7 residue of purine bases; this overwhelmingly occurs
at guanine sites (Ahmad, 2010). Hydrolysis of the second chloride group allows reaction with
either a second purine or a protein. Both intra-strand and inter-strand crosslinks are formed,
although intra-strand 1,2-guanine-guanine are most common (~65 %), followed by 1,2-
adenine-guanine (~25 %), with inter-strand links accounting for just 1% of total adducts
(Ahmad, 2010; Eastman, 1999; Siddik, 2003). It is the intra-strand links which are postulated
to be the toxic lesions. Aquated cDDP is also highly reactive towards thiol groups, and a
significant proportion of the drug reacts with S-donor ligands including microfilaments and
the abundant tripeptide glutathione (GSH). Reaction with other amino acids is also possible
(Appleton, 1999). Indeed, less than 5% of the total cDDP within a cell may associate with
DNA (Fuertes, Alonso, & Pérez, 2003; Mandic, Hansson, Linder, & Shoshan, 2003). That
cDDP does not fully react with these ligands before reaching DNA is by virtue that
interactions are kinetically slow, and the reaction with guanine bases thermodynamically
favourable (Jung & Lippard, 2007; Reedijk, 1999). In some cases, transfer of platinum from
protein to DNA may occur (Reedijk, 1999).
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Figure 3: Intracellular activation of cDDP through aquation reactions. Upon uptake of
cDDP into the cytoplasm, the relatively low intracellular concentration of chloride ions
promotes hydrolysis of a single chloride group, generating mono-aquated cDDP, a reactive
electrophile. Reaction of this electrophile with cellular nucleophiles, most commonly purine
nucleotides or protein thiol groups, promotes subsequent hydrolysis of the remaining chloride
group of cDDP, again generating a nucelophile which reacts with cellular electrophillic sites.
Thus, cDDP forms the bulky adducts with DNA and/ or proteins which underlie its cytotoxic
activity, interfering with normal cellular function and resulting in activation of DNA repair
pathways, stress signalling and, eventually, apoptosis.
1.4.2 Cellular Response to cDDP – Cytotoxicity and Resistance
The response of cells treated with cDDP is complex, and may involve cell death by the
mitochondrial or receptor-mediated pathways of apoptosis, necrosis, senescence or survival
(Ahmad, 2010; L. Liu et al., 2008; Mandic et al., 2002; Puig et al., 2008). The way a cell
processes cDDP and the damage it causes ultimately determines cell fate. This is a key point
since resistance to cDDP, both intrinsic and acquired, is a major limiting factor in clinical use
of the drug; the relapse rate due to acquired resistance may be as high as 95% in small cell
lung cancer patients (Giaccone G., 2000). Classically such resistance mechanisms occur by
decreasing cDDP-DNA interactions, or by increasing damage tolerance or repair once it has
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occurred (Fuertes et al., 2003; Kelland, 2007). Resistance to cDDP is in most cases multi-
factorial, and involves changes in distinct cellular pathways. A two-fold level of resistance
has been estimated using patient samples, although in vitro studies suggest resistant cells may
require more than fifty times greater drug concentrations for significant toxicity to occur
(Siddik, 2003).
Binding of cDDP to DNA introduces bulky adducts which significantly distort the structure
of the double helix (Eastman, 1999; Jung & Lippard, 2007). These lesions may be recognised
with varying specificity by numerous proteins, and such DNA-damage recognition has been
reviewed in detail (Jung & Lippard, 2007; Siddik, 2003; D. Wang & Lippard, 2005).
Platinated DNA adducts are mostly repaired by the nucleotide excision repair (NER)
pathway, by which whole damaged oligonucleotides may be removed from DNA.
Upregulation and inhibition of NER proteins is associated with decreased and increased
cDDP sensitivity respectively, whilst the hypersensitivity of testicular cancers to cDDP
treatment has been explained by low levels of NER in these tumours (Ahmad, 2010; Jung &
Lippard, 2007; Siddik, 2003; D. Wang & Lippard, 2005). On the other hand, the mismatch
repair (MMR) pathway has been shown to contribute to cytotoxicity. It is hypothesised that
MMR proteins bind DNA on strands opposite platinum adducts and undergo several futile
repair cycles, eventually resulting in apoptosis, and loss of MMR may aid resistance (Ahmad,
2010; Jung & Lippard, 2007; Kelland, 2007; Siddik, 2003). Recognition of cDDP-DNA
adducts may also lead to cell death by more indirect mechanisms. High mobility group
(HMG) proteins show specificity in binding cDDP damaged DNA, and may prevent enzymes
involved in NER accessing the lesions. Alternatively, large protein complexes at abundant
sites of DNA damage may titrate proteins such as HMGs away from endogenous sites of
action (Ahmad, 2010; Siddik, 2003). Whilst p53 and other related proteins such as p73 have
been shown to be induced by cDDP, no clear link between p53 status and sensitivity has been
established, highlighting that cellular responses may be cell and condition specific (Ahmad,
2010; Jung & Lippard, 2007; Siddik, 2003; D. Wang & Lippard, 2005). Translesion synthesis
of DNA past cDDP adducts during DNA replication may also be increased to improve
tolerance of DNA damage in cDDP resistant cells (Köberle, Tomicic, Usanova, & Kaina,
2010).
Cell death may occur through either apoptosis or necrosis, and indeed cDDP may induce both
in a population of cells in a non-mutually exclusive manner. The apoptotic program may be
1.4 Introduction – Cis-Diamminedichloroplatinum
51
engaged through multiple pathways converging upon caspases and/ or calpains, the exact
route appears to be context-dependent (Jung & Lippard, 2007; Mandic et al., 2002; Siddik,
2003). Poly(ADP ribose) polymerase-1 (PARP-1) attaches poly(ADP ribose) polymers to
specific targets in response to DNA damage, utilising NAD+ and ATP. Overactivation of
PARP-1 upon cDDP treatment may deplete cellular stores of NAD+ and ATP, resulting in
necrotic cell death (Jung & Lippard, 2007).
DNA damage may halt the cell cycle by engaging cell cycle checkpoints to allow for DNA
repair. Treatment with cDDP may result in a transient S-phase arrest, yet the majority of cells
arrest at the G2/ M-phase transition (Eastman, 1999; Siddik, 2003). Cells arrested at this stage
attempt repair of platinated DNA, and eventually undergo an aberrant mitosis leading to cell
death (Eastman, 1999). In rare cases these aberrant mitoses may generate viable cells,
promoting clonogenic outgrowth with a cDDP resistant phenotype (Puig et al., 2008).
The intracellular concentration of cDDP is an important factor in determining the extent of
DNA modification. Decreased accumulation may occur either through as yet obscure changes
in the passive uptake process or by decreased expression of copper transporters (Holzer et al.,
2004; Kelland, 2007; Siddik, 2003). Increased drug efflux appears to be a less common mode
of resistance, and cDDP itself is not a substrate for the multidrug resistance (MDR) proteins,
although increased expression of copper transporting ATPases has been shown to reduce
intracellular drug concentration (Kelland, 2007; R. J. B. King & Robins, 2006b; Siddik,
2003).
The interactions of cDDP with biomolecules other than DNA are also important in
understanding its mode of action. The most influential of these may by binding of cDDP by
the abundant endogenous antioxidant GSH. The high reactivity of aquated cDDP with thiol
groups allows the drug to be sequestered before reaction with DNA, and increased expression
of this tripeptide is a confirmed means of resistance in some cell types. GSH-cDDP
conjugates may also be actively transported out of the cell (Fuertes et al., 2003; Kelland,
2007; R. J. B. King & Robins, 2006b; Siddik, 2003). Consideration of this mechanism must
be tempered by understanding that binding of GSH by cDDP may deplete the intracellular
antioxidant pool and promote cell death, especially since ROS production may be stimulated
by cDDP treatment (Martins, Santos, Curti, Bianchi, & Santos, 2008). Furthermore, it has
been proposed that these proteins may also act as a 'drug reservoir' for prolonged platination
of DNA (Reedijk, 1999). The activity of other proteins may be negatively affected by cDDP
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binding. The Hsp90 chaperones may be inhibited by cDDP treatment, as may several
glycolytic enzymes and ETC respiratory complexes (Aull et al., 1979; Donnelly & Blagg,
2008; Rodríguez-Enríquez et al., 2009; R. Zhou, Vander Heiden, & Rudin, 2002).
The extensive modification of cellular protein has been shown to induce ER stress and cell
death signalling in enucleated cells, a death pathway independent of nuclear effects (Mandic
et al., 2003). Furthermore, the ER has been directly implicated in mediating cellular
sensitivity to cDDP through the level of expression of IP3R-1, and ER Ca2+ release is an early
response to cDDP in some cell types (Kawai, Nakao, Kunimura, Kohda, & Gemba, 2006;
Tsunoda et al., 2005). However, the degree to which effects at the ER contribute to the
efficacy of cDDP and whether this effect is generally applicable remains unknown.
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1.5 Aims of Thesis
1.5.1 Summary and Aims of Thesis
Cancer is a disease affecting millions worldwide, and future incidence is set to increase with
changing lifestyles and increasing longevity in the global population. Section 1.1 of this
introductory chapter has outlined both the scale of the problem and the strategies which may
be used in attempts to overcome it. Chemotherapy remains a key player in both the
management and treatment of this disease. In Section 1.4 greater detail is given on the
properties and activity of the well studied chemotherapy drug cDDP. An alkylating-like
agent, the antineoplastic effects of cDDP are considered to be mediated through DNA
damage. Less well characterised effects of cDDP may also occur through direct damage to
cellular proteins. Despite its widespread usage, the clinical efficacy of cDDP is limited by
cancer cell chemoresistance, both intrinsic and acquired. Current strategies to augment cDDP
cytotoxicity target common resistance mechanisms (see Section 1.4.2), and aim to maximise
drug accumulation, prevent cDDP detoxification, increase tumour cell DNA damage and
inhibit damage repair (Fuertes et al., 2003; Köberle et al., 2010). It is not known whether
changes in effects not directly mediated by DNA damage, such as ER stress induction or
alterations in cellular metabolism, contribute to the efficacy of cDDP treatment, and this is
the issue this thesis seeks to address, with particular focus on the ER and mitochondria. The
aims of the thesis may be broadly divided into three categories:
 Use a NSCLC cell line to model cDDP resistance – Exposure to cDDP has been
reported to induce cell death through multiple pathways, with varying requirements
for cell death effectors such as caspases, calpains, ROS and Ca2+. Two sub-types of
the A549 cell line with differing propensity to undergo cDDP-induced cell death will
be investigated throughout this work. The A549-CR cell line was derived and selected
for survival and growth in the presence of cDDP through prolonged culture of the
parental wild type A549-WT cell line, which retains sensitivity to cDDP treatment, in
the presence of a low concentration of cDDP. The difference in cDDP sensitivity
between the two cell lines will be demonstrated, and the mode of cell death induced
by cDDP will be determined with reference to previous literature, to establish whether
the system is appropriate for investigating factors modulating cDDP cytotoxicity.
Such work will contribute to the understanding of how cDDP causes cell death in
1.5 Aims of Thesis
54
cancer cells. Variations in the response of the two A549 cell lines to cDDP treatment
shall be used further in the investigation to identify properties of the ER and
mitochondria which may modulate cDDP sensitivity.
 Investigate the role of the ER in cDDP-induced cell death – The ER is recognised as
an organelle capable of inducing cell death through multiple pathways. The
intracellular ER Ca2+ store is targeted during cell death induction by ER stress and
apoptosis, both of which may result from cDDP treatment. ER Ca2+ handling will be
compared in A549-WT cells and A549-CR cells to elucidate the contribution of Ca2+
and the ER in modulating cDDP sensitivity.
 Examine mitochondrial response to cDDP treatment – Mitochondria are key
regulators in both the life and death of a cell. Changes in mitochondrial activity may
promote cell survival or sensitise to cell death. The response of mitochondria to cDDP
treatment, and the mechanism of any dissimilarities observed, will be investigated in
A549-WT cells and A549-CR cells. The contribution of differences in this response to
altered cDDP sensitivity will be explored.
Identification of novel cellular responses to cDDP treatment may provide alternative targets
to improve the efficacy of cDDP based chemotherapy, and potentially circumvent
chemoresistance. Greater understanding of how cDDP affects cellular physiology as a whole,
and how these effects outside of the nucleus may contribute to cell death, may allow for
targeted sensitisation of tumour cells to cDDP chemotherapy, reduce the acquisition of drug
resistance and allow for the use of decreased drug concentrations, potentially limiting the
occurrence of undesirable side effects associated with the drug. Conversely, modulation of
extranuclear targets of cDDP may provide a unique strategy to protect non-tumour cells from
cDDP-induced cell death whilst maintaining the anti-tumour activity of the drug.
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2. Materials and Methods
2.1 Drugs and Reagents
Thapsigargin (Tg), cDDP, EGTA, ascorbic acid, TEMPOL, N-acetyl cysteine (NAC), 2-
aminoethoxydiphenyl borate (2-APB), BAPTA-AM, ionomycin, diethylmaleate (DEM) and
cyclosporine A (CsA) were purchased from Sigma-Aldrich. Hoechst 33342 (Hoechst), z-
VAD-FMK and IETD-FMK were purchased from Enzo Life Sciences. D-2,3-O-
Isopropylidene-6-O-(2-Nitro-4,5-Dimethoxy)benzyl-myo-Inositol 1,4,5
TrisphosphateHexakis(Propionoxymethyl) Ester (caged IP3) was purchased from SiChem.
Fluo-4-AM, Fura-2-AM, monochlorobimane (MCB) and tetramethylrhodamine methyl ester
(TMRM) were purchased from Invitrogen. Calpain inhibitor ALLN was purchased from
Calbiochem.
2.2 Cell Culture and Manipulation
A549-WT and A549-CR cell lines were maintained in Dulbecco’s Modified Eagle Medium
(DMEM)/ F12 1:1 + GlutaMAX (Invitrogen) supplemented with 10% foetal bovine serum,
100 units/ ml penicillin and 100 µg/ ml streptomycin (Invitrogen) (‘normal cell culture
medium’) at 37 oC in 5% CO2. Unless otherwise indicated, A549-WT and A549-CR cells
treated with cDDP were maintained in normal cell culture medium supplemented with 75 µM
cDDP at 37 oC in 5% CO2 for the indicated time period. A549 Rho-0 cells were maintained in
Dulbecco’s Modified Eagle Medium (DMEM)/ F12 1:1 + GlutaMAX (Invitrogen)
supplemented with 10% foetal bovine serum, 100 units/ ml penicillin, 100 µg/ ml
streptomycin (Invitrogen) and 50 µg/ ml uridine at 37 oC in 5% CO2. HeLa cells were
maintained in DMEM + GlutaMAX (Invitrogen) supplemented with 10% foetal bovine
serum, 100 units/ ml penicillin and 100 µg/ ml streptomycin (Invitrogen) at 37 oC in 5% CO2.
Cells were passaged every 3-4 days upon reaching 90% confluence.
During cell imaging procedures, fluorescent dye loading, drug pre-treatment for imaging
procedures and measurement of aequorin bioluminescence cells were bathed in Krebs-Ringer
buffer (KRB; 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1 mM MgSO4, 1 g/ l glucose, 20
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mM HEPES, 1 mM CaCl2, pH 7.4) with the indicated supplements, unless otherwise
indicated. During ‘Ca2+ free’ experiments cells were bathed in nominally ‘Ca2+ free’ KRB
(125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1 mM MgSO4, 1 g/ l glucose, 20 mM HEPES,
pH 7.4) with indicated the supplements. During overnight imaging of A549 cell morphology,
cells were loaded with fluorescent dyes and imaged in normal cell culture medium at 37 oC in
a heated imaging chamber perfused with 5% CO2 for the entire duration of the experiment.
For transfection of cDNA constructs A549-WT or A549-CR cells were seeded in 6-well
tissue culture plates (Falcon) or onto 22 mm diameter glass coverslips in 6-well tissue culture
plates 24 hours before transfection at 40-60% confluence. Cells contained in individual wells
of the culture plate were transfected with a total of 4 µg cDNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions, and incubated at 37 oC for 48 hours
before experimental procedures began.
2.3 Imaging Apparatus
Confocal images were acquired using a Zeiss 510 LSM Meta confocal microscope system
(Carl Zeiss Ltd.) with a 40x oil immersion objective lens (N.A. 1.3) or a 63x oil immersion
objective lens (N.A. 1.4), and cells maintained at 37 oC throughout the experimental time
course. Excitation illumination was provided by emission lines from a helium/ neon laser, an
argon laser, a 405 nm laser diode or a Coherent Enterprise UV laser. Where indicated, linear
unmixing of fluorescence emission was performed using Zeiss LSM 4.0 software (Carl Zeiss
Ltd.), using reference spectra previously obtained from A549-WT cells singly expressing the
relevant recombinant fluorophore(s).
Measurements of SOCE Ca2+ signals using Fura-2-AM were made using an Axiovert
inverted epifluorescence microscope (Carl Zeiss Ltd.) with a 20x fluorite objective lens (N.A.
0.45). Images were collected using a Hamamatsu 4880 cooled charge-coupled device camera
(Hamamatsu Corporation), and recorded and analysed using Kinetic Imaging software
(Kinetic Imaging Ltd.). Excitation illumination was provided by light from a xenon arc lamp
passing through a computer controlled filter wheel (Cairn Research). Coverslips were
maintained at 37 oC throughout the experimental time course.
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Overnight timelapse images of A549-WT and A549-CR cells, determination of cellular GSH
and Fura-2-AM measurements of A549-WT cell response to ATP were made using an
Olympus IX71 inverted epifluorescence microscope (Olympus) fitted with a computer
controlled motorised stage (Applied Scientific Instrumentation) with a 40x fluorite objective
lens (N.A. 0.6). Images were collected using a Hamamatsu C10600-10B cooled charge-
coupled device camera (Hamamatsu Corporation), and recorded and analysed using Simple
PCI 6.6.0.0 software (Hamamatsu Corporation). Excitation illumination was provided by
light from a metal halide arc lamp passing through a computer controlled filter wheel (Prior
Scientific).
2.4 Estimation of Cell Viability by Flow Cytometry
A549 cells were cultured in 6-well tissue culture plates (Falcon) for 24 hours following cell
seeding before intervention. For caspase inhibitor experiments, A549-WT cells were
incubated in normal cell culture medium + 20 µM z-VAD-FMK or in normal cell culture
medium + 20 µM z-VAD-FMK + 75 µM cDDP for 24 hours before assay. For calpain
inhibitor experiments, A549-WT cells were incubated in normal cell culture medium + 50
µM ALLN or in normal cell culture medium + 50 µM ALLN + 75 µM cDDP for 24 hours
before assay. For CsA experiments A549-WT cells were incubated in normal cell culture
medium + 5 µM CsA or in normal cell culture medium + 5 µM CsA + 75 µM cDDP for 24
hours before assay. For antioxidant experiments A549-WT cells were incubated in normal
cell culture medium + 1 mM ascorbic acid or in normal cell culture medium + 1 mM ascorbic
acid + 75 µM cDDP, in normal cell culture medium + 200 µM TEMPOL or in normal cell
culture medium + 200 µM TEMPOL + 75 µM cDDP or in normal cell culture medium + 5
mM NAC or in normal cell culture medium + 5 mM NAC + 75 µM cDDP for 24 hours
before assay. Cells transfected with IP3R-1 cDNA constructs (Miyawaki et al., 1999) were
incubated for 48 hours after transfection before the culture medium was changed either to
fresh normal cell culture medium or normal cell culture medium + 75 µM cDDP and cells
were incubated for a further 24 hours before assay. For Ca2+ chelation experiments with
BAPTA-AM, A549-WT cells were incubated in normal cell culture medium + BAPTA-AM
at 1 µM, 3 µM or 10 µM or pretreated with BAPTA-AM at 1 µM, 3 µM or 10 µM for 30
minutes before addition of 75 µM cDDP for 24 hours before assay. For Ca2+ chelation
experiments with EGTA, A549-WT cells were incubated in normal cell culture medium + 1.4
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mM EGTA or in normal cell culture medium + 1.4 mM EGTA + 75 µM cDDP for 24 hours
before assay. For cell viability experiments with 2-APB, A549-WT cells were incubated in
normal cell culture medium + 10 µM 2-APB or pretreated with + 10 µM 2-APB for 30
minutes before addition of 75 µM cDDP for 24 hours before assay.
Following the indicated cell treatment periods, culture medium was collected from each well
in which cell viability was to be assayed. Adherent cells were removed by partial digestion
with trypsin, resuspended in normal cell culture medium and combined with the original
culture medium. The resulting cell suspension was centrifuged at 500 G for 5 minutes and the
cell pellet resuspended in PBS containing 5 µg/ ml Hoechst 33342 at a density of
approximately 1 million cells/ ml. The cell suspensions were incubated at 37 oC for 10
minutes before storage on ice until the start of the assay. 1 µg/ ml PI was added to cell
suspensions immediately before measurement. Fluorescence was measured using a CyAN
ADP flow cytometer (Beckman-Coulter) using 405 nm and 488 nm excitation wavelengths.
A minimum population size of 50,000 cells was assayed under each experimental condition.
Data were analysed using Summit 4.3 software (Beckman-Coulter) using threshold PI
fluorescence set according to non-treated control A549-WT and A549-CR cells to
discriminate between live (‘low PI’) and dead (‘PI positive’) cells.
2.5 Timelapse Imaging of A549 Cell Morphology
A549 cells were cultured in 24 well cell culture plates (Falcon) for 24 hours. Prior to
imaging, cells were incubated in normal cell culture medium + 5 µg/ ml Hoechst 33342 for
15 minutes at 37 oC, washed twice with PBS and returned to normal cell culture medium in a
custom built heated imaging chamber at 37 oC perfused with 5% CO2. Image acquisition
occurred every 20 minutes with excitation illumination provided by light from a metal halide
arc lamp passing through a Chroma D-350/50x excitation filter (Chroma Technology). After
1 hour of image acquisition, 75 µM cDDP was added to the appropriate wells, and images
acquired for a further 24 hours. A minimum of 10 individual image fields of at least 20 cells
were studied under each experimental condition in each individual experiment. Cell divisions
were counted manually according to the morphological criteria outlined in Figure 6 A.
Divisions were judged to have been successfully completed once both daughter cells
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generated by the division returned to a morphology indistinguishable from surrounding cells
which were not undergoing division or cell death.
2.6 Aequorin Measurements
A549-WT and A549-CR cells seeded onto 22 mm diameter glass coverslips and transiently
transfected with cytoplasmic aequorin cDNA constructs (Chiesa et al., 2001) were incubated
in KRB + 1 mM Ca2+ + 5 µM coelenterazine at 37 oC for 90 minutes before transfer to a
thermostated perfusion chamber. Coverslips were maintained at 37 oC under continuous
perfusion throughout the experimental procedure. A custom built luminometer was used to
for measurement of bioluminescence (Cairn Research), and photon counts calibrated to
[Ca2+] according to Brini M. et al (Brini et al., 1995).
For ATP stimulation experiments, aequorin transfected cells were perfused with KRB + 1
mM Ca2+ + 100 µM ATP before the experiment was terminated by perfusion with KRB + 10
mM Ca2+ + 100 µM digitonin until no further photon count signal was detected.
For Ca2+ influx experiments, A549-WT and A549-CR cells transiently transfected with
cytoplasmic aequorin were perfused with KRB + 1 mM Ca2+ for 60 s before the following
changes in perfusate were made: (i) nominally ‘Ca2+ free’ KRB for 60-90 s; (ii) nominally
‘Ca2+ free’ KRB + 500 nM Tg for 40 s before perfusion was halted for approximately 300 s;
(iii) KRB + 1 mM Ca2+ until the photon count signal returned to a stable value and (iv) KRB
+ 10 mM Ca2+ + 100 µM digitonin until no further photon count signal was detected.
2.7 IP3R Stimulation Using Cell Permeable Caged IP3
A549-WT and A549-CR cells were seeded onto 22 mm diameter glass coverslips 24 hours
before imaging. Cells were incubated at room temperature in KRB + 1 mM Ca2+ + 1 µM cell
permeable photolabile caged IP3 (SiChem) for 45 minutes before the addition of 5 µM Fluo-
4-AM to the buffer solution and incubation at room temperature for a further 20 minutes.
Both the buffer solution and coverslips were protected from light during the entire period of
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incubation at room temperature. After this incubation, coverslips were washed twice with
KRB + 1 mM Ca2+ and imaged immediately.
Image acquisition occurred every 1 second, with excitation illumination provided by the 488
nm emission line of an argon laser, and emitted fluorescence collected above 505 nm using a
long pass emission filter. Uncaging of IP3 occurred after acquisition of the initial 5 images
through 1 second of illumination of the entire image field with the 351 nm and 364 nm
emission lines of a Coherent Enterprise UV laser at maximum output, and images acquired
for a further 195 s. Fluorescence signals from individual cells were normalised to the mean
fluorescence signal of the initial 5 images of that cell. The mean normalised fluorescence
signal measured in A549-WT and A549-CR cells was divided by the mean normalised
fluorescence signal measured in control A549-WT cells not subjected to the period of UV
illumination was at corresponding time points to correct for the effects of Fluo-4 bleaching
due to the imaging process.
2.8 Measurement of [Ca2+]cyt and SOCE Using Fura-2
A549-WT and A549-CR cells were seeded onto 22 mm diameter glass coverslips 24 hours
before measurement. Prior to imaging, cells were incubated in KRB + 1 mM Ca2+ + 1 μM 
Fura-2-AM at 37 oC for 20 minutes. Following incubation, coverslips were washed twice
with KRB + 1 mM Ca2+, transferred to nominally ‘Ca2+ free’ KRB and imaged immediately.
Image acquisition occurred every 10 s. Basal cytosolic Fura-2 fluorescence was measured for
120 s preceding the addition of 500 nM Tg, and images acquired for a further 300 s before
the addition of 1 mM Ca2+ directly to the KRB bathing solution. Images were recorded until
the fluorescence signal returned to a stable value. Control cells were imaged in nominally
‘Ca2+ free’ KRB for 420 s before the addition of 1 mM Ca2+ directly to the KRB bathing
solution, and images acquired for a further 180 s. Background fluorescence was calculated
from a region in each image not occupied by cells, and subtracted from each time point
individually.
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2.9 Western Blotting
For immunodetection of endogenous protein expression, A549-WT and A549-CR cells were
cultured in 6-well tissue culture plates for 24 hours, before further incubation in either normal
cell culture medium or normal cell culture medium + 75 μM cDDP for 24 hours prior to 
harvesting samples. For immunodetection of transient IP3R overexpression, A549-WT
transiently transfected with IP3R-1 cDNA constructs were incubated in either normal cell
culture medium or normal cell culture medium + 75 μM cDDP for 24 hours before harvesting 
samples. Control cells were cultured under the same conditions without transfection.
Cells were washed with PBS on ice and lysed directly in lysis buffer consisting of 4% SDS
(w/v), 20% glycerol and 125 mM Tris-HCl, pH 6.8. Total cellular protein concentration was
quantified using the Pierce BCA protein assay kit (G. E. Healthcare) according to the
manufacturer’s instructions, and 30 μg of sample protein diluted in loading buffer consisting 
of 1% SDS (w/v), 50% sucrose (w/v), bromophenol blue, 10% β-mercaptoethanol and 0.625 
mM Tris-base, pH 6.6. Samples were separated by electrophoresis on NuPAGE 4-12%
polyacrylamide gels (Invitrogen) and electroblotted onto PVDF membranes (Millipore).
Membranes were incubated in PBS + 0.05% Tween-20 (PBST) + 5% fat-free milk or PBST +
5% bovine serum albumin (BSA) for 1 hour at room temperature before the addition of
primary antibody.
Primary antibody specific for IP3R-1 (rabbit anti-IP3R-1 (Abcam)) was diluted 1:500 in PBST
+ 5% BSA and incubated with membranes overnight at 4 oC. Primary antibody specific for
p53 (mouse-anti p53 DO-1 (Santa Cruz)) was diluted 1:1000 in PBST + 5% fat-free milk and
incubated with membranes for 2 hours at room temperature. Primary antibody specific for β-
actin (mouse anti-β-actin (Sigma-Aldrich)) was diluted 1:4000 in PBST + 5% fat-free milk 
and incubated with membranes for 2 hours at room temperature. MitoProfile® Total
OXPHOS Human antibody cocktail (raised in mouse (MitoSciences)) was diluted 1:250 in
PBST + 5% fat-free milk and incubated with membranes overnight at 4 oC.
For immunodetection of Akt, membranes were stained with Ponceau-S (Sigma Aldrich) and
imaged immediately following electroblotting. Membranes were incubated in PBS + 0.05%
Tween-20 (PBST) + 5% fat-free milk for 1 hour at room temperature, before incubation with
primary antibody specific for Akt (rabbit anti-pan Akt (Cell Signalling)) or Ser473 phospho-
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Akt (rabbit anti-Ser473 phospho Akt (Cell Signalling) diluted 1:1000 in PBST + 5% fat-free
milk for 2 hours.
Membranes were incubated with goat anti-rabbit horseradish peroxidase conjugated
secondary antibody (Thermo Scientific) diluted 1:4000 in PBST + 5% BSA or goat anti-
mouse horseradish peroxidase conjugated secondary antibody (Thermo Scientific) 1:4000 in
PBST + 5% fat-free milk, as appropriate, for 1 hour at room temperature, and visualised
using the ECL Plus Western Blotting Detection System (G. E. Healthcare). Quantification of
protein band intensity was performed using ImageJ software.
2.10 Oxidative Stress Induced by TMRM Photoactivation
A549-WT and A549-CR cells were seeded onto 22 mm diameter glass coverslips 24 hours
before measurement. Cells were incubated in KRB + 1 mM Ca2+ + 200 nM TMRM for 20
minutes at 37 oC. Where indicated, cells were further incubated in either KRB + 1 mM Ca2+ +
200 nM TMRM + 1mM ascorbic acid, KRB + 1 mM Ca2+ + 200 nM TMRM + 1 μM CsA or 
KRB + 1 mM Ca2+ + 200 nM TMRM + 10 μM CsA for 30 minutes before imaging, or further 
incubated in nominally ‘Ca2+ free’ KRB + 500 nM Tg + 2 mM EGTA or nominally ‘Ca2+
free’ KRB + 1 μM BAPTA-AM + 2 mM EGTA for 20 minutes before imaging. All drugs 
added were present throughout the entire experimental protocol.
Image acquisition occurred every 1 second using a confocal microscope, with excitation
illumination provided by the 543 nm emission line of a helium/ neon laser at 10% of maximal
output. Fluorescence emission was collected at wavelengths above 560 nm using a long pass
emission filter. Data were analysed using Zeiss LSM 510 software. Briefly, after applying an
intensity threshold to remove background fluorescence, the mean fluorescence intensity of
the illuminated field of cells was calculated for each frame of the image series, and
normalised relative to the initial mean fluorescence of the illuminated field. Statistical
significance was assessed through comparison of the mean normalised fluorescence intensity
of the final 5 frames of the image series using a paired Student’s t-test.
2. Materials and Methods
63
2.11 [Ca2+]ER Measurements Using Recombinant D1ER Cameleon Probe
A549-WT and A549-CR cells seeded onto 22 mm diameter glass coverslips and transiently
transfected with D1ER cameleon cDNA constructs were incubated in normal cell culture
medium or normal cell culture medium + 75 μM cDDP for 24 hours at 37 oC before
measurement. Images were acquired using a confocal microscope. The D1ER probe contains
two recombinant fluorophores, cyan fluorescent protein (CFP) and yellow fluorescent protein
(YFP) (Palmer, Jin, Reed, & Tsien, 2004). Control A549-WT cells were incubated in KRB +
500 nM Tg + 1.4 mM EGTA for 10 minutes to deplete ER store Ca2+ before measurement.
Excitation illumination was provided by the 405 nm emission of a laser diode, and
fluorescence emission collected between 456 nm and 756 nm using the Zeiss Meta detector.
Linear unmixing was used to separate CFP and YFP emission, and images were analysed
using Zeiss LSM 510 4.0 software. The proportion of probe in the Ca2+ bound form
undergoing Förster resonance energy transfer (FRET) was estimated using the acceptor
photobleaching method (Karpova et al., 2003). Five sequential images of transfected cells
were acquired prior to and immediately following a 40 iteration period of YFP
photobleaching using the 488 nm and 514 nm emission lines of an argon laser at maximum
output. The fluorescence emission intensities of CFP and YFP were determined in the single
images immediately preceding and immediately following the period of photobleaching, and
used to determine the percentage change in CFP fluorescence emission intensity and YFP
fluorescence emission intensity due to the photobleaching process. Changes are expressed as
‘FRET Ratio’, calculated thus:
‘FRET Ratio’ = Percentage Increase in CFP Intensity / Percentage Decrease in YFP Intensity
2.12 Measurement of [Ca2+]cyt After cDDP Treatment Using Fura-2
A549-WT and A549-CR cells were cultured in 24 well tissue culture plates for 24 hours
before imaging. Excitation illumination was provided by light from a metal halide arc lamp
passing through a Chroma D340xV2 excitation filter (Chroma Technology) or a Chroma
D380xV2 excitation filter (Chroma Technology), and images acquired every 150 s in all
experiments. Background fluorescence at 340 nm and 380 nm excitation was determined
using regions not occupied by cells in each field of view, and subtracted individually from
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Fura-2 340 nm and 380 nm fluorescence signals respectively, before the background-
corrected 340 nm : 380 nm Fura-2 fluorescence ratio was calculated. Data were normalised
relative to the initial 340 nm : 380 nm Fura-2 fluorescence ratio in non-treated A549-WT
cells.
For acute measurement of [Ca2+]cyt up to 60 minutes after cDDP exposure, A549 cells were
incubated in KRB + 1 mM Ca2+ + 1 µM Fura-2-AM + 1 mM probenecid for 15 minutes at 37
oC, washed twice with KRB + 1 mM Ca2+ and imaged immediately. For treatment with 2-
APB, cells were further incubated in KRB + 10 µM 2-APB + 1 mM probenecid for 15
minutes at 37 oC before imaging. Following 10 minutes of image acquisition to determine
baseline Fura-2 fluorescence, 75 µM cDDP was added directly to the appropriate samples,
and data acquired for a further 60 minutes. Data was acquired at the same time point for each
test condition from cells in adjacent wells of the tissue culture plate loaded simultaneously
with Fura-2-AM. Statistical significance was assessed through comparison of the
background-corrected 340 nm : 380 nm Fura-2 fluorescence ratio of the final 10 frames of the
image series using a paired Student’s t-test.
For measurement of [Ca2+]cyt 24 hours after cDDP exposure, A549-WT and A549-CR cells
were incubated in normal cell culture medium or normal cell culture medium + 75 μM cDDP 
for 24 hours at 37 oC, before 1 µM Fura-2-AM + 1 mM probenecid was added directly to the
cell culture medium and incubated for 15 minutes at 37 oC. After incubation, cells were
washed twice with KRB + 1 mM Ca2+ and imaged immediately. Images were acquired for 10
minutes. Values for Rmin and Rmax were determined separately for A549-WT and A549-CR
cells immediately following acquisition of experimental data using A59 cells cultured and
loaded with Fura-2 in adjacent wells of the same tissue culture plate. Rmin was determined by
incubation of cells in nominally ‘Ca2+ free’ KRB + 1 mM EGTA + 1 µM ionomycin, and
Rmax by incubation of cells in KRB + 10 mM Ca2+ + 1 µM ionomycin. Ca2+ concentrations
were calculated from background-corrected Fura-2 fluorescence ratios using the following
equation:
[Ca2+] = Kd * (R - Rmin) / (Rmax - R) * Sf2 / Sb2
Where the dissociation constant for Fura-2 binding of Ca2+ Kd = 225 nM, R = background-
corrected Fura-2 fluorescence ratio, Rmin = background-corrected Fura-2 fluorescence ratio in
the absence of Ca2+, Rmax = background-corrected Fura-2 fluorescence ratio under saturating
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Ca2+ binding conditions, Sf2 = background-corrected Fura-2 380 nm fluorescence signal in the
absence of Ca2+ and Sb2 = background-corrected Fura-2 380 nm fluorescence signal under
saturating Ca2+ binding conditions.
2.13 mtDNA Copy Number Quantification by RT-qPCR
A549-WT and A549-CR cells were cultured in 6 well tissue culture plates for 24 hours in
normal cell culture medium or normal cell culture medium + 75 µM cDDP, before isolation
of the total cellular DNA content. Cells were lysed directly in culture plates and solutions of
total cellular DNA were made from individual wells of the culture plate using the DNeasy
Blood and Tissue Kit (Qiagen). Quantification of mtDNA copy number in isolated DNA
preparations was made by RT-qPCR with the Dynamo SYBR Green qPCR Kit (New
England Biolabs). The primer set used for mtDNA amplification was 5′-
CCTGACTCCTACCCCTCACA-3′ and 5′-ATCGGGTGATGATAGCCAAG-3′, and the 
primer set used for β-actin amplification was 5′- TCACCCACACTGTGCCCATCTACGA-3′ 
and 5′-CAGCGGAACCGCTCATTGCCAATGG-3′. RT-qPCR was performed using a 
Mastercycler ep Realplex RT-qPCR system (Eppendorf) through 40 cycles of 95 oC for 15 s,
56 oC for 15 s and 72 oC for 20 s. Quantification was made via a standard curve. β-actin was 
used as a nuclear gene standard, and mtDNA copy number expressed normalised to the β-
actin content of that sample.
2.14 Measurement of Cellular H202 and O2•‾ Production
A549-WT and A549-CR cells were cultured in 24 well tissue culture plates for 24 hours in
normal cell culture medium or normal cell culture medium + 75 µM cDDP before
measurement.
For measurement of cellular H202 production, cells were washed twice with PBS and
incubated in PBS + 5 mM glucose + 2 µM 5-(and 6)-chloromethyl-2′,7′-
dichlorohydrofluorescein diacetate (DCF) for 40 minutes. Fluorescence emission was
measured at 520 nm under 495 nm excitation illumination every 2 minutes during the 40
minute incubation period. The rate of change in fluorescence intensity was calculated using
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time points between 10 minutes and 30 minutes following DCF addition in which the rate of
change in fluorescence remained linear. Background fluorescence was measured in control
A549-WT and A549-CR cells without DCF loading and subtracted from experimental values
before calculation of rate of change of fluorescence.
For measurement of cytosolic O2•‾ production, cells were incubated in normal cell culture
medium + 0.5 µM dihydroethidium (DHE) for 20 minutes at 37 oC, washed twice with PBS
and fluorescence emission at 635 nm under 535 nm excitation illumination recorded using a
microplate reader. Background fluorescence was measured in control A549-WT and A549-
CR cells without DHE loading and subtracted from experimental values before calculation of
mean fluorescence.
For measurement of mitochondrial O2•‾ production, cells were incubated in PBS + 1 g/ l
glucose + 5 µM MitoSOX for 10 minutes at 37 oC, washed twice with PBS and fluorescence
emission at 595 nm under 510 nm excitation illumination recorded using a microplate reader.
Background fluorescence was measured in control A549-WT and A549-CR cells without
MitoSox loading and subtracted from experimental values before calculation of mean
fluorescence. Performed by Dr. M. Wieckowski.
2.15 Measurement of Cellular GSH
A549-WT and A549-CR cells were cultured in 24 well tissue culture plates for 24 hours in
normal cell culture medium or normal cell culture medium + 75 µM cDDP before imaging.
Cells were incubated in KRB + 1 mM Ca2+ + 50 µM monocholorobimane (MCB) for 1 hour
and images taken immediately. Control A549-WT cells were incubated in KRB + 50 mM
diethylmaleate (DEM) for 15 minutes prior to MCB loading. MCB loading time was
determined empirically by measuring MCB fluorescence in A549-WT cells and A549-CR
cells during the dye loading period, the point at which no further change in fluorescence was
detected representing the point of GSH saturation. Excitation illumination was provided by
light from a metal halide arc lamp passing through a Chroma D-350/50x excitation filter
(Chroma Technology). Ten images containing a minimum of twenty cells per image field
were collected under each individual condition, and mean MCB fluorescence calculated using
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MetaMorph 6.1 software (Molecular Devices). Fluorescence intensities were normalised
relative to non-treated A549-WT cells.
2.16 Measurement of ΔΨ 
A549-WT and A549-CR cells were cultured in 6 well tissue culture plates for 24 hours in
normal cell culture medium or normal cell culture medium + 75 µM cDDP before imaging.
Cells were incubated in KRB + 1 mM Ca2+ + 10 nM TMRM for 20 minutes at 37 oC and
images taken immediately. Serial z-sections were acquired throughout the image field using a
Zeiss LSM 510 confocal microscope. Excitation illumination was provided by the 543 nm
emission line of a helium/ neon laser, and fluorescence emission was collected at
wavelengths above 560 nm using a long pass emission filter. Mean TMRM fluorescence was
calculated from at least ten images containing a minimum of twenty cells under each
individual condition after maximal projection and thresholding of images to remove
background fluorescence using MetaMorph 6.1 software. Fluorescence intensities were
normalised relative to non-treated A549-WT cells.
2.17 Mitochondrial Respiratory Complex I Activity Assays
A549-WT cells, A549-CR cells and A549 Rho-0 were cultured in 6 well tissue culture plates
for 24 hours in normal cell culture medium or normal cell culture medium prior to assay.
Measurement of either rotenone-insensitive or rotenone-sensitive activity of mitochondrial
respiratory complex I was made using two separate protocols.
For measurement of rotenone-insensitive complex I activity, enzyme activity was assessed
using MitoSciences Microplate Assay for Human Complex I Activity (MitoSciences)
according to the manufacturer’s instructions. Proteins were extracted from the cell pellets by
incubation in non-ionic lauryl maltoside detergent + protease inhibitors for 30 minutes on ice
and centrifuged at 1600 g at 4 oC for 20 minutes. 200 µg of sample protein was loaded into
each well of a microplate and incubated for 3 hours at room temperature for immunocapture
of complex I. Microplate wells containting buffer without sample addition were used as
controls to allow subtraction of background fluorescence. Following incubation, microplate
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wells were rinsed with buffer solution, 200 µl assay solution added to each well and
absorbance measured at 450 nm every minute for 30 minutes using a microplate reader. The
linear rate of increase in absorbance at 450 nm after background subtraction was calculated
for each sample, and data expressed as rate of change in absorbance at 450 nm per minute per
µg loaded protein.
For measurement of rotenone-sensitive complex I activity, the oxidation of NADH to NAD+
dependent upon passage of electrons through complex I to ubiquinone was monitored by
spectrophometry before and after the addition of rotenone. Cells were harvested by manual
scraping into phosphate buffer (25 mM KH2PO4 + 10 mM MgCl2, pH 7.2), centrifuged at 500
g for 5 minutes and lysed through three sequential freeze-thaw cycles. Assays were
performed at 30 oC in assay solutions consisting of: 20 µl sample solution + 800 µl phosphate
buffer + 10 µl 100 mM KCN + 50 µl 50 mg/ ml BSA + 80 µl H20. Absorbance was measured
at 340 nm every 20 s for 5 minutes following addition of 10 µl 5mM ubiquinone. Assay
solutions were mixed for 3 minutes upon addition of 20 µl 1 mM rotenone, and absorbance
measured for a further 5 minutes. Complex I activity was calculated as: Activity (nmol
minute-1 ml-1) = (Change in 340 nm absorbance minute-1 before rotenone addition/ Change in
340 nm absorbance after rotenone minute-1 addition) x 50 x 106 / 6.81 x 103 M-1 cm-1. Total
protein concentration in the assay solution was quantified immediately following
measurement, using the Pierce BCA protein assay kit (G. E. Healthcare) according to the
manufacturer’s instructions, and activity normalised per µg protein. Performed by Dr. Z. Yao.
2.18 Measurement of Cellular O2 Consumption
A549-WT and A549-CR cells were cultured in 6 well tissue culture plates for 24 hours in
normal cell culture medium or normal cell culture medium + 75 µM cDDP. Before
measurement cells were washed twice with PBS, and adherent cells were removed by partial
digestion with trypsin and resuspended in recording medium (1.38 mM NaCl, 5.6 mM KCl,
4.2 mM NaHCO3, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.6 mM CaCl2, 10 mM D-glucose, 10
mM HEPES). O2 consumption was measured using a Clark type electrode at 37 oC in a
population of approximately one million cells. The maximal cellular oxidative capacity was
measured after addition of 2 µM FCCP to uncouple the ETC. The assay solution was
collected from the electrode chamber at the end of the experimental period, and the
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concentration of cells estimated. O2 consumption rates were normalised relative to the
number of cells present during measurement. Performed by Dr. G. Szabadkai.
2.19 mtDNA Sequencing by GeneChip® Resequence Analysis
The GeneChip® Human Mitochondrial Resequencing Array 2.0 (Mitochip) (Affymetrix) was
used to interrogate the entire mtDNA sequence. The 16.5kb mitochondrial genome was
amplified in two fragments using the Expand Template Long PCR kit from Roche
Diagnostics according to the manufacturer's protocol. PCR primers were Mito1-2F
ACATAGCACATTACAGTCAAATCCCTT
CTCGTCCC, Mito1-2R ATTGCTAGGGTGGCGCTTCCAATTAGGTGC-9307, Mito3F
TCATTTTTATTGCCACAACTAACCTCCTCGGACTC and Mito3R
CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT-7814. Cycling conditions
consisted of an initial denaturation step of 3 minutes at 94°C, followed by 10 cycles of
denaturation for 10 seconds at 94°C, annealing for 30 seconds at 60°C and extension for 10
minutes at 8°C; then 25 cycles of denaturation for 10 seconds at 94°C, annealing for 30
seconds at 60°C and extension for 10 minutes + an additional 20 seconds per cycle at 68°C;
and a final extension step of 10 minutes at 68°C. Concentration of DNA in the long PCR
products was determined using Nanodrop spectrophotometry and equimolar concentrations of
the two PCR products were pooled. Performed by Mary Sweeney. These were digested with
DNAseI. Prehybridization, hybridization, washing and scanning of the GeneChip® were
performed according to the Affymetrix CustomSeq Resequencing protocol. Sequences were
analysed using GSEQ 4.2 software. SNPs were automatically called by GSEQ and presented
in a SNP viewer format. Performed by Kerra Pearce.
2.20 mtDNA PCR and sequencing
Primer sets specific to the six regions of mtDNA identified by Mitochip sequencing as
containing point mutations present in the A549-CR cell line but not the A549-WT cell line
were used to amplify these regions through PCR. PCR reactions were performed in a final
volume of 25 µl, using BioTaq DNA Polymerase (Bioline USA Inc., Boston, MA), as
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follows: one cycle at 95°C for 2 minutes, followed by 30 cycles at 95 °C for 30 s, 50 °C for
30 s, and 72 °C for 40 s, and finally one cycle at 72 °C for 5 minutes. PCR products were
purified by Microclean (Microzone Limited, Haywards Heath, UK), directly sequenced using
the Big Dye v3.1 Terminator System and analysed on an automated sequencer (ABI 3130,
Applied Biosystems, Carlsbad, CA). Sequence data were analyzed using Sequencher (version
4.8) and sequences were compared with the human mtDNA consensus sequence, NCBI
reference sequence: NC_012920.1. Performed by the group of Dr. S. Rahman.
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3.1 Characterisation of cDDP-Induced Cell Death in A549 Cells
3.1.1 A549-CR Cells Have Reduced Sensitivity to cDDP Treatment
To investigate extranuclear effects which may modulate tumour cell sensitivity to cDDP, an
in vitro model of acquired cDDP resistance was employed. A drug-resistant cell line was
derived through one year of continuous culture of the parental, cisplatin-sensitive A549-WT
cell line in the presense of 5 µM cDDP, generating the cDDP-resistant A549-CR cell line
(Tajeddine, N., Unpublished). A549-WT and A549-CR cells were incubated in normal cell
culture medium containing cDDP in the concentration range 0-100 μM for 24 hours. After 
this period of incubation, cell viability was assayed using the ability of live cells to exclude
the plasma membrane-impermeant fluorescent dye PI. No significant increase in the
percentage of PI stained cells in comparison with untreated control cells was caused by
treatment with cDDP at concentrations up to and including 20 μM in either cell type (Figure 
4). A significant increase in the percentage of PI positive A549-WT cells was observed using
cDDP concentrations of 50 μM (46.4 ± 4.8% PI positive), 75 μM (50.0 ± 6.6% PI positive) or 
100 μM (53.4 ± 6.6% PI positive), increasing more than 30% above the basal level in 
untreated control A549-WT cells (Figure 4). The percentage of PI positive A549-CR cells
after treatment with 50 μM (19.0 ± 7.8% PI positive), 75 μM (25.0 ± 4.1% PI positive) or 100 
μM (31.1 ± 5.1% PI positive) cDDP was approximately halved in comparison to A549-WT 
cells under the same conditions (Figure 4).
These data estimate the median lethal dose (LD50) of cDDP in A549-WT cells after a 24 hour
period of treatment to be 75 μM, and an approximately two-fold, statistically significant 
difference in cDDP sensitivity exists between A549-WT and A549-CR cells at this drug
concentration (p < 0.01). For this reason, treatment of cells using 75 μM cDDP over a 24 
hour period of exposure was selected for use in further investigations.
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Figure 4: Cell death induced by 24 hours incubation with 75 µM cDDP is reduced in
A549-CR cells relative to the A549-WT cell line. A549-WT cells and A549-CR cells were
incubated in normal cell culture medium + cDDP in the concentration range 0 – 100 µM for
24 hours, and cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’. Data
represent the mean of three independent experiments ± S.E.M. * p < 0.05.
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3.1.2 cDDP Treatment Induces p53 Accumulation in Both A549-WT Cells and A549-CR
Cells
Upon damage to DNA, activation and increased cellular levels of the tumour suppressor
protein p53 may cause cell cycle arrest, activate DNA damage repair pathways and induce
apoptosis. Since exposure to cDDP may result in both intra-strand and inter-strand DNA
crosslinks, the relative induction of p53 was determined by western blot in A549-WT cells
and A549-CR cells cultured either in normal cell culture medium or in normal cell culture
medium + 75 µM cDDP for 24 hours (Figure 5 A). Treatment with cDDP increased cellular
p53 protein levels by approximately seven-fold in A549-WT cells (p < 0.05) and nine-fold in
A549-CR cells (p < 0.05), relative to non-treated A549-WT cells and non-treated A549-CR
cells respectively (Figure 5 B). No significant difference existed in cellular p53 protein levels
between A549-WT cells and A549-CR cells incubated in normal cell culture medium or
following exposure to cDDP (Figure 5 B). Thus, cDDP treatment induced a comparable
strong increase in p53 protein level in both A549-WT cells and A549-CR cells. However,
whilst the absolute level of expression of p53 protein does not differ between A549-WT cells
and A549-CR cells, differences in p53 transcription promoting activity may not be excluded
by the present data, and should therefore be assessed using a suitable reporter gene assay,
measuring induction of p53 target genes, or the enrichment of p53 at target promoters
investigated via chromatin immunoprecipitation.
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Figure 5: Exposure to cDDP causes comparable induction of p53 protein in both A549-
WT cells and A549-CR cells. A549-WT cells and A549-CR cells were incubated in normal
cell culture medium or normal cell culture medium + 75 µM cDDP for 24 hours, and cellular
p53 protein levels measured by western blot. (A) Representative p53 western blot and (B)
quantification of mean p53 band intensity. Data represents the mean of three independent
experiments + S.E.M. * p < 0.05.
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3.1.3 cDDP Inhibits Proliferation and Induces Apoptosis in A549 Cells
A549 cells treated with cDDP begin to lose plasma membrane integrity within 24 hours, as
determined by PI staining. We next sought to characterise the mode of cell death induced by
cDDP in this cell model. Since cell death is best defined through a set of morphological
criteria (Kroemer et al., 2009), time-lapse images of A549 cells treated with 75 μM cDDP 
were made during the 24 hour treatment period. Few control cells of either cell type
underwent morphological changes associated with cell death without cDDP treatment,
indicating the imaging process itself does not cause toxicity (Figure 6 C). Incubation with
cDDP induced clear morphological changes in A549-WT cells (Figure 6 D). The first
morphologically altered cells appeared approximately 6 hours after drug addition,
characterised by reduced cell size, a rounded cellular shape, irregular plasma membrane
structure and concomitant nuclear condensation. Condensed nuclei fragmented as the cell
death process continued (Figure 6 D Hoechst panel), and significant blebbing of the plasma
became evident during the latter stages. Together this sequence of events is consistent with an
apoptotic mode of cell death. Following 24 hours exposure to cDDP, the vast majority of
A549-WT cells displayed morphological changes and abnormal nuclei. Incubation of A549-
CR cells with cDDP induced morphological changes in a number of cells as described for
A549-WT cells, again consistent with apoptotic cell death. These changes followed a similar
time course, with the first morphologically altered cells appearing approximately 6 hours post
drug addition. However, in contrast to the A549-WT cell line, most A549-CR cells did not
undergo morphological changes in plasma membrane and nuclear structure during the cDDP
treatment period (Figure 6 E), consistent with the cDDP resistant phenotype of this cell line.
The marked decrease in Hoechst fluorescence intensity in cells not undergoing morphological
changes is likely due to a combination of dye extrusion by live cells and bleaching of the
fluorophore due to the imaging process (Figure 6 C, D & E).
During mitosis cells adopt a distinct morphology from both apoptotic cells and those cells not
undergoing division (Figure 6 A and B). It is notable that whilst a number of cells were
observed to divide up to approximately 7 hours after cDDP treatment, cell division ceased
thereafter (Table 1). There was no statistically significant difference in the time at which the
last successful cell division occurred after cDDP treatment between A549-WT and A549-CR
cells. Dividing cells were observed throughout the 24 hour imaging period in untreated
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control cells. Thus, treatment of cells with 75 µM cDDP inhibited cellular proliferation in
both the A549-WT and A549-CR cell lines.
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Figure 6 C: Under normal growth conditions cell death is uncommon in A549 cells.
Dividing cells were commonly observed throughout the entire experimental period in both
A549 cell lines incubated in normal growth medium (black arrows, Bright Field panel).
Rarely, single cells adopted a small, rounded irregular plasma membrane morphology (white
arrow, Bright Field panel) and condensed fragmented nuclear morphology (white arrow,
Hoechst panel) characteristic of dying cells, whilst the majority of cells did not undergo
morphological changes.
Figure 6 D: Exposure to cDDP induced apoptosis in A549-WT cells. A549-WT cells were
prepared for time lapse imaging of cellular morphology as described in ‘Methods 2.5’, and
maintained in normal cell culture medium + 75 µM cDDP from the beginning of the imaging
process. Morphology characteristic of cell division was observed at the start of the
experimental time period before cDDP addition (black arrows mark representative cells,
Bright Field panel, 0 hours). Cells adopting morphology associated with apoptosis first
appeared approximately 6 hours post cDDP addition, characterised by reduced cell size, a
rounded cellular shape and irregular plasma membrane structure (white arrows mark
representative cells, Bright Field panel), with concomitant condensation and fragmentation of
nuclei (white arrows mark representative cells, Hoechst panel). The majority of cells
undergoing such morphological changes had begun to do so 12 hours post drug addition.
Figure 6 E: Exposure to cDDP induced apoptosis in A549-CR cells. A549-CR cells were
prepared for time lapse imaging of cellular morphology as described in ‘Methods 2.5’, and
maintained in normal cell culture medium + 75 µM cDDP from the beginning of the imaging
process. Cells adopting morphology associated with apoptosis first appeared approximately 6
hours post cDDP addition, characterised by reduced cell size, a rounded cellular shape and
irregular plasma membrane structure (white arrows mark representative cells, Bright Field
panel), with concomitant condensation and fragmentation of nuclei (white arrows mark
representative cells, Hoechst panel). The majority of cells undergoing such morphological
changes had begun to do so 12 hours post drug addition. The majority of cells did not
undergo morphological changes during the experimental time period.
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Table 1: cDDP treatment inhibits cell division in A549 cells. A549-WT and A549-CR
cells were incubated in normal cell culture medium or normal cell culture medium + 75 µM
cDDP in a heated imaging chamber, and images acquired throughout the 24 hour treatment
period. Cell divisions were counted as outlined in ´Methods 2.5’. There was no statistically
significant difference between the time of the last successful cell division which occurred in
A549-WT and A549-CR cells after cDDP addition.
Mean Time Last Successful Cell
Division Completed / minutes
Experiment
1
Experiment
2
Experiment
3
Mean /
minutes
Standard
Deviation
S.E.M.
A549-WT
n = 10
1149 1440 1433 1436 166.1 95.9
A549-WT
+ cDDP
n = 10
327 443 349 373 61.6 35.6
A549-CR
n = 10
1055 1440 1435 1437 221.0 127.6
A549-CR
+ cDDP
n = 10
341 482 458 427 75.4 43.6
3.1.4 Activation of Caspases, But Not Calpains, is Involved in cDDP Induced A549-WT
Cell Death
Incubation of A549-WT cells with 75 μM cDDP leads to cell death with an apoptotic 
morphology. Apoptosis is mediated through the proteolytic activation of executioner
caspases. The involvement of these proteases was confirmed by assessing the effect of the
pan-caspase inhibitor z-VAD-FMK on cDDP induced cell death. Whilst the basal rate of cell
death in control cells was unaffected by caspase inhibition, incubation of A549-WT cells with
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75 μM cDDP + 20 μM z-VAD-FMK significantly decreased the percentage of PI positive 
cells measured after 24 hours cDDP exposure (33.3 ± 5.6% PI positive, p < 0.05) compared
with A549-WT cells without caspase inhibition (52.8 ± 9.6% PI positive, p < 0.05) (Figure
7).
It has been suggested that activation of caspase-8 may be involved in mediating cDDP
induced cell death (Lacour et al., 2004; Toyozumi et al., 2004). To determine whether
caspase-8 activation contributed to cDDP induced cell death in this A549 cell model, A549-
WT cells were incubated with caspase-8 inhibitor IETD-FMK during the cDDP treatment
period. No significant difference in the percentage of PI positive cells was measured between
A549-WT cells treated with both 2 µM IETD-FMK and 75 µM cDDP and A549-WT cells
treated with 75 µM cDDP without caspase-8 inhibition (42.5 ± 1.23% PI positive vs. 40.3 ±
6.5% PI positive, respectively, p < 0.05) (Figure 8), suggesting caspase-8 is not required for
cDDP-induced cell death in this model. IETD-FMK did not alter cell death in control A549-
WT cells without exposure to cDDP.
Inhibition of caspases could not fully prevent cell death caused by cDDP. Calpain proteases
are also capable of engaging the cell death pathway in a pro-apoptotic manner, and thus the
effect of calpain inhibition using the pharmacological inhibitor ALLN was also studied. No
significant difference in the percentage of PI positive cells was measured between A549 cells
incubated in normal cell culture medium + 75 µM cDDP + 50 µM ALLN and control A549
cells treated with cDDP without calpain inhibition (Figure 9). Thus, under the present
experimental conditions, calpain activation does not play a major role in cDDP induced cell
death of A549-WT cells.
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Figure 7: Pharmacological inhibition of caspases inhibits cDDP induced cell death in
A549-WT cells. A549-WT cells were incubated in normal cell culture medium or normal cell
culture medium + 75 µM cDDP in the absence or presence of 20 μM pan-caspase inhibitor z-
VAD-FMK for 24 hours, and cytotoxicity assayed by PI exclusion as outlined in ‘Methods
2.4’. Data represent the mean of three independent experiments + S.E.M. * p < 0.05. ** p <
0.01.
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Figure 8: Pharmacological inhibition of caspase-8 does not inhibit cDDP induced cell
death in A549-WT cells. A549-WT cells were incubated in normal cell culture medium or
normal cell culture medium + 75 µM cDDP in the absence or presence of 2 μM caspase-8 
inhibitor IETD-FMK for 24 hours, and cytotoxicity assayed by PI exclusion as outlined in
‘Methods 2.4’. Data represent the mean of three independent experiments + S.E.M. ** p <
0.01.
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Figure 9: Pharmacological inhibition of calpains does not inhibit cDDP induced cell
death in A549-WT cells. A549-WT cells were incubated in normal cell culture medium or
normal cell culture medium + 75 µM cDDP in the absence or presence of 50 μM calpain 
inhibitor ALLN for 24 hours, and cytotoxicity assayed by PI exclusion as outlined in
‘Methods 2.4’. Data represent the mean of three independent experiments + S.E.M. ** p <
0.01.
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3.1.5 CsA Does Not Prevent Cell Death in A549-WT Caused by cDDP
Opening of the mPTP is associated with necrotic cell death, and may mediate the cytotoxic
effects of some chemotherapy drugs. Thus far, the only known component of the mPTP to be
verified as playing a major role in opening of the pore is Cyp D. To determine whether
necrotic cell death acting through mPT contributes to cDDP induced cell death in the present
A549 cell model, A549-WT cells were incubated for 24 hours with 75 μM cDDP in the 
absence or presence of 5 μM CsA, an inhibitor Cyp D activity known to inhibit mPT 
(Griffiths & Halestrap, 1993). CsA treatment did not prevent loss of plasma membrane
integrity in A549-WT cells caused by cDDP, but rather caused a significant increase in the
percentage of PI positive cells measured after 24 hours exposure to 75 µM cDDP relative to
A549-WT cells treated with 75 µM cDDP without CsA pre-treatment (73.2 ± 1.0% and 61.9
± 0.6% respectively, p < 0.05) (Figure 10).
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Figure 10: Pre-incubation of A549-WT cells with CsA increases cDDP induced cell
death in A549-WT cells. A549-WT cells were incubated in normal cell culture medium or
normal cell culture medium + 75 µM cDDP in the absence or presence of 5 μM CsA, an 
inhibitor of mPT, for 24 hours, and cytotoxicity assayed by PI exclusion as outlined in
‘Methods 2.4’. Data represent the mean of three independent experiments + S.E.M. * p <
0.05.
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3.1.6 cDDP Induced ROS Production is Greater in A549-WT Cells Than in A549-CR Cells
It has been reported that cDDP treatment may cause an increase in the rate of intracellular
ROS production, leading to cell death in a number of cell types (Brozovic, Ambriović-Ristov, 
& Osmak, 2010). Thus ROS production was measured in A549-WT cells and A549-CR cells
using ROS sensitive fluorescent dyes to investigate whether incubation with cDDP altered the
rate of ROS production in the present cell model. No significant difference was observed in
the rate of increase in fluorescence of DCF between A549-WT cells and A549-CR cells
incubated in normal cell culture medium, indicating a comparable rate of production of H2O2
(Figure 11). Following 24 hours incubation with 75 µM cDDP, a significant increase in the
rate of change in fluorescence of DCF was observed in A549-WT cells relative to control
A549-WT cells without cDDP exposure (0.46 ± 0.03 AU/ minute vs 0.90 ± 0.11 AU/ minute
respectively, p < 0.01), however no significant change was observed in the rate of change of
DCF fluorescence measured in A549-CR cells following the same cDDP treatment period,
relative to control A549-CR cells without cDDP exposure (Figure 11).
ROS production was further investigated in both A549 cell lines using DHE and MitoSox to
investigate cytoplasmic and mitochondrial O2•‾ production respectively. No significant
difference in fluorescence intensity was measured in A549-WT cells and A549-CR cells
loaded with DHE or MitoSox following incubation in normal cell culture medium. A
significant increase in fluorescence intensity was observed in A549-WT cells incubated with
75 µM cDDP over 24 hours, relative to control A549-WT cells without cDDP exposure, in
cells loaded with either DHE (122.0 ± 8.1 AU vs 75.1 ± 6.3 AU respectively, p < 0.05)
(Figure 12) or MitoSox (68.5 ± 12.7 AU vs 7.9 ± 1.9 AU respectively, p < 0.05) (Figure 13).
Similarly, fluorescence intensity measured in A549-WT cells incubated with 75 µM cDDP
over 24 hours, relative to control A549-WT cells without cDDP exposure, in cells loaded
with either DHE (83.0 ± 4.2 AU vs 58.9 ± 2.0 AU respectively, p < 0.05) (Figure 12) or
MitoSox (27.2 ± 3.0 AU vs 10.3 ± 1.4 AU respectively, p < 0.05) (Figure 13). The change in
flourescence intensity of DHE (Figure 12) and MitoSox (Figure 13) following cDDP
exposure was significantly greater in A549-WT cells than in A549-CR cells.
Thus, prior to cDDP treatment, no significant difference in H2O2 or O2•‾ production exists
between A549-WT cells and A549-CR cells. Incubation with cDDP induces a significant
increase in H2O2 or O2•‾ production, however this effect is significantly more pronounced in
A549-WT cells than in A549-CR cells.
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Figure 11: Exposure to cDDP increases the rate of H202 production in A549-WT cells,
but does not alter the rate of H202 production in A549-CR cells. A549-WT cells and
A549-CR cells were incubated in normal cell culture medium or normal cell culture medium
+ 75 µM cDDP for 24 hours, and the rate of H202 production measured using a microplate
reader as the rate of increase in DCF fluorescence in cells incubated in buffer solution
containing 2 µM DCF over 40 minutes. Data represent the mean of three independent
experiments + S.E.M. * p < 0.05.
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Figure 12: Exposure to cDDP increases cytosolic O2•‾ production in A549-WT cells, but
does not alter cytosolic O2•‾ production in A549-CR cells. A549-WT cells and A549-CR
cells were incubated in normal cell culture medium or normal cell culture medium + 75 µM
cDDP for 24 hours, and cytosolic O2•‾ production measured using a microplate reader as the
intensity of fluorescence in cells loaded with 0.5 µM DHE for 20 minutes following the
incubation period. Data represent the mean of three independent experiments + S.E.M. * p <
0.05.
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Figure 13: Exposure to cDDP increases mitochondrial O2•‾ production in A549-WT
cells, but does not alter mitochondrial O2•‾ production in A549-CR cells. A549-WT cells
and A549-CR cells were incubated in normal cell culture medium or normal cell culture
medium + 75 µM cDDP for 24 hours, and mitochondrial O2•‾ production measured using a
microplate reader as the intensity of fluorescence in cells loaded with 5 µM MitoSox for 10
minutes following the incubation period. Data represent the mean of three independent
experiments + S.E.M. * p < 0.05.
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3.1.7 Increased ROS Production is Not Required for A549-WT Cell Death Induced by
cDDP
Whilst exposure to cDDP over a 24 hour treatment period caused an increase in the rate of
ROS production in the cytosol and mitochondria of both A549-WT and A549-CR cells, the
increase was markedly less pronounced in cDDP-resistant A549-CR cells. Given that
increased ROS production may activate cell death pathways, these data suggested that
changes in ROS production might play a role in promoting cell death induced by cDDP, thus
the effect of incubation of A549-WT cells with antioxidants during the cDDP treatment
period was investigated. Addition of 5 mM NAC almost completely abolished the increase in
PI positive A549-WT cells measured after 24 hours exposure to 75 µM cDDP relative to
control A549-WT cells treated with 75 µM cDDP without NAC (15.4 ± 2.8% and 45.16 ±
9.0% respectively, p < 0.05) (Figure 14). However, NAC contains a prominent thiol group,
raising the possibility that this protective effect may have been due, at least in part, to a direct
chemical interaction with cDDP. Incubation with NAC reduced DNA damage-induced
phosphorylation of the H2AX histone subunit, suggesting a direct inhibition of DNA
modification by cDDP (Appendix IV). Direct proof of direct interaction between NAC and
cDDP would require the demonstration that incubation with NAC effectively prevents the
formation of DNA platination by cDDP, which is not dependent upon ROS production. No
significant difference was observed between the percentage of PI positive control A549-WT
cells measured after 24 hours exposure to 75 µM cDDP and A549-WT cells exposed to 75
µM cDDP + 200 µM TEMPOL (Figure 15) or 75 µM cDDP + 1 mM ascorbic acid
(Appendix I Figure 1), neither of which contain reactive thiol groups. It is notable that the
dataset for the effect of TEMPOL on cDDP-induced cell death at present lacks a positive
control, thus may not yet be properly interpreted. Treatment with cDDP causes an increase in
cellular O2•‾ production in A549-WT cells (Figure 12), thus to exclude ROS production as a
factor contributing to cell death in the present experimental system, the ability of TEMPOL
to prevent changes in O2•‾ generation following cDDP treatment must also be demonstrated.
Increased ROS production therefore does not appear to be required for cDDP induced cell
death in A549-WT cells.
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Figure 14: NAC fully prevents cDDP-induced cytotoxicity in A549-WT cells. A549-WT
cells were incubated in normal cell culture medium + 5 mM NAC or in normal cell culture
medium + 5 mM NAC + 75 µM cDDP for 24 hours and cytotoxicity assayed by PI exclusion
as outlined in ‘Methods 2.4’. Data represent the mean of three independent experiments +
S.E.M. * p < 0.05. ** p < 0.01.
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Figure 15: TEMPOL does not prevent cDDP-induced cytotoxicity in A549-WT cells.
A549-WT cells were incubated in normal cell culture medium + 200 µM TEMPOL or in
normal cell culture medium + 200 µM TEMPOL + 75 µM cDDP for 24 hours and
cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’. Data represent the mean of
three independent experiments + S.E.M. * p < 0.05.
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3.1.8 Akt Phosphorylation is Reduced in A549-CR Cells Relative to A549-WT Cells
Mutations in the mtDNA of cancer cells may lead to increased activity of Akt, a change
known to induce cell growth, protein translation and inhibit pro-apoptotic BCL-2 family
proteins, thus the phosphorylation state of Akt at the activating Ser473 residue (hereafter
‘phospho-Akt’) in A549-WT cells and A549-CR cells was investigated by western blotting
(Figure 16 A). The ratio of phospho-Akt to total cellular Akt detected by western blot was
reduced by approximately 45% in A549-CR cells relative to A549-WT cells (p < 0.05),
whilst 24 hours incubation with 75 µM cDDP caused an approximately 20% decrease in this
ratio in A549-WT cells relative to non-treated control A549-CR cells (p < 0.05), but did not
significantly alter this ratio in A549-CR cells (Figure 16 B). Thus, in comparison to A549-
WT cells, Akt activation is reduced in A549-CR cells both prior to and following exposure to
cDDP.
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Figure 16: Akt phosphorylation is significantly decreased in A549-CR cells relative to
A549-WT cells. A549-WT cells and A549-CR cells were incubated in normal cell culture
medium or normal cell culture medium + 75 µM cDDP for 24 hours, and the ratio of active
Ser473 phospho-Akt to total cellular Akt determined by western blot. (A) Representative
total Akt and Ser 473 phospho-Akt western blots. (B) Quantification of normalised Ser473
phospho-Akt : total Akt protein band intensities. Data were normalised to non-treated A549-
WT cells and represent the mean of three independent experiments + S.E.M. * p < 0.05.
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3.2 The Contribution of ER Ca2+ Signalling to cDDP-Sensitivity
3.2.1 IP3R Function is Inhibited in A549-CR Cells
Effects at the ER have been implicated in cDDP cytotoxicity, but the importance of this
organelle in the cellular response to cDDP remains unknown (Kawai et al., 2006; Mandic et
al., 2003). The question as to whether the ER plays a role in cDDP sensitivity in A549 cells
was first explored by making comparative measurements of ER function between A549-WT
and A549-CR cells. Ca2+ release is a central function of the ER in both a physiological and
pathophysiological context, thus the Ca2+ release properties of the ER were investigated in
A549-WT and A549-CR cells transfected with cytoplasmic aequorin cDNA constructs.
Stimulation of A549 cells with extracellular ATP results in Ca2+ efflux from the ER mediated
by IP3 binding to IP3Rs (Zhao et al., 2000). Addition of 100 μM ATP to A549-WT cells 
evoked a rapid cytosolic Ca2+ signal (peak [Ca2+]cyt = 1.08 ± 0.14 μM) (Figure 17 A), whilst 
no detectable changes in [Ca2+]cyt were observed in A549-CR cells (Figure 17 A). A
comparable number of photons were detected in experiments with both A549-WT and A549-
CR cells (Table 2), indicating equal expression of the probe. Challenge of control HeLa cells
with 100 μM ATP generated a rise in intracellular Ca2+ similar to that in A549-WT cells
(Figure 17 B).
The difference in intracellular Ca2+ response following application of extracellular ATP in the
two A549 cell lines might be equally well explained through altered purinergic receptor
expression, changes in the signalling pathway leading to IP3 generation or inhibition of ER
Ca2+ release. To further investigate this, the function of the IP3R in both cell lines was
directly probed using a cell permeable, photolabile caged IP3 compound (hereafter referred to
simply as ‘caged IP3’), and changes in [Ca2+]cyt measured using Fluo-4. Uncaging of caged
IP3 through UV illumination resulted in a rapid increase of Fluo-4 fluorescence in A549-WT
cells (peak = 1.18 ± 0.02 AU) and A549-CR cells (peak = 1.10 ± 0.02 AU) (Figure 18 A &
B). The difference in response of the two cell types was highly statistically significant (p <
0.01). Imaging of cells loaded with the caged IP3 compound without UV illumination did not
result in any Fluo-4 fluorescence changes (Figure 18 C & Appendix II Figure 1). IP3R
function is therefore reduced in A549-CR cells relative to the A549-WT cell line.
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Figure 17: Cytosolic Ca2+ signalling invoked by extracellular ATP is inhibited in A549-
CR cells, relative to A549-WT cells. A549-WT cells, A549-CR cells and HeLa cells
transiently transfected with cytoplasmically targeted aequorin were stimulated by perfusion
with KRB + 100 µM ATP, and bioluminescence recorded in a custom built luminometer.
Photon counts were calibrated to [Ca2+] as outlined in ‘Methods 2.5’. (A) Mean changes in
[Ca2+]cyt measured in A549-WT cells and A549-CR cells following challenge with
extracellular ATP. (B) Mean changes in [Ca2+]cyt measured in control HeLa cells following
challenge with extracellular ATP. Traces represent the mean response of a minimum of five
coverslips from three independent experiments ± S.E.M. * p < 0.05.
Table 2: Total number of photons collected over the entire experimental time-course
for ATP stimulation of aequorin transfected cells is comparable for A549-WT cells and
A549-CR cells.
Total Number of Detected Photons
Experiment 1 Experiment 2 Experiment 3 Experiment 4
A549-WT 510483 531447 1593459 1551850
A549-CR 340470 409805 812267 1579633
HeLa 15808570 26615256 20649907 15996487
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Figure 18: IP3R function is reduced in A549-CR cells relative to A549-WT cells. Cells
were loaded with photolabile caged IP3 and 5 µM Fluo-4-AM, and fluorescence intensity
recorded after IP3 uncaging caused by a period of UV illumination, as described in ‘Methods
2.6’. (A) Representative image sequence demonstrating changes in Fluo-4 fluorescence in
A549-WT cells prior to and following UV illumination. (B) Mean changes in dye bleaching
corrected normalised Fluo-4 fluorescence in A549-WT and A549-CR cells loaded with caged
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IP3 following UV illumination. (C) Mean changes in normalised Fluo-4 fluorescence without
dye bleaching correction in A549-WT cells loaded with caged IP3 without the UV
illumination period. Traces represent the mean response of a minimum of five coverslips
from four independent experiments ± S.E.M. * p < 0.05.
3.2.2 Decreased SOCE Following ER Ca2+ Store Depletion in A549-CR Cells
Activation of the SOCE pathway upon depletion of the ER Ca2+ store results in a prolonged
rise in [Ca2+]cyt, and allows for restoration of normal [Ca2+]ER. ER function plays a key role in
activating this Ca2+ entry pathway through the action of the integral ER membrane protein
STIM-1 activating the plasma membrane Orai Ca2+ channel upon a decrease in ER luminal
Ca2+. Given the IP3-induced Ca2+ release from the ER in A549-CR cells, ER function was
further studied by investigating the ability of the organelle to induce SOCE following
pharmacological depletion of the ER Ca2+ store. Further, since prolonged rises in
intracellular Ca2+ may activate both the apoptotic and necrotic pathways of cell death
(Section 1.2.6), and reduced intracellular Ca2+ signalling often correlates with reduced
sensitivity to apoptotic stimuli (Pinton, Giorgi, Siviero, Zecchini, & Rizzuto, 2008; R Rizzuto
et al., 2003), reduced activation of SOCE may contribute to the cDDP resistant phenotype of
A549-CR cells. Indeed, knockdown of Orai expression has previously been demonstrated to
reduce the sensitivity of prostate cancer cells to cDDP (Flourakis et al., 2010).
[Ca2+]cyt was measured using aequorin targeted to the cytoplasm, and depletion of Ca2+ from
the ER induced by addition of 500 nM Tg. To differentiate between Ca2+ release induced by
Tg and influx of extracellular Ca2+ into the cytoplasm, Tg treatment occurred in nominally
‘Ca2+ free’ KRB, and subsequent re-addition of Ca2+ to the extracellular buffer allowed
examination of Ca2+ influx pathways. Control cells were treated with nominally ‘Ca2+ free’
KRB without Tg before re-addition of Ca2+. It was not possible to identify increases in
[Ca2+]cyt attributable to emptying of Tg-sensitive Ca2+ stores in either A549 cell line, likely
due to the low Ca2+ affinity of aequorin which makes the probe unsuitable for measuring the
slow, low amplitude Ca2+ signals caused by Tg (Figure 19 B & D). Re-addition of Ca2+ to the
external buffer solution generated a large cytosolic Ca2+ signal (peak [Ca2+]cyt = 2.89 ± 0.12
μM) in A549-WT cells after treatment with Tg (Figure 19 B). Control A549-WT cells 
showed much smaller changes in [Ca2+]cyt, peaking at less than 1 μM, upon return to buffer 
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containing Ca2+ (Figure 19 A). Conversely, the increase in [Ca2+]cyt in A549-CR cells upon
reperfusion of buffer containing Ca2+ was not significantly greater in Tg treated cells (Figure
19 D) than in control A549-CR cells (Figure 19 C), and did not exceed 1 μM in either case. 
The total number of photons detected resulting from aequorin bioluminescence in
experiments with both A549-WT and A549-CR cells were again comparable, indicating
comparable aequorin expression in the cell lines. (Table 3).
SOCE following depletion of ER Ca2+ was further investigated using Fura-2. A549 cells
loaded with the Ca2+ indicator dye were again treated with 500 nM Tg in nominally 'Ca2+
free' KRB before the reintroduction of Ca2+ to the extracellular buffer. Emptying of ER Ca2+
into the cytosol after Tg addition was evident in both cell lines as a similar prolonged low
amplitude increase in the normalised Fura-2 fluorescence ratio (A549-WT peak = 1.12 ± 0.03
AU, A549-CR peak = 1.14 ± 0.02 AU) (Figure 20 A). Addition of Ca2+ to the buffer solution
after 5 minutes Tg treatment caused a 2-fold increase in the normalised Fura-2 fluorescence
ratio in A549-WT cells (peak = 1.98 ± 0.03 AU) and a 1.5-fold increase in A549-CR cells
(peak = 1.57 ± 0.09 AU) (Figure 20 A). The difference in peak response after Ca2+ readdition
is statistically significant (p < 0.05). Control cells did not undergo Tg treatment. No changes
in normalised Fura-2 fluorescence ratio were measured upon addition of extracellular Ca2+ to
the buffer solution in control cells of either A549 cell line (Figure 20 B). SOCE is thus
diminished in A549-CR cells relative to A549-WT cells.
Table 3: Total number of photons collected over the entire experimental time-course for
investigation of SOCE in aequorin transfected cells is comparable for A549-WT cells
and A549-CR cells.
Total Number of Detected Photons
Experiment 1 Experiment 2 Experiment 3 Experiment 4
A549-WT 153629 258119 202651 -
A549-WT + Tg 201835 408866 352746 -
A549-CR 428524 522684 979947 1254771
A549-CR + Tg 597870 443226 - -
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Figure 19: SOCE following pharmacological depletion of [Ca2+]ER is reduced in A549-
CR cells relative to A549-WT cells. A549-WT cells and A549-CR cells transiently
transfected with cytoplasmic aequorin were incubated with 500 nM Tg in nominally ‘Ca2+
free’ KRB to deplete the ER Ca2+ store, before readdition of Ca2+ to the bathing buffer
solution. Bioluminescence was recorded in a custom built luminometer and photon counts
were calibrated to [Ca2+] as outlined in ‘Methods 2.5’. (A) Mean [Ca2+]cyt measured in A549-
WT cells and (C) mean [Ca2+]cyt measured in A549-CR cells upon reperfusion of Ca2+
containing buffer following 5 minutes incubation in nominally ‘Ca2+ free KRB’. (B) Mean
[Ca2+]cyt measured in A549-WT cells and (D) mean [Ca2+]cyt measured in A549-CR cells
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upon reperfusion of Ca2+ containing buffer following 5 minutes incubation in nominally
‘Ca2+ free KRB’ + 500 nM Tg. Traces represent the mean response of a minimum of five
coverslips from three independent experiments ± S.E.M. * p < 0.05.
Figure 20: SOCE following pharmacological depletion of [Ca2+]ER is reduced in A549-
CR cells relative to A549-WT cells. A549-WT cells and A549-CR cells loaded with Fura-2
were incubated with 500 nM Tg in nominally ‘Ca2+ free’ KRB to deplete the ER Ca2+ store,
before readdition of Ca2+ to the bathing buffer solution. (A) Mean normalised Fura-2 340 nm
: 380 nm ratio measured in A549-WT cells and A549-CR cells upon reperfusion of Ca2+
containing buffer following incubation in nominally ‘Ca2+ free KRB’ + 500 nM Tg. (B)
Mean normalised Fura-2 340 nm : 380 nm ratio measured in A549-WT cells and A549-CR
cells upon reperfusion of Ca2+ containing buffer following incubation in nominally ‘Ca2+ free
KRB’. Traces were normalised relative to A549-WT cells and represent the mean response of
a minimum of seven coverslips from three independent experiments ± S.E.M. * p < 0.05.
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3.2.3 IP3R-1 Expression Level Does Not Alter A549-WT cDDP Sensitivity
Reduced expression of IP3Rs in A549-CR cells could account for the inhibition of IP3-
dependent Ca2+ signalling observed in this cell line. Decreased expression of IP3R-1 relative
to the parental cells in a bladder cancer cell line with acquired cDDP-resistance has
previously been demonstrated to closely associate with the acquisition of drug resistance
(Tsunoda et al., 2005). IP3R-1 is highly expressed in A549 cells (H. Xue et al., 2000), and in
light of the previous literature linking IP3R-1 to cellular sensitivity to cDDP treatment, this
isoform was selected for further investigation in this study. The relationship between the
expression of IP3R-1 and cDDP resistance was investigated thus in the present cell model.
Western blot analysis was performed on both A549-WT and A549-CR cells without drug
treatment and after 24 hours incubation with 75 μM cDDP. No difference in the level of 
IP3R-1 protein expression was observed between untreated control A549-WT and A549-CR
cells (Figure 21 A & B). Likewise, cDDP did not significantly alter the expression of IP3R-1
in A549-WT or A549-CR cells, nor was there any difference in the expression of this IP3R
isoform between cDDP treated A549-WT and A549-CR cells (Figure 21 A & B).
The potential for modulating the IP3R expression level as a means of increasing the efficacy
of cDDP treatment was further investigated by overexpressing IP3R-1 in A549-WT and
A549-CR cells. Transient transfection of an IP3R-1 construct dramatically increased the
protein expression level of IP3R-1, as measured by western blot (Figure 22 A). However, the
percentage of PI positive cells after 24 hours treatment using 75 μM cDDP did not differ 
between untransfected A549-WT cells (45.9 ± 5.0%), A549-WT cells transfected with the
IP3R-1 construct (47.7 ± 7.8%) nor A59-WT cells transiently transfected with a control ER-
targetted GFP construct (48.2 ± 6.0%) (Figure 22 B). A549-CR cells transiently transfected
with ER-GFP or IP3R-1 showed a marked basal toxicity in comparison to A549-WT cells
transfected with the same cDNA constructs (Figure 21 B). No difference in the percentage of
PI positive cells measured after 24 hours incubation with 75 μM cDDP was observed 
between A549-CR cells expressing ER-GFP (47.2 ± 6.3%) or A549-CR cells overexpressing
IP3R-1 (51.0 ± 6.3%) (Figure 22 B). The transfection efficiency of siRNA targeted towards
IP3R-1 mRNA did not prove effective enough for efficient IP3R-1 silencing in either A549-
WT cells or A549-CR cells (data not shown), thus this approach did not form part of the
investigation.
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Together these data show the expression level of the IP3R-1 is not a modulator of cDDP
sensitivity in this A549 cell model.
Figure 21: IP3R-1 expression does not differ between A549-WT cells and A549-CR cells.
A549-WT cells and A549-CR cells were incubated in normal cell culture medium or normal
cell culture medium + 75 µM cDDP for 24 hours before immunoblotting as described in
‘Methods 2.8’. (A) Representative IP3R-1 western blot. (B) Quantification of IP3R-1 band
intensity. Data represents the mean of three independent experiments + S.E.M.
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Figure 22: IP3R-1 overexpression does not alter A549-WT cell cDDP sensitivity. A549-
WT cells and A549-CR cells transfected with ER-GFP or an IP3R-1/ GFP construct were
incubated in normal cell culture medium or normal cell culture medium + 75 µM cDDP 24
hours, and cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’. (A)
Representative IP3R-1 western blot for untransfected control and IP3R-1/ GFP transfected
A549-WT cells and A549-CR cells. (B) Percentage of PI positive cells measured following
incubation of control, ER-GFP transfected and IP3R-1/ GFP transfected A549-WT cells and
A549-CR cells with cDDP. Note increased basal toxicity in A549-CR cells following
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transfection. Data represent the mean of three independent experiments + S.E.M. * p < 0.05.
** p < 0.01.
3.2.4 Chelation of Intracellular Ca2+ Modulates A549-WT Cell Death Induced by cDDP
A549-CR cells exhibited decreased intracellular Ca2+ signalling in comparison with A549-
WT cells. Since increases in intracellular Ca2+ may activate cell death pathways, the potential
for modulating Ca2+ signalling as a means to alter A549-WT sensitivity to cDDP was
investigated using the cell permeable Ca2+ chelator BAPTA-AM. A549-WT cells were pre-
incubated with 1 μM, 3 μM or 10 μM BAPTA-AM for 30 minutes before 24 hours incubation 
with 75 μM cDDP. BAPTA-AM did not cause toxicity in A549-WT cells without cDDP 
addition over a 24 hour period at any concentration tested (Figure 23). Ca2+ chelation using 1
μM or 3 μM BAPTA-AM did not cause a statistically significant decrease in the percentage 
of cells which lost plasma membrane integrity after cDDP treatment, as measured by PI
staining. Pre-treatment with 10 μM BAPTA-AM provided a 10% decrease in PI positive cells 
caused by cDDP compared to control A549-WT cells without Ca2+ chelation (41.3 ± 3.7%
and 52.3 ± 2.2% respectively, p < 0.05) (Figure 23).
Cell death induced by cDDP in A549-WT cells is partially dependent upon Ca2+,
demonstrated by the protective effect of 10 μM BAPTA-AM during cDDP exposure. To 
determine whether this effect reflects a requirement for extracellular Ca2+, A549-WT cells
were pre-incubated with 1 mM EGTA for 30 minutes prior to 75 μM cDDP treatment. As the 
plasma membrane is impermeable to EGTA, pre-incubation of cells with EGTA can chelate
extracellular Ca2+ but not prevent intracellular Ca2+ signalling. No difference in the
percentage of PI positive cells caused by 24 hours cDDP treatment was observed between
control cells and those pre-incubated with EGTA (Figure 25), indicating changes in
intracellular Ca2+ homeostasis, rather than chelation of external Ca2+, are responsible for the
protective effects of BAPTA-AM.
It is notable that both the dataset concerning the effect of BAPTA-AM and that concerning
the effect of EGTA on cDDP-induced cell death lack positive control data to demonstrate that
these agents inhibit cellular Ca2+ signalling in the expected manner, and thus may not yet be
properly interpreted. As an appropriate control experiment, the ability of each Ca2+ chelator
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to inhibit changes in [Ca2+]cyt in A549-WT cells upon stimulation with extracellular ATP
relative to cells stimulated without Ca2+ chelation, following 24 hours incubation with the
chelator, should be demonstrated, thus ensuring that Ca2+ signalling is effective prevented
over the entire 24 hour cDDP treatment period. In the case of BAPTA-AM treatment,
changes in intracellular Ca2+ should be expected to be greatly reduced. In the case of EGTA,
the initial peak in [Ca2+]cyt, resulting from intracellular stores, should be unaffected, however
the plateau in raised cytosolic Ca2+ levels attributable to SOCE should not occur, or be
greatly reduced, as EGTA treatment is expected to reduce the extracellular free Ca2+
concentration to nominal levels. These effects of BAPTA-AM and EGTA have been
previously extensively demonstrated in wide variety of primary cells and cancer cell lines
(Berridge et al., 2003).
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Figure 23: Ca2+ chelation by BAPTA-AM partially inhibits cDDP-induced cell death in
A549-WT cells. A549-WT cells were incubated in normal cell culture medium or normal cell
culture medium + 75 µM cDDP in the presence of BAPTA-AM in the concentration range 0
– 10 µM for 24 hours, and cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’.
Data represent the mean of three independent experiments + S.E.M. * p < 0.05.
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Figure 24: Ca2+ chelation by EGTA does not inhibit cDDP-induced cell death in A549-
WT cells. A549-WT cells were incubated in normal cell culture medium or normal cell
culture medium + 75 µM cDDP in the presence of 1.4 mM EGTA for 24 hours, and
cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’. Data represent the mean of
three independent experiments + S.E.M. ** p < 0.01.
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3.2.5 Oxidative Stress Induced Through TMRM Photoactivation Does Not Model
Pathophysiological ER-Mitochondria Ca2+ Transfer in A549 Cells
Cell death induced by cDDP in cDDP-sensitive A549-WT cells appeared to have a partial
requirement for intracellular Ca2+. Furthermore, cDDP-resistant A549-CR cells showed an
inhibition of intracellular Ca2+ responses after stimulation with extracellular ATP, an IP3
releasing ligand, or direct activation of the IP3R. Together these data suggested that Ca2+
release from the ER could participate in mediating cDDP toxicity. Since the IP3R forms part
of a complex directly regulating Ca2+ transfer along the ER-mitochondria axis (Szabadkai et
al., 2006), decreased function of this channel may render A549-CR cells less sensitive to cell
death caused by mitochondrial Ca2+ overload. To examine this possibility, a model of
phototoxicity induced by TMRM illumination was employed.
In some cell types, mitochondria loaded with rhodamine dyes have been shown to undergo
store Ca2+ dependent depolarisation, mediated by the mPT, in response to ROS generated by
dye illumination inducing Ca2+ release from the ER/SR, presumably through IP3Rs and RyRs
(Jacobson & Duchen, 2002). This process is characterised by transient ‘flickering’
depolarisations of one or more mitochondria, followed by a global collapse of ΔΨm. Indeed,
such short lived changes in ΔΨm were observed in both A549 cell lines loaded with 200 nM
TMRM within approximately 15 minutes of continuous illumination (Figure 25 A). This
period of transient loss and recovery of ΔΨm was followed by a steady decline in ΔΨm
throughout the experimental time course, followed up to 50 minutes continuous illumination.
No significant difference existed in either the kinetics of depolarisation of mitochondria or in
the final TMRM fluorescence intensity between A549-WT and A549-CR cells (Figure 25 B).
However, neither the period of transient ‘flickering’ nor the slow global loss of ΔΨm in A549-
WT cells could be prevented by store Ca2+ depletion prior to illumination using 500 nM Tg +
2mM EGTA nor 2mM EGTA + 1 µM BAPTA-AM (Figure 25 C). Furthermore,
preincubation of A549-WT cells with 1 or 10 M CsA, an inhibitor of Cyp D, did not
alter this depolarisation (Figure 25 C). In contrast, addition of 1 mM ascorbic acid at the
beginning of the illumination period fully prevented A549-WT mitochondrial depolarisation
(Figure 25 D), whilst A549-WT cells loaded with 50 nM TMRM did not undergo any
changes in ΔΨm over the experimental time course (Figure 25 E). Together these data
demonstrate that TMRM phototoxicity in A549-WT cells is not dependent upon
interorganelle Ca2+ transfer but is fully mediated by the production of ROS above a certain
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threshold level, thus is not an appropriate model to investigate pathophysiological ER-
mitochondrial communication in the A549 cell line.
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Figure 25: Loss of ΔΨ in A549 cells induced by TMRM photoactivation does not occur 
through Ca2+ dependent mPT, but is fully dependent upon ROS generation. To attempt
to model pathological interorganelle Ca2+ transfer between the ER and mitochondria, A549-
WT cells and A549-CR cells loaded with 200 nM TMRM were imaged continuously for 50
minutes, and TMRM fluorescence intensity measured to monitor changes in ΔΨ occurring in 
this period, as outlined in ‘Methods 2.9’. (A) Representative image sequence demonstrating
transient loss of ΔΨ (‘flickering’) observed in both A549-WT cells and A549-CR cells within 
15 minutes of continuous illumination. Depolarised mitochondria are marked by the white
arrow. (B) Mean normalised TMRM fluorescence intensity measured in A549-WT cells and
A549-CR cells under 50 minutes continuous illumination. Traces were normalised to the
mean fluorescence of the first ten images and represent the mean of at least seven coverslips
from three independent experiments ± S.E.M. (C) Representative normalised TMRM
fluorescence intensity measured in A549-WT cells under 50 minutes continuous illumination
following depletion of cellular Ca2+ using 500 nM TG + 2 mM EGTA or 1 µM BAPTA-AM
+ 2 mM EGTA, or pre-incubation with 1 µM or 10 µM Cyp D inhibitor CsA. (D) Mean
normalised TMRM fluorescence intensity measured in A549-WT cells under 50 minutes
continuous illumination in the presence of 1 mM ascorbic acid. (E) Mean normalised TMRM
fluorescence intensity measured in A549-WT cells loaded with 50 nM TMRM under 50
minutes continuous illumination. Traces were normalised to the fluorescence of the first ten
images and represent the mean of at least two coverslips from two independent experiments ±
S.E.M.
3.2.6 cDDP Treatment Does Not Deplete ER Ca2+
IP3R function is reduced in A549-CR cells, whilst pre-incubation with 10 μM BAPTA-AM, 
but not 1 mM EGTA, afforded some inhibition of A549-WT cell death after cDDP treatment,
suggesting Ca2+ release from the ER may contribute to cDDP cytotoxicity. To determine
whether cDDP treatment caused depletion of the ER Ca2+ store, comparative measurements
of [Ca2+]ER were made in control A549-WT and A549-CR cells without cDDP treatment and
in A549-WT and A549-CR cells after treatment with 75 μM cDDP over a 24 hour period, 
using the FRET-based, ER-targeted cameleon probe D1ER (Palmer et al., 2004). Basal
[Ca2+]ER did not significantly differ between A549-WT cells (‘FRET-ratio’ = 1.24 ± 0.04
AU) and A549-CR cells (‘FRET-ratio’ = 1.32 ± 0.07 AU) (Figure 26). Although incubation
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with cDDP is associated with an increasing trend in the ‘FRET-ratio’ of the probe in both
A549-WT cells (‘FRET ratio’ = 1.49 ± 0.07 AU) and A549-CR cells (‘FRET ratio’ = 1.64 ±
0.16 AU), there is no statistically significant difference in ‘FRET-ratio’ between non-treated
and cDDP treated cells of either A549 cell line, nor between cDDP treated A549-WT cells
and cDDP treated A549-CR cells (Figure 26). Pharmacological depletion of ER Ca2+ in
A549-WT cells using Tg was associated with a statistically significant decrease in the
‘FRET-ratio’ of the probe compared with untreated A549-WT cells (‘FRET-ratio’ = 0.78 ±
0.02 AU, p < 0.01) (Figure 26). The ER is thus not depleted of Ca2+ by 24 hours cDDP
treatment.
Exposure to cDDP has been reported to induce changes in [Ca2+]cyt in a number of cell types
(Al-Bahlani et al., 2011; Kawai et al., 2006; Splettstoesser, Florea, & Büsselberg, 2007)
within one hour of drug exposure. However, no cytosolic Ca2+ signals were observed using
Fura-2 in A549-WT cells or A549-CR cells up to one hour post addition of 75 µM cDDP to
the cell bathing solution (Figure 27). No changes in [Ca2+]cyt were observed in control A549-
WT cells and A549-CR imaged under the same conditions without cDDP treatment (Figure
27).
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Figure 26: ER store Ca2+ content is not depleted by cDDP treatment in either A549-WT
cells or A549-CR cells. A549-WT cells and A549-CR cells transiently transfected with the
ER targeted D1ER cameleon Ca2+ probe were incubated in normal cell culture medium or
normal cell culture medium + 75 µM cDDP for 24 hours. Control A549-WT cells were
incubated in KRB + 500 nM Tg + 1.4 mM EGTA for 10 minutes to deplete ER store Ca2+
before measurement. D1ER ‘FRET ratio’ was used as an indicator of [Ca2+]ER, and estimated
by acceptor photobleaching as described in ‘Methods 2.10’. Data represent the mean of three
independent experiments + S.E.M. * p < 0.05.
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Figure 27: cDDP treatment does not cause acute changes in [Ca2+]cyt in A549-WT cells
or A549-CR cells. Flouresence in A549-WT cells and A549-CR cells loaded with Fura-2
was monitored for one hour in the absence or presence of 75 µM cDDP in a heated imaging
chamber. (A) Mean normalised Fura-2 340 nm : 380 nm ratio measured in A549-WT cells
and (C) A549-CR cells without cDDP exposure. (B) Mean normalised Fura-2 340 nm : 380
nm ratio measured in A549-WT cells and (D) A549-CR cells following addition of 75 µM
cDDP. Traces were normalised relative to non-treated A549-WT cells and represent the mean
of three independent experiments ± S.E.M.
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3.2.7 IP3R Inhibition by 2-APB Does Not Inhibit cDDP-Induced A549-WT Cell Death
Although cDDP does not decrease the [Ca2+]ER, Ca2+ signalling through IP3Rs could play a
role in the induction of cell death in a manner which does not cause chronic store depletion.
To test whether Ca2+ release through IP3Rs is involved in cell death signalling after cDDP
treatment, the effect of the addition of the cell permeable IP3R channel blocker 2-
aminoethoxydiphenyl borate (2-APB) prior to cDDP treatment was investigated. As a control
experiment, pre-treatment of A549-WT cells with 10 µM 2-APB for 30 minutes completely
inhibited changes in [Ca2+]cyt in A549-WT cells induced by the addition of 100 µM ATP to
the external buffer medium, as measured by Fura-2 (p < 0.05) (Figure 28), confirming the
ability of this agent to block intracellular Ca2+ signalling in A549-WT cells. Having validated
the action of 2-APB in the present A549 cell model, the potential role of IP3R-mediated Ca2+
release in cDDP-induced cell death was investigated through pharmacological inhibition of
the receptor Ca2+ channel. A549-WT cells were incubated with 10 μM 2-APB for 30 minutes 
prior to, and during, treatment with 75 μM cDDP. The percentage of PI positive cells after 
cDDP treatment over a 24 hour period was not significantly different in control A549-WT
cells exposed to cDDP in normal cell culture medium or A549-WT cells pre-treated with 10
μM 2-APB prior to drug treatment (48.6 ± 9.3% vs. 46.9 ± 0.1% respectively) (Figure 29), 
demonstrating IP3R mediated Ca2+ release is not required for cell death induction by cDDP in
the A549-WT cell line.
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Figure 28: 2-APB prevents agonist-induced Ca2+ signalling in A549-WT cells. A549-WT
cells loaded with Fura-2 were challenged with 100 µM ATP. Cells treated with 2-APB were
pre-incubated with 10 µM 2-APB for 15 minutes prior to ATP challenge. Traces were
normalised relative to non-treated A549-WT cells and represent the mean of three
independent experiments ± S.E.M. * p < 0.05.
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Figure 29: 2-APB does not inhibit cDDP-induced cytotoxicity in A549-WT cells. A549-
WT cells were incubated in normal cell culture medium or in normal cell culture medium +
75 µM cDDP for 24 hours and cytotoxicity assayed by PI exclusion as outlined in ‘Methods
2.4’. Where indicated, cells were pre-incubated with 10 µM 2-APB for 15 minutes prior to
cDDP addition. Data represent the mean of three independent experiments + S.E.M.
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3.3.1 Cellular Level of GSH Tripeptide Does Not Differ Between A549-WT Cells and
A549-CR Cells
Although cell death induced by cDDP in A549-WT cells does not depend upon increased
ROS production, A549-CR cells produced ROS at a significantly reduced rate following 24
hours exposure to 75 µM cDDP compared to A549-WT cells under the same conditions,
potentially indicating that decreased ROS production may be a secondary result of another
adaptation in A549-CR cells. Increased cellular levels of GSH, a major cytosolic and
mitochondrial antioxidant peptide which may directly bind cDDP, is a recognised mechanism
of tumour cell cDDP resistance which might also explain the difference in the rate of ROS
production observed between A549-WT and A549-CR cells. However, no significant
difference in fluorescence intensity was measured in A549-WT and A549-CR cells loaded to
saturation with 50 mM MCB (Figure 30), indicating that the basal cellular GSH pool is
similar in both cell types. Furthermore, incubation of A549-WT and A549-CR cells with 75
µM cDDP for 24 hours caused a comparable small significant decrease of approximately 5%
in MCB fluorescence (p < 0.01) (Figure 30), thus increased ROS production following cDDP
treatment is not due to a greater depletion of GSH in A549-WT cells than in A549-CR cells.
Control A549-WT cells pre-incubated with 50 mM DEM for 15 minutes to deplete the
cellular GSH pool showed a significant decrease of approximately 40% in MCB fluorescence
(p < 0.01) (Figure 30), demonstrating that MCB may reliably detect changes in GSH in A549
cells.
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Figure 30: MCB fluorescence intensity does not differ between A549-WT cells and
A549-CR cells. A549-WT cells were incubated in normal cell culture medium or in normal
cell culture medium + 75 µM cDDP for 24 hours, and cellular GSH measured as the intensity
of fluorescence in cells loaded with 50 µM MCB for one hour following the incubation
period. Control A549-WT cells were incubated with 50 mM DEM for 15 minutes prior to
MCB loading. Data were normalised relative to non-treated A549-WT cells and represent the
mean of three independent experiments + S.E.M. * p < 0.05.
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3.3.2 Mitochondrial Function Does Not Differ Between A549-WT and A549-CR Cells
Mitochondria are the major source of intracellular ROS generation, and are closely linked to
cell fate, thus the difference in the rate of ROS production in A549-WT and A549-CR cells
after cDDP treatment may be indicative of altered mitochondrial function. This possibility
was investigated through comparison of functional state of mitochondria in A549-WT and
A549-CR cells without exposure to cDDP, measuring the parameters of ΔΨ and cellular O2
consumption. No significant difference was observed in the mean fluorescence signal
measured in A549-WT and A549-CR cells loaded with 50 nM TMRM, indicating that basal
ΔΨ before exposure to cDDP is comparable in both cell types (Figure 31). Similarly, the rate 
of cellular O2 consumption and the degree of respiratory uncoupling in mitochondria
measured with a Clark-type electrode did not differ significantly between A549-WT and
A549-CR cells which had not been incubated with cDDP (Figure 32 & Table 4). Therefore,
the basal activity of mitochondria in A549-WT and A549-CR cells is comparable before
exposure to cDDP.
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Figure 31: ΔΨ does not differ between A549-WT cells and A549-CR cells. A549-WT
cells and A549-CR cells were incubated in normal cell culture medium or in normal cell
culture medium + 75 µM cDDP for 24 hours, and ΔΨ measured as the intensity of 
fluorescence in maximal confocal projections of cells loaded with 50 nM TMRM. Data were
normalised relative to non-treated A549-WT cells and represent the mean of three
independent experiments + S.E.M.
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Figure 32: Cellular O2 consumption is increased in A549-WT cells and A549-CR cells
following cDDP treatment. A549-WT and A549-CR cells were cultured in 6 well tissue
culture plates for 24 hours in normal cell culture medium or normal cell culture medium + 75
µM cDDP. O2 consumption was measured using a Clark type electrode at 37 oC and
normalised relative to the number of cells present during the assay. Data represent the mean
of three independent experiments + S.E.M. * p < 0.05. ** p < 0.01.
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Table 4: The ratio of cellular O2 consumption due to uncoupled respiration : basal
cellular O2 consumption does not differ between A549-WT cells and A549-CR cells
under normal growth conditions or following exposure to cDDP. A549-WT cells and
A549-CR cells were incubated in normal cell culture medium or in normal cell culture
medium + 75 µM cDDP for 24 hours. O2 consumption was measured using a Clark type
electrode at 37 oC, and O2 consumption not due to oxidative phosphorylation was measured
following the addition of 7 µM oligomycin. Data were normalised relative to the number of
cells present during the assay.
A549-WT
A549-WT +
cDDP
A549-CR
A549-CR +
cDDP
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M.
Basal O2
Consumption/
nmol/cell/minute
3.43 0.29 7.84 0.92 3.43 0.39 5.00 0.29
Uncoupled O2
Consumption/
nmol/cell/minute
2.26 0.26 5.70 0.81 1.80 0.24 3.39 0.35
Ratio
‘Uncoupled :
Basal’
0.71 0.14 0.75 0.10 0.54 0.08 0.68 0.06
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3.3.3 cDDP Treatment Induces Increased Cellular Oxygen Consumption in A549-WT and
A549-CR Cells
A marked difference in the rate of intracellular ROS production was observed between A549-
WT and A549-CR exposed to cDDP, thus the functional state of mitochondria in A549-WT
and A549-CR cells incubated with 75 µM cDDP for 24 hours was investigated, again
measuring the parameters of ΔΨ and cellular O2 consumption. No significant difference was
observed in the mean fluorescence signal measured in A549-WT and A549-CR cells loaded
with 50 nM TMRM following cDDP treatment, indicating that ΔΨ was comparable in both 
cell types (Figure 32). Likewise, incubation with cDDP did not significantly alter the degree
of respiratory uncoupling in either A549-WT cells or A549-CR cells. However, the rate of
cellular O2 consumption was significantly increased in A549-WT cells following incubation
with cDDP compared to A549-WT cells not treated with cDDP (7.84 ± 0.92 nmol O2 / cell /
minute vs. 3.43 ± 0.29 nmol O2 / cell / minute, p < 0.01) (Figure 32). A similar, although less
pronounced, effect was measured in A549-CR cells in which the rate of cellular O2
consumption was significantly increased following incubation with cDDP compared to A549-
CR cells not treated with cDDP (5.00 ± 0.29 nmol O2 / cell / minute vs. 3.43 ± 0.31 nmol O2 /
cell / minute, p < 0.01) (Figure 32). The rate of cellular O2 consumption was significantly
greater in A549-WT cells incubated with cDDP than in A549-CR cells incubated with cDDP
(p < 0.05). Treatment with cDDP therefore increased mitochondrial oxidative activity in both
A549-WT and A549-CR cells.
3.3.4 cDDP Treatment Increases Maximal Cellular Oxidative Capacity Only in A549-WT
Cells
Treatment with cDDP induced a significant increase in basal cellular O2 consumption in both
A549-WT and A549-CR cells. The maximal rate of mitochondrial oxidative activity was also
determined in A549-WT and A549-CR cells before and after 24 hours incubation with 75 µM
cDDP by measuring cellular O2 consumption in the presence of 2 µM FCCP. No significant
difference was measured in the maximal rate of mitochondrial oxidative activity between
A549-WT and A549-CR cells without exposure to cDDP (Figure 33). Treatment with cDDP
increased the maximal rate of mitochondrial oxidative activity in A549-WT cells compared to
control A549-WT cells not exposed to cDDP (7.58 ± 0.78 nmol O2 / cell / minute vs. 4.01 ±
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0.55 nmol O2 / cell / minute, p < 0.01), however no significant difference was observed in the
maximal rate of mitochondrial oxidative activity in A549-CR cells with or without cDDP
treatment (Figure 33).
Figure 33: Maximal cellular oxidative capacity is increased in A549-WT cells, but not
A549-CR cells, following cDDP treatment. A549-WT cells and A549-CR cells were
incubated in normal cell culture medium or in normal cell culture medium + 75 µM cDDP for
24 hours. The maximal cellular oxidative capacity was measured after addition of 2 µM
FCCP to uncouple the ETC. O2 consumption rates were normalised relative to the number of
cells present during the assay. Data represent the mean of three independent experiments +
S.E.M. * p < 0.05.
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3.3.5 mtDNA Copy Number is Increased Following cDDP Treatment
Comparable cellular O2 consumption and ΔΨ was measured in both A549-WT cells and 
A549-CR cells, whilst 24 hours incubation with 75 µM cDDP caused a significant increase in
cellular O2 consumption in both cell types. However, this increase was significantly more
pronounced in A549-WT cells, and, unlike A549-WT cells, no increase in the total oxidative
capacity of A549-CR cells was observed after cDDP treatment. Since the maximal rate of
cellular O2 consumption measured with a Clark-type electrode after addition of FCCP reflects
the maximal activity of the mitochondrial respiratory chain, the difference in mitochondrial
activity after cDDP treatment, and between the A549-WT and A549-CR cell lines, may be
due to differences in the relative expression level of respiratory chain components. As key
subunits of the respiratory chain are encoded by the mitochondrial genome, the mtDNA copy
number of A549-WT cells and A549-CR cells was determined by RT-qPCR after 24 hours
incubation in normal cell culture medium or in normal cell culture medium + 75 µM cDDP.
No significant difference in mtDNA copy number was measured between A549-WT cells or
A549-CR cells maintained in normal cell culture medium (Figure 34). Following incubation
with cDDP, mtDNA copy number was significantly increased by approximately 40% in
A549-WT cells (p < 0.01) and increased by approximately 60% in A549-CR cells (p < 0.01),
relative to non-treated A549-WT control cells and non-treated A549-CR control cells
respectively (Figure 34). The increase in mtDNA copy number in A549-CR cells was
significantly greater than that in A549-WT cells (p < 0.05).
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Figure 34: cDDP treatment results in increased mtDNA copy number. A549-WT cells
were incubated in normal cell culture medium or in normal cell culture medium + 75 µM
cDDP for 24 hours, and mtDNA copy number determined relative to β-actin gene abundance 
by RT-qPCR. Data were normalised to non-treated A549-WT cells, and represent the mean
of seven independent experiments + S.E.M. * p < 0.05.
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3.3.6 Expression of Mitochondrial Respiratory Complex I is Increased in A549-CR Cells
Relative to A549-WT Cells
Treatment with cDDP increased the mtDNA copy number in both A549-WT cells and A549-
CR cells. This replication of DNA might have been accompanied by increased expression of
genes encoding respiratory chain components, and potentially result in increased cellular
oxygen consumption following cDDP exposure. To investigate this possibility, the abundance
of mitochondrial respiratory complexes was determined by immunoblotting using an
antibody cocktail reactive towards single subunits of complex I, complex II, complex III,
complex IV and ATP synthase (Figure 35 A). Importantly, each selected subunit is highly
labile and rapidly degraded if not assembled into the full complex, thus the abundance of
these subunits reflects the abundance of the entire respiratory complex.
A significant increase of approximately 50% in the abundance of respiratory complex I was
measured in A549-CR cells relative to A549-WT cells (p < 0.05) (Figure 35 B). Notably, a
similar strong increasing trend in A549-CR cells in comparison to A549-WT cells was
observed in the relative abundance of respiratory complex IV, although this difference was
not calculated to be significant (p = 0.06). The abundance of respiratory complexes I – IV
was not significantly different following 24 hours incubation with 75 µM cDDP in A549-WT
cells or A549-CR cells compared to non-treated control A549-WT cells and non-treated
control A549-CR cells respectively. Treatment with cDDP resulted in a significant increase
of approximately 40% in the abundance of ATP synthase in A549-WT cells relative to non-
treated controls, but did not cause changes in ATP synthase abundance in A549-CR cells
(Figure 35 B).
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Figure 35: Expression of mitochondrial respiratory complex I is increased in A549-CR
cells relative to A549-WT cells. A549-WT cells and A549-CR cells were incubated in
normal cell culture medium or normal cell culture medium + 75 µM cDDP for 24 hours, and
the relative abundance of mitochondrial respiratory complexes determined by western blot.
(A) Representative western blot and (B) quantification for single subunits of mitochondrial
respiratory complexes I – IV and ATP synthase, indicative of the abundance of the entire
complex. Complex abundance data were normalised relative to non-treated A549-WT cells,
and represent the mean of five sets of samples from three independent experiments + S.E.M.
* p < 0.05. *** p = 0.06.
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3.3.7 Novel Point Mutations are Present in the mtDNA of A549-CR Cells
Although the level expression of mitochondrial respiratory complexes was consistently
increased in A549-CR cells compared to the A549-WT cell line, basal mitochondrial function
did not differ, and cDDP induced changes in cellular O2 consumption and maximal oxidative
capacity were significantly less prominent in A549-CR cells. Mutations in mtDNA have
previously been associated with both tumourigenesis and cancer cell resistance to
chemotherapy, and may reduce the activity of the mitochondrial respiratory chain. To
determine whether such changes contributed to the differences observed in mitochondrial
oxidative activity between A549-WT and A549-CR cells, the mtDNA sequence of both cell
types was determined using Mitochip V 2.0 sequencing (Affymetrix). Variation from the
revised Cambridge mtDNA Reference Sequence (rCRS) was detected at a total of eighteen
points in A549-WT cell mtDNA and 24 points in A549-CR cell mtDNA (Appendix III Table
1). Of these variations: sixteen point mutations were common to both A549-WT and A549-
CR mtDNA, representing previously reported SNPs in either the test samples or reference
sequence; one previously unreported point mutation was detected in the MT-ND5 gene of
A549-WT cells but not in A549-CR cells; three previously reported SNPs were detected in
the D-loop region of A549-CR mtDNA but not A549-WT mtDNA; five previously
unreported point mutations, one in the D-loop region and three in the MT-CYTB gene, were
detected in A549-CR mtDNA but not A549-WT mtDNA, and one previously unreported
point mutation was detected in the MT-ND2 gene of both cell types, existing in heteroplasmy
in A549-WT mtDNA and homoplasmy in A549-CR mtDNA. Mitochip sequencing thus
identified six previously unreported variations present in A549-CR mtDNA but not A549-
WT mtDNA (Table 5).
Sanger sequencing was used to further confirm the six A549-CR mtDNA variants present
only in A549-CR cells identified by Mitochip sequencing. D-loop point mutation 225G>T
and MTND2 point mutation 4587T>C were both confirmed as correct. However, each of the
four point nucleotides identified as potential novel varients in the MT-CYTB gene in A549-
CR cells were identical to rCRS in four replicates, indicating potential Mitochip sequencing
errors (Table 6). The mtDNA of A549-CR cells therefore contains two previously unreported
variations which might affect respiratory chain function which are not present in the mtDNA
of A549-WT cells (Figure 36).
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Table 5: Previously unreported mtDNA point mutations identified by Mitochip
sequencing present in A549-CR cells but not present A549-WT cells. A549-WT cells and
A549-CR cells were incubated in normal cell culture medium for 24 hours. Sequence analysis
of the mtDNA genome was performed using Mitochip V2.0 following PCR amplification of
mtDNA as described in ‘Methods 2.20’. Italics = deviation from revised Cambridge reference
sequence. * Exists in heteroplasmy.
rCRS
Position
Reference A549-WT A549-CR
Gene
Gene
Product
Amino
Acid
Change
225 G G T D-Loop N/A
Non-
Coding
4587 T T / C * C MT-ND2 ND2
Phe 40
Leu
15042 G G A MT-CYTB Cyt b
Gly 99
Glu
15352 A A G MT-CYTB Cyt b
Glu 202
Glu
15656 A A G MT-CYTB Cyt b
Ile 1304
Val
15659 C C T MT-CYTB Cyt b
Pro 305
Ser
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Table 6: Previously unreported mtDNA point mutations identified by Sanger
sequencing present in A549-CR cells but not present A549-WT cells. Primer sets specific
to the six regions of mtDNA identified by Mitochip sequencing as containing point mutations
present in the A549-CR cell line but not the A549-WT cell line were used to amplify these
regions through PCR, and sequencing performed as described in ‘Methods 2.21’. Italics =
deviation from revised Cambridge reference sequence. * Exists in heteroplasmy.
rCRS
Position
Reference A549-WT A549-CR
Gene
Gene
Product
Amino
Acid
Change
225 G G T D-Loop N/A
Non-
Coding
4587 T T / C * C MT-ND2 ND2
Phe 40
Leu
15042 G G G MT-CYTB Cyt b N/A
15352 A A A MT-CYTB Cyt b N/A
15656 A A A MT-CYTB Cyt b N/A
15659 C C C MT-CYTB Cyt b N/A
3.3 Mitochondrial Function and cDDP-Sensitivity
140
Figure 36: Schematic representation of previously unreported mtDNA point mutations
present in A549-CR cells but not present in A549-WT cells. Of six previously unreported
mutations as determined by Mitochip sequencing and Sanger sequencing, one mapped to the
non-coding D-loop region, one mapped to the MT-ND2 gene and four mapped to the MT-
CYTB gene.
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3.3.8 Rotenone Sensitive Respiratory Complex I Activity is Decreased in A549-CR Cells
Relative to A549-WT Cells
Several novel mtDNA mutations which may affect respiratory chain activity were found to be
present in A549-CR cells but absent in A549-WT cells. Intruigingly, one previously
unreported point mutation was found to be present in the respiratory complex I MT-ND2 gene
in heteroplasmy in A549-WT cells but in homoplasmy in A549-CR cells, whilst the
abundance of complex I was increased by approximately 50% in A549-CR cells relative to
A549-WT cells. The effects of this mutation were thus investigated by measuring both the
rotenone-insensitive and rotenone-sensitive activity of mitochondrial respiratory complex I in
A549-WT cells and A549-CR cells.
Rotenone-insensitive complex I activity was measured using MitoSciences Microplate Assay
for Human Complex I Activity. This assay measures the rate of increase of absorbance in the
assay solution due to reduction of a chemical dye which acts as a H+ acceptor during NADH
oxidation by immunocaptured complex I. The reaction is not dependent upon successful
transfer of an electron through the respiratory complex to ubiquinone, thus acts as a measure
of only the NADH dehydrogenase type activity of complex I. No significant difference in the
rate of increase in absorbance due to dye reduction was observed between A549-WT and
A549-CR cells, indicating complex I NADH dehydrogenase activity was not altered (Figure
37). The rate of dye reduction by immunocaptured respiratory complex I isolated from
mtDNA deficient A549 Rho-0 cells was less than 20% of that measured in A549-WT cells
and A549-CR cells (Figure 37). Thus, no difference exists in the rotenone-insensitive activity
of respiratory complex I in A549-WT cells and A549-CR cells.
Rotenone-sensitive complex I activity was measured by calculating the change in the rate of
NADH oxidation, measured by absorbance at 340 nm in a spectrophotomter, after addition of
rotenone to the assay solution. NADH oxidation in this assay depends upon successful
transfer of electrons to Ubq, present in excess, thus acts as a measure of the overall activity of
complex I. The difference in the rate of change in absorbance at 340 nm following addition of
rotenone was significantly greater in A549-WT cell lysates than that measured in A549-CR
cell lysates (3.19 ± 0.46 nmol/ minute/ ml/ µg vs 1.67 ± 0.18 nmol/ minute/ ml/ µg, p < 0.05)
(Figure 38), indicating that rotenone-sensitive respiratory complex I activity is reduced in
A549-CR cells relative to A549-WT cells.
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Figure 37: No difference exists in the rotenone-insensitive NADH oxidase activity of
respiratory complex I between A549-WT cells and A549-CR cells. A549-WT cells and
A549-CR cells were incubated in normal cell culture medium or normal cell culture medium
+ 75 µM cDDP for 24 hours, and the activity of immunocaptured respiratory complex I
determined using MitoSciences Microplate Assay for Human Complex I Activity. The rate of
increase in absorbance of the assay solution, dependent upon complex I activity, was
monitored for 30 minutes. Data represent the mean of three independent experiments+
S.E.M.
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Figure 38: Rotenone-sensitive complex I activity is inhibited in A549-CR cells relative to
A549-WT cells. The activity of immunocaptured respiratory complex I determined as
described in ‘Methods 2.17’ from A549-WT cells and A549-CR cells maintained in normal
cell culture medium. The decrease in the rate of NADH oxidation in the presence of excess
ubiquinone following addition of rotenone to cell lysates was determined using a
spectrophotometer. Data represent the mean of three independent experiments+ S.E.M. * p <
0.05.
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4. Discussion
4.1 In Vitro Modelling of cDDP Cytotoxicity and Resistance Using A549 Cells
Although cDDP remains a mainstay of chemotherapy regimes, the precise mechanisms which
underpin the antineoplastic effects of the drug remain unclear (Siddik, 2003). At the
subcellular level, cDDP has been observed to act upon a range of targets, including the
nucleus, mitochondria, the ER and plasma membrane channels and transporters (Brozovic et
al., 2010; Mandic et al., 2003; Martins et al., 2008; Siddik, 2003). The present study has
sought to further current knowledge on the contribution of effects outside of the nucleus to
cellular response to cDDP, focussed upon the ER and mitochondria, by identifying functional
differences in these organelles between two A549 cell lines with differing cDDP sensitivity,
before and after cDDP exposure. The A549 cell line is well characterised and established as
an in vitro model, derived from a clinically relevant tumour type, for studying both cDDP
cytotoxicity and tumour drug resistance (Beleford et al., 2010; Brozovic et al., 2010; Giard et
al., 1973; Liu et al., 2008).
The LD50 of cDDP over 24 hours drug treatment in A549-WT cells was determined to be 75
µM, whilst A549-CR cells displayed approximately two-fold cDDP resistance at this
concentration (Figure 4). Although a drug concentration of 75 µM is significantly greater
than clinical estimates of cDDP concentration within tumour cells, approximately 10 µM
(Puig et al., 2008), in vitro studies of cDDP using cell lines commonly require increased drug
concentration, spanning the range 20 µM - 100 µM (Del Bello, Moretti, Gamberucci, &
Maellaro, 2007; Dursun et al., 2006; Garrido et al., 2008; Kawai et al., 2006; L. Liu, Xing, &
Chen, 2009; Mandic et al., 2003; Splettstoesser et al., 2007). The mean concentration of
cDDP used in published studies was recently estimated to be 50 µM (Berndtsson et al.,
2007). Use of a drug concentration at the upper end of this range was necessitated by the lack
of significant effects on cell survival in either cell type using cDDP concentrations up to and
including 20 µM, suggesting a degree of intrinsic resistance in A549-WT cells. A549 cells
have previously been reported to show the least sensitivity to cDDP in a panel of lung tumour
derived cell lines (J. Chen, Emara, Solomides, Parekh, & Simpkins, 2010) and both results
may be considered consistent with the relative resistance to cDDP of NSCLC compared to
other tumour types (Stephens & Aigner, 2009). A two-fold level of resistance in A549-CR
cells in comparison to A549-WT cells represents a relatively modest change in sensitivity in
contrast to some in vitro models which may exceed a level of 50 – 100-fold acquired cDDP
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resistance, although such modest changes are also reported, and may tally more closely with
levels of resistance observed in patients undergoing chemotherapy (Köberle et al., 2010;
Siddik, 2003). Treatment of A549-WT cells and A549-CR cells with 75 µM cDDP over a 24
hour period thus provides an appropriate experimental condition, within an accepted
concentration range to study cDDP cytotoxicity, at which a clear difference in the response of
A549-WT cells and A549-CR cells may be measured.
The cytotoxic effects of cDDP were assessed in this study by measuring the ability of cells
under varying drug treatment conditions to exclude the membrane-impermeable fluorescent
dye PI, monitoring the loss of plasma membrane integrity associated with necrosis and the
latter stages of apoptosis to define a cell as ‘live’ or ‘dead’. It is notable however that such
measurements provide only a static indication of the effect of a given drug or treatment on the
viability of a cell population at a given time, and do not provide information on long term
cellular growth and survival. For example, such methodology does not distinguish between a
live cell capable of continued growth and proliferation, a cell in which cell death pathways
are delayed but not prevented, a quiescent cell which may resume proliferation and a cell
which has lost proliferative ability; in all cases cells will be defined as ‘live’. Indeed,
combined with the PI exclusion method, the drug concentration(s) required to induce acute
apoptosis and/ or prevent further long term cell growth may be identified and compared.
Clonogenic survival assays, in which the ability of cells to form proliferating colonies
following a period of cDDP exposure is assessed, may therefore be better suited to determine
the combined effect of cDDP on A549 cell survival and proliferative potential. Further, such
experiments may clarify whether cDDP-resistance in the A549-CR cell line represents
delayed cell death or an ability to continue proliferation following cDDP exposure.
4.2 cDDP Induces Caspase-Dependent Apoptosis and Caspase-Independent Cell Death in
A549 Cells
Following exposure to cDDP, cell death may occur through multiple routes, including
apoptosis and/ or necrosis, dependent upon both the cell type and cDDP concentration under
investigation. To determine the mode of cell death induced by the LD50 concentration of
cDDP used in the present A549 cell model, imaging of both plasma membrane and nuclear
morphology was performed at regular intervals throughout the 24 hour drug treatment period
on A549-WT cells and A549-CR cells. For both cell lines, the first morphological changes
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associated with cell death began to occur approximately six hours after drug addition (Figure
6 D and E). These changes were characterised by decreased cellular volume, a ‘rounding’ of
cellular architecture, irregular plasma membrane structure, condensation and fragmentation
of Hoechst-stained nuclei and, in the latter stages, apparent fragmentation of the cell, and as
such are consistent with the morphological definition of apoptosis (Galluzzi et al., 2007;
Kroemer et al., 2009). In vitro treatment with cDDP has previously been widely reported to
lead to apoptotic cell death in a range of cell lines, including A549 cells (Del Bello et al.,
2007; Alan Eastman, 1999; Kelland, 2007; L. Liu et al., 2008; Mandic et al., 2002; Siddik,
2003), and similar morphological changes in plasma membrane structure in response to
cDDP have recently been reported in another lung adenocarcinoma cell line and a human
kidney cell line (Liu et al., 2008; Sancho-Martínez, Piedrafita, Cannata-Andía, López-
Novoa, & López-Hernández, 2011). Furthermore, whilst the first apoptotic cells appear six
hours after cDDP addition, within 12 hours the majority of A549 cells which undergo cell
death during the experimental period showed changes in morphology associated with
apoptosis. This time-course is again in agreement with previous data from numerous cell
models which detected pro-apoptotic signalling, including Bid cleavage and the release of
cytochrome c and AIF from mitochondria, occurring between six and nine hours post cDDP
exposure (L. Liu et al., 2009, 2008; Mandic et al., 2002; Sancho-Martínez et al., 2011). Thus,
75 µM cDDP induces apoptotic cell death in A549-WT cells and A549-CR cells.
Apoptotic cells became evident in both A549-WT cells and A549-CR cells approximately six
hours after drug addition. However, by 24 hours post drug addition, apoptotic cells
represented a relatively small proportion of A549-CR cells whilst the majority of A549-WT
cells showed a degree of morphological changes associated with apoptosis (Figure 6 D and
E), in agreement with the difference in cDDP sensitivity measured by PI exclusion (Figure 4).
It is notable that apoptotic cells appeared at similar time points in both cell types following
cDDP addition, and is indicative of overlapping drug sensitivity. Given that both cell lines
represent mixed rather than clonal cell populations, it is possible that a sub-population of
A549-CR cells may have undergone selection for continued growth in the presence of low
concentrations of cDDP, yet show similar sensitivity to acute apoptosis induced by higher
concentrations of cDDP as A549-WT cells. Alternatively, the earliest apoptotic cells may
represent those undertaking a cellular process such as DNA replication, which may sensitise
the cDDP cytotoxicity and account for the similarities in the initial response to cDDP
between the cell lines. It is not clear from the present data whether the cDDP resistant
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phenotype of the A549-CR cell line represents insensitivity to the cytotoxic action of the drug
or rather a delay in the death process, and would require further cell viability studies at time
points beyond 24 hours post drug addition.
The morphology of A549-WT cells following 24 hours of cDDP exposure indicates the
majority of cells to be dead or dying (Figure 6 D). As such, cellular measurements taken at
this time point may not accurately reflect normal cellular behaviour, as targeting of key
regulators of cell metabolism and structure by the apoptotic pathway drastically alters cellular
function. Measurements were performed following 24 hours incubation with cDDP as this
experimental condition caused loss of plasma membrane integrity measured by PI staining in
50% of A549-WT cells, and a clear two-fold cDDP resistance was observed in A549-CR
cells under the same conditions (Figure 4). The reason for the discrepancy in apparent A549-
WT cell death at the 24 hour time point measured by FACS analysis or morphological
imaging is unknown. It is possible that A549-WT cells enter into the apoptotic pathway by 24
hours, but not all reach the latter stages of apoptosis in which plasma membrane integrity is
lost, thus are categorised as ‘live’ by PI incorporation, or that a proportion of dead cells are
lost during cell collection for FACS analysis. The investigation may thus benefit from
measurements made at earlier time points following cDDP addition, when an increase in the
proportion of PI positive A549 cells may be measured, yet not all cells have undergone
changes in cellular structure associated with apoptosis. Indeed, such a methodology may
reveal interventions which delay the onset of cDDP-induced apoptosis, and thus may
contribute to altered cellular sensitivity to cDDP.
The progression of cells through the stages of the cell cycle is governed by key checkpoints,
including those regulated by DNA damage. The efficacy of a given chemotherapy drug in
killing cancer cells may vary with the stage of the cell cycle at which a tumour cell is exposed
to the drug (Schwartz & Shah, 2005), depending upon its particular mode of action. Such cell
cycle specific action necessitates several rounds of administration of chemotherapy in order
to eliminate tumour cells which remained in a drug-insensitive phase of the cell cycle during
the initial treatment. As an alkylating-like agent, cDDP is considered to be a cell cycle-
independent drug, capable of inducing cell death at any stage of the cell cycle (M A Shah &
Schwartz, 2001; Siddik, 2003). However, cellular sensitivity to cDDP may vary during the
cell cycle, with maximal sensitivity in G1 and declining sensitivity with the onset of S-phase
and G2 (Donaldson, Goolsby, & Wahl, 1994; M A Shah & Schwartz, 2001). Cell cycle arrest
at G2 may allow for repair of cDDP-DNA adducts and prevent aberrant mitosis, and indeed
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abrogation of G2-M phase cell cycle arrest increases the sensitivity of some cell lines to
cDDP treatment (Demarcq, Bunch, Creswell, & Eastman, 1994; Siddik, 2003). Cells grown
to confluent culture may display a different distribution of the cellular population in the
phases of the cell cycle than those at lower density, actively proliferating in the log-phase of
cell growth. The initial density of cells during investigation of cDDP-induced apoptosis
(Figure 6) may thus have influenced the sensitivity of A549 cells to cDDP treatment, even
though cells adopting a mitotic morphology were observed in non-treated cells throughout the
24 hour investigation period (Figure 6C). As such, the investigation of cellular cDDP
sensitivity would benefit from being repeated, seeding cells at an initial density which
ensures confluence is not reached and the cell culture remains in the log-phase of growth
throughout the experimental time period. Furthermore, such data may be extended through
synchronising cells at different stages of the cell cycle before cDDP treatment, to investigate
whether, and to what degree, the ability of cDDP to induce cell death varies during the cell
cycle in the A549 cell line.
Exposure to cDDP prevented cell division in both A549-WT cells and A549-CR cells (Figure
6 and Table 1), consistent with significant accumulation of p53 protein following cDDP
treatment in both cell types (Figure 5). This observation matches with previous work linking
cDDP treatment, the DNA damage response and cell cycle arrest (reviewed in Siddik, 2003).
Although loss of p53 has been linked with both increased sensitivity (Basu & Krishnamurthy,
2010; Fujiwara et al., 1994; Osaki et al., 2000) and increased resistance (R. Brown et al.,
1993; Fan et al., 1995; C. L. Johnson, Lu, Huang, & Basu, 2002) of tumour cells to cDDP-
induced cell death, the comparable p53 accumulation in A549-WT cells and A549-CR cells,
accompanied by significantly reduced cell death in A549-CR cells compared to the A549-WT
line, further demonstrates that inhibition of the p53 response is not a pre-requisite for cDDP
resistance. It has been suggested that inhibition of tumour cell proliferation by cDDP may
represent a major part of its antineoplastic activity (Havelka, Berndtsson, Olofsson, Shoshan,
& Linder, 2007; Puig et al., 2008). That cDDP treatment can induce identical cell cycle arrest
in both A549 cell lines but differing effects on cell viability suggests the cytotoxic activity
and cytostatic activity may, at least in part, be mediated by separate signalling pathways.
The precise signalling pathways involved in cDDP-induced cell death are complex, and may
differ between cell models, with conflicting reports upon which effectors are responsible for
the death process. To clarify this issue, cell death resulting from cDDP exposure was further
investigated in the A549-WT cell line. Activation of caspase enzymes is responsible for the
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major morphological changes associated with apoptosis and caspase involvement in cDDP-
induced cell death is well reported (Basu & Krishnamurthy, 2010; Del Bello et al., 2007;
Dursun et al., 2006; Siddik, 2003), and indeed incubation with the pharmacological pan-
caspase inhibitor z-VAD-FMK significantly reduced the percentage of PI positive A549-WT
cells measured following cDDP treatment (Figure 7), further confirming cDDP induces
caspase-dependent apoptosis in A549-WT cells.
The role of caspase-8 has proved particularly divisive, with evidence accumulated both for
(Lacour et al., 2003; Spierings, de Vries, Vellenga, & de Jong, 2003; Toyozumi et al., 2004)
and against (Splettstoesser et al., 2007; Vakifahmetoglu, Olsson, Tamm, et al., 2008) a
requirement in cDDP-induced apoptosis. Incubation of A549-WT cells with IETD-FMK, a
pharmacological inhibitor of caspase-8, did not inhibit the increase in PI positive cells
measured after 24 hours incubation with cDDP (Figure 8), thus signalling through caspase-8
does not appear to be involved in this A549 cell model, and confirms previous work by Liu
and co-workers who similarly observed that IETD-FMK did not alter A549 cell apoptosis
induced by cDDP (Liu et al., 2008).
Whilst inhibition of caspases reduced A549-WT cell death in response to cDDP by
approximately 50%, a significant increase in the percentage of PI positive A549-WT cells
was still measured following 24 hours drug exposure in comparison to untreated control cells,
suggesting that caspase-independent cell death might also occur. Indeed, in other studies
pharmacological caspase inhibition has not fully prevented cell death induced by cDDP, and
death inhibition may commonly range from 20-50% (Del Bello et al., 2007; L. Liu et al.,
2009; Mandic et al., 2002). Notably, pharmacological caspase inhibition in A549 cells by Liu
et al. delayed cDDP-induced cytochrome c release and cell death compared to controls
without caspase inhibition up to 16 hours post drug addition, however at later time points
cDDP-induced cell death did not differ between these groups, indicating multiple modes of
cell death may be in operation (Liu et al., 2008).
Necrotic cell death may result from cDDP treatment in some models, although it has been
suggested that this response results mostly from very high, supramaximal cDDP
concentrations in the 0.1 – 1 mM range, and a recent report described a switch from apoptotic
to necrotic renal cell death with increasing cDDP concentration, with intermediate
concentrations eliciting both death modalities in the cell population (Dursun et al., 2006;
Mandic et al., 2002; Sancho-Martínez et al., 2011). Interestingly, it has been suggested that
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this apoptosis-necrosis switch may occur due to direct inhibition of executioner caspases by
cDDP after engagement of the apoptotic machinery (Sancho-Martínez et al., 2011), a
situation possibly akin to pharmacological caspase inhibition. Similarly, the p53 status of
cells treated with cDDP has been proposed as regulating whether cDDP induces apoptosis or
necrosis following mitotic catastrophe (Vakifahmetoglu, Olsson, Tamm, et al., 2008). Thus,
under conditions of caspase inhibition, some cells may die through necrosis after initial
engagement of the apoptotic machinery. However, the abrupt gain in cellular volume and
plasma membrane rupture characteristic of necrosis (Kroemer et al., 2009) was not observed
during morphological imaging of A549-WT cells treated with cDDP (Figure 6 D).
Permeability transition of mitochondria may also lead to cell death. Inhibition of the Cyp D
component of the mPTP using CsA however increased the cytotoxic effect of cDDP (Figure
10). Such toxic effects of CsA in combination with cDDP have been reported previously, and
notably a similar effect was observed using an alternative Cyp D inhibitor, sanglifhrin A (X.
Han et al., 2010; Mandic et al., 2002). It is possible that inhibition of the peptidl-prolyl cis-
trans isomerise activity of Cyp D may prove deleterious to cell survival in light of protein
damage by cDDP, however such reasoning remains no more than hypothesis for further
testing.
Recently, a role for the involvement of calpains in mediating cDDP-induced cell death, at
least in in vitro models, has begun to emerge. Although the exact role of calpains during cell
death is not known, activation of these enzymes may in turn activate caspases and/ or cleave
key cellular targets including cytoskeletal proteins, causing cell death (Liu et al., 2009). A
number of studies have suggested a key role for calpain activation in pro-apoptotic cleavage
of Bid, release of pro-apoptotic molecules including AIF from the mitochondria, caspase
activation and induction of p73 following cDDP exposure (Al-Bahlani et al., 2011; Del Bello
et al., 2007; L. Liu et al., 2009, 2008; Mandic et al., 2002; Splettstoesser et al., 2007). Indeed,
Liu et al have suggested the calpain-mediated cell death pathway is the predominant means
of caspase activation in A549 cells treated with cDDP (Liu et al., 2008). Although in the
current investigation changes in [Ca2+]cyt and [Ca2+]ER were not observed in response to
cDDP (Figures 26 & 27), this need not preclude a role for calpain activation since multiple
mechanisms of activation other than Ca2+ exist (Del Bello et al., 2007). However,
pharmacological inhibition of calpains using ALLN, an inhibitor of m-calpain, µ-calpain and
cathepsins, did not inhibit A549-WT cell death induced by cDDP (Figure 9). The reason for
such disparity with previous work is unclear. Dursun and co-workers have suggested that
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calpains are important only for necrotic type cell death induced by cDDP (Dursun et al.,
2006), whilst in the present study necrotic morphology is not observed. Alternatively, a
number of previous studies have used calpeptin, a more specific calpain inhibitor, rather than
ALLN to inhibit calpain activation. Whether differences in the mode of enzyme inhibition
may impact upon cDDP sensitivity is not known but should be investigated before
discounting a role for calpains in this model. Finally, the role of calpains in the present
experimental system may be redundant with that of caspases, and thus only apparent under
conditions of concomitant caspase inhibition, which may produce an additive inhibition of
cDDP induced cell death.
AIF release from mitochondria may result in caspase-independent nuclear condensation and
cell death in certain cell types, and several links between AIF release and cDDP sensitivity
have been made in recent years (L. Liu et al., 2009; X. Yang, Fraser, Abedini, Bai, & Tsang,
2008). However, AIF release from mitochondria in response to cDDP appears to be
dependent upon calpain activation (Liu et al., 2009), and given the lack of alterations in
A549-WT cell death under conditions of calpain inhibition (Figure 9), seems unlikely to be a
major requirement in the current model.
4.3 Increased ROS Production is Not Required for cDDP-Induced Cell Death in A549
Cells
Treatment with cDDP has been reported to increase the rate of ROS generation in a diverse
range of cell types, including both tumour and non-tumour tissues (Berndtsson et al., 2007;
Brozovic, Ambriović-Ristov, & Osmak, 2010; Kawai, Nakao, Kunimura, Kohda, & Gemba, 
2006; Martins, N. A. G. Santos, Curti, Bianchi, & A. C. Santos, 2008; Santandreu, Roca, &
Oliver, 2010). Such increased ROS production may play a role in cell death following cDDP
treatment, and under some experimental conditions has been suggested to make a major
contribution to cDDP-induced apoptosis (Berndtsson et al., 2007; Brozovic et al., 2010;
Havelka et al., 2007). The nature of this contribution is complex and remains unclear, but has
been suggested to involve oxidative damage of nuclear DNA, ER stress, mitochondrial
oxidative dysfunction, antioxidant depletion, pro-apoptotic activation of mitogen-activated
protein kinases and altered plasma membrane composition and fluidity leading to clustering
of CD95 (Brozovic & Osmak, 2007; Brozovic et al., 2010; H.-L. Huang et al., 2003; Lacour
et al., 2004; Mandic et al., 2003).
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An increased production of O2•‾ was measured both in the cytosol and mitochondria of both
A549-WT cells and A549-CR cells following 24 hours incubation with cDDP (Figure 12 &
Figure 13), in agreement with previous observations of O2•‾ production induced by cDDP in
colon carcinoma and renal cells (Berndtsson et al., 2007; Kawai et al., 2006). Strikingly, this
increase in cellular O2•‾ levels was significantly less apparent in A549-CR cells compared to
the A549-WT cell line (Figure 12 & Figure 13). Similarly, whilst exposure to cDDP
increased the rate of production of H2O2 in A549-WT cells, no significant difference was
observed in the rate of H2O2 production by A549-CR cells following cDDP treatment
compared to non-treated control A549-CR cells (Figure 11). The reason for a lack of a
significant increase in H2O2 production caused by cDDP in A549-CR cells is not clear, but
may be related to differences in ROS detoxification by A549-WT cells and A549-CR cells,
such as decreased MnSOD activity, or alternatively due to the reduced rate of O2•‾ production
in A549-CR cells following cDDP treatment compared to the A549-WT cell line.
Given the potential role of ROS production in cDDP cytotoxicity and the disparity in cDDP-
induced ROS production between A549-WT cells and A549-CR cells, the contribution of
ROS to cell death in this experimental system was investigated through addition of
antioxidants to A549-WT cells during the cDDP treatment period. NAC fully prevented any
increase in the percentage of PI positive A549-WT cells measured after cDDP treatment
compared to control A549-WT cells (Figure 14). However, caution should be exercised in the
interpretation of data derived from experiments involving co-incubation of cDDP and NAC.
The aquated, reactive form of cDDP forms a nucleophile with high reactivity towards thiol
groups, such as that contained in the NAC molecule, thus there exists the possibility of direct
binding and inactivation of cDDP by the antioxidant. Although NAC is commonly used in
investiagtion of cDDP and ROS generation (Mandic et al., 2003; Park, Choi, Bang, Huh, &
Kim, 2002; Tajeddine et al., 2008), where possible alternative antioxidants without prominent
thiol groups should be used to reduce the potential of experimental artefacts arising from
direct drug detoxification. Accordingly, no protective effect against cDDP cytotoxicity was
afforded by incubation of A549-WT cells with TEMPOL (Figure 15) or ascorbic acid
(Appendix I Figure 1) during the drug treatment period. Thus, increased ROS production
does not appear to be a significant requirement for cDDP-induced cell death in this
experimental model. This finding is in contradiction with a number of other studies
demonstrating a clear requirement for ROS production in cDDP cytotoxicity (Berndtsson et
al., 2007; Brozovic et al., 2010; Kawai et al., 2006; Santandreu et al., 2010), whilst ascorbic
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acid abrogated renal toxicity associated with cDDP treatment (Antunes, Darin, & Bianchi,
2000; Fatima, Arivarasu, & Mahmood, 2007; Maliakel, Kagiya, & Nair, 2008). Such
differences may be due to cellular differences in the experimental systems and drug
concentrations employed.
Since increased ROS production has been suggested to be the causative factor in cDDP-
induced CD95 clustering and cell death through the receptor-mediated pathway (H.-L. Huang
et al., 2003), that ROS production is not a component required for A549-WT cell death
following cDDP treatment further suggests caspase-8 does not play a role in cDDP
cytotoxicity in this experimental system.
4.4 cDDP Altered Mitochondrial Function in A549-WT Cells But Not A549-CR Cells
Although cDDP-induced cell death in A549 cells is not dependent upon increased ROS
generation, a marked reduction in cellular O2•‾ and H2O2 production was observed in A549-
CR cells following exposure to cDDP in comparison with the A549-WT cell line. Such a
difference might be indicative of another altered cellular response to cDDP which itself
contributes to modulate cDDP sensitivity, and a secondary effect of which results in
diminished ROS generation. A reduction in cellular cDDP uptake resulting in a lesser degree
of interference with cellular processes might explain the difference in ROS generation, and
indeed all differences between A549-WT cells and A549-CR cells following cDDP exposure.
Reduced drug accumulation is a recognised mechanism of tumour cell cDDP resistance
(Siddik, 2003), and cannot be excluded without measurement of cDDP uptake kinetics in the
two cell lines. However, p53 accumulation (Figure 5) and GSH depletion (Figure 30) caused
by cDDP treatment did not differ between A549-WT cells and A549-CR cells, whilst the
cDDP-induced increase in mtDNA copy number was significantly greater in A549-CR cells
(Figure 34). These observations of similarities in magnitude of the DNA damage response
and slight GSH depletion suggest that, rather than representing differences of degree, specific
dissimilarities exist in cellular response to cDDP.
GSH represents an important and abundant cellular scavenger of free radicals which might
account for the difference in ROS generation measured between A549 cell lines, and GSH
overexpression has been linked to tumour cell cDDP resistance (Godwin, 1992; Siddik,
2003), inactivating cDDP through direct reaction. However, no significant difference was
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observed in cellular levels of GSH in A549-WT cells and A549-CR cells measured by MCB
fluorescence (Figure 30). Further investigations are required to determine whether changes in
other cellular antioxidant systems might account for reduced ROS production by A549-CR
cells following cDDP treatment.
Recent work has suggested the expression of mitochondrial uncoupling protein-2 (UCP2)
may alter the sensitivity of cells to the cytotoxic effects of cDDP (Santandreu et al., 2010).
Leukaemia cells resistant to cDDP expressed increased levels of UCP2 and maintained a
reduced ΔΨ compared to cDDP-sensitive cells, accompanied by reduced ROS production 
under conditions of cellular stress and resistance to cDDP-induced apoptosis (Harper et al.,
2002). However, neither ΔΨ (Figure 31) nor the degree of uncoupling of mitochondrial 
oxidative respiration (Table 4) were significantly different between A549-WT cells and
A549-CR cells, both under normal cell growth conditions and following cDDP treatment,
indicating increased mitochondrial uncoupling through UCP2 does not account for the
difference in ROS production observed.
The mitochondrial electron transport chain is the primary source of O2•‾ generation in most
cell types (Koopman et al., 2010; Orrenius, 2008), and as such differences in mitochondrial
activity and/ or function following cDDP treatment could explain reduced ROS generation in
A549-CR cells compared to A549-WT cells. No significant differences were measured in ΔΨ 
(Figure 31), basal cellular O2 consumption (Figure 32), maximal cellular oxidative capacity
(Figure 33), or mtDNA copy number (Figure 34) indicating that under normal cell growth
conditions basal mitochondrial function is comparable in A549-WT cells and A549-CR cells.
Following cDDP treatment, the basal rate of cellular O2 consumption increased in both A549
cell lines (Figure 32), consistent with the observed increase in cellular O2•‾ production.
Notably, the drug induced increase in mitochondrial oxidative activity was significantly
greater in A549-WT cells than in the A549-CR cell line, again in agreement with the
observed difference in O2•‾ production following cDDP exposure. The difference in H2O2
production might be explained by differences in the level of O2•‾ generation and the
superoxide dismustase activities of ROS detoxification systems in the two cell lines. Total
cellular oxidative capacity was also significantly increased after the cDDP treatment period in
A549-WT cells, but unaltered in A549-CR cells (Figure 33). Thus, cDDP treatment caused an
increase in mitochondrial oxidative activity of A549-WT cells, and a significantly less
pronounced increase in A549-CR cells, a pattern which strongly correlates with, and may
explain, differences in drug-induced ROS production between the two cell lines.
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Differences in the oxidative activity of mitochondria following cDDP treatment are notable,
as regulation of mitochondrial respiratory complexes (Lemarie & Grimm, 2011) and electron
flux through the ETC is emerging as a key determinant in the induction of apoptosis. Partial
depletion or complete loss of ETC components in osteocarcinoma cybrid cells generated
using mtDNA donor cells harbouring a range mtDNA mutations resulted in marked
resistance to apoptosis via the mitochondrial pathway in response to staurosporine and
etoposide (Kwong et al., 2007). Interestingly, the same mutations sensitised cybrid cells to
ER stress-induced apoptosis, suggesting the protective effect may depend upon the apoptotic
stimulus and signalling pathways activated. In a similar manner, reduced activity of the ETC
in human leukaemia cells induced resistance to the microtubule destabilising agent Taxol (Jia
et al., 1997). Conversely, increased mitochondrial activity may sensitise cancer cells to cDDP
treatment. Pyruvate generated through glycolysis is converted to acetyl-CoA for entry into
the TCA cycle by the action of pyruvate dehydrogenase (PDH), the enzymatic activity of
which is in turn regulated by pyruvate dehyrogenase kinase (PDK). Decreased conversion of
pyruvate to acetyl-CoA is common is tumour cells, and may contribute to the characteristic
Warburg effect. Dichloroacetate (DCA), a drug commonly used for treatment of lactic
acidosis, effectively inhibits PDK activity, relieving inhibition of PDH, and increases
mitochondrial activity by boosting entry of pyruvate into the TCA cycle (Sébastien Bonnet et
al., 2007). DCA enhanced the cytotoxic effects of cDDP in HeLa cells (Xie et al., 2011), and
a novel fusion drug comprised of cDDP and DCA showed greater activity in inducing
apoptosis of cancer cells than either drug alone (Dhar & Lippard, 2009). This fusion drug was
further able to restore drug sensitivity to cDDP-resistant ovarian cancer cells. Thus, the
functional difference in mitochondria identified between A549-WT cells and A549-CR cells
following cDDP treatment may directly contributed to modulating cDDP sensitivity in
tumour cells, and warrants further investigation. Restoration of increased ETC activity
following cDDP treatment may increase A549-CR cell response to the drug, and provide a
rationale for chemotherapy regimes combining cDDP with drugs selectively targeted to
boosting mitochondrial function.
Whilst increased activity of the ETC may sensitise cancer cells to the cytotoxic effects of
cDDP, the mechanism behind the increase in cellular oxygen consumption observed in A549-
WT cells following treatment with cDDP is not clear. Mitochondrial dysfunction and
inhibition of mitochondrial respiratory complex activity following cDDP treatment has been
demonstrated by a number of studies (Cullen, Yang, Schumaker, & Z. Guo, 2007;
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Kruidering, Van de Water, de Heer, Mulder, & Nagelkerke, 1997; H. Ma et al., 2010;
Martins, N. A. G. Santos, Curti, Bianchi, & A. C. Santos, 2008; Sancho-Martínez, Piedrafita,
Cannata-Andía, López-Novoa, & López-Hernández, 2011; Santandreu et al., 2010). This is
the first report of a cDDP-induced increase in cellular O2 consumption, and as such requires
confirmation through an independent method. Why the present observations differ from
previous literature is not clear, but may depend upon differences in the genetic background of
the model systems and their response to cDDP, or indeed the type of experimental model,
non-tumour or tumour tissue, as mitochondrial injury induced by cDDP has been studied as a
mechanism of chemotherapy side effects (Cullen et al., 2007). Methodological differences
may also play a role, both in the time period following cDDP exposure in which
measurements are made, and the measurements of mitochondrial function taken, as a number
of studies rely upon measurements of ΔΨ and ROS production which depend upon a number 
of other factors in addition to ETC activity.
Increased mitochondrial oxidative activity has previously been reported following exposure
to cytotoxic agents. Genistein, a topioisomerase inhibitor, showed inhibitory effects on the
proliferation of MCF-7 breast cancer cells, Jurkat cells and transformed mouse fibroblasts
causing cell cycle arrest at the G2/ M phase checkpoint, accompanied by increased
mitochiondrial activity as measured by MTT assay (Pagliacci et al., 1993). Treatment with
cDDP may also induce significant G2/ M phase arrest (Siddik, 2003), and it is possible that
increased mitochondrial enzymatic activity may represent, in certain experimental models, a
stress-induced metabolic adaptation. Mitochondrial proliferation as an adaptive response to
ETC damage and dysfunction, upregulating the activity of dysfunction mitochondria in order
to maintain basal function, might also account for increased cellular O2 consumption in
A549-WT cells following incubation with cDDP, and such responses have been observed in
cells following exposure to both radiation and toxic pharmacological agents (Karbowski et
al., 2001; Kluza et al., 2004; C.-F. Lee, Liu, Hsieh, & Wei, 2005; Limoli et al., 2003;
Mancini et al., 1997; Nugent et al., 2007; Pagliacci et al., 1993; Reipert, Berry, Hughes,
Hickman, & Allen, 1995). A link between the DNA damage response and mitochondrial
biogenesis has been suggested to occur through ATM-dependent activation of 5’-AMP
activated protein kinase (AMPK) (Fu, Wan, Lyu, Liu, & Qi, 2008). Although the maximal
cellular oxidative capacity of A549-WT cells was significantly increased following the cDDP
treatment period (Figure 33), no changes in the abundance of mitochondrial respiratory
complexes were measured in A549-WT cells or A549-CR cells (Figure 35). This finding
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suggests that the changes in A549-WT mitochondrial oxidative activity induced by cDDP are
not due to a drug-induced increase in mitochondrial proliferation, but may in fact represent a
change in regulation or substrate availability. Glucose uptake and the activity of glycolytic
enzymes may be inhibited by cDDP (Aull et al., 1979; Rodríguez-Enríquez et al., 2009; R.
Zhou et al., 2002), therefore it is conceivable that metabolic shifts may occur to maintain
cellular energy production following changes in the activity of metabolic pathways caused by
cDDP. Long term adaptations in cells selected for growth in cDDP, through altered enzyme
expression levels for example, could account for differences in mitochondrial activity
measured after acute cDDP treatment.
4.5 mtDNA Copy Number of A549 Cells was Increased Following cDDP Treatment
Recent work has increasingly recognised mitochondria as clinically relevant target organelles
of cDDP chemotherapy, at both the level of protein damage and mtDNA modification
(Cullen et al., 2007; Sharma & Edwards, 1983; Tajeddine et al., 2008; Z. Yang et al., 2006).
Indeed, cDDP may bind mtDNA with equal affinity as with nuclear DNA, and cDDP-
mtDNA adducts may in some cases outnumber cDDP-DNA adducts in the nucleus (Murata,
Hibasami, Maekawa, Tagawa, & Nakashima, 1990; Olivero, Chang, Lopez-Larraza, Semino-
Mora, & Poirier, 1997; Podratz et al., 2011). Such accumulation may in part be driven by the
mitochondrial membrane potential, and adducts may persist due to the lack of a NER
pathway in mitochondria, required to remove cDDP adducts from DNA (Murata et al., 1990;
Olivero et al., 1997; Singh & Maniccia-Bozzo, 1990). Further, unlike the nuclear genome,
mtDNA is not associated with histone proteins, thus may be particularly vulnerable to
oxidative and chemical damage.
The mtDNA copy number of both A549-WT cells and A549-CR cells was increased by
incubation with cDDP (Figure 36). It is appreciated that cDDP-mtDNA adducts may interfere
with the qPCR reaction used to estimate mtDNA copy number in the present investigation.
Inhibition of Taq polymerase progression by cDDP-mtDNA lesions in a PCR assay has been
reported (Garrido et al., 2008), however template DNA for this study was prepared from
isolated mitochondria treated with cDDP in the millimolar range, thus its relevance to studies
involving treatment of whole cells with lower cDDP concentrations may be questioned.
Increased mtDNA replication in A549 cells treated with cDDP should be confirmed through
an independent method such as BrdU incorporation assays. The integrity of mtDNA
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molecules replicated in the presence of cDDP should also be investigated, as present results
do not preclude cycles of abortive mtDNA replication, generating mtDNA fragments
including the amplified sequence.
Treatment with cDDP has previously been reported to cause depletion of cellular mtDNA
content in cardiac, hepatic and neuronal models (El-Awady, Moustafa, Abo-Elmatty, &
Radwan, 2011; Garrido et al., 2008; Podratz et al., 2011). Conversely, separate studies have
observed an increase in cellular mtDNA content in colon carcinoma cells and renal and
hepatic tissues following cDDP exposure (Gerschenson, Paik, Gaukler, Diwan, & Poirier,
2001; Maniccia-Bozzo, Espiritu, & Singh, 1990; Santandreu et al., 2010). Interestingly,
mtDNA content may be increased, decreased or unchanged in different tissues of animal
models of cDDP chemotherapy (Gerschenson et al., 2001; Maniccia-Bozzo et al., 1990),
suggesting cell specific responses to cDDP may be important in determining this effect.
Conceptually, whilst depletion of mtDNA may be accounted for through direct inhibition of
the mtDNA replication process, the mechanism behind an increase in mtDNA copy number
caused by cDDP treatment is not immediately obvious. Such an increase may be in
agreement with a general drug-induced proliferation of mitochondria, however since cDDP
did not cause significant changes in the abundance of mitochondrial respiratory complexes in
either cell type (Figure 35), this is unlikely to be the case in this model.
Alternatively, increased mtDNA content might be interpreted as an adaptive response to
mtDNA damage. Current knowledge suggests mitochondria lack the capacity to repair bulky
cDDP-DNA intrastrand adducts (Singh & Maniccia-Bozzo, 1990), therefore increased
replication of mtDNA may represent a means to maintain a pool of undamaged mtDNA
above a threshold level required to maintain mitochondrial function. Exposure to low levels
of ROS has been demonstrated to lead to an increase of mtDNA copy number in a human
osteocarcinoma cell line (C.-F. Lee et al., 2005). In this osteocacinoma model, higher ROS
exposure dramatically decreased mtDNA content, thus differences in ROS production by
cells treated with cDDP may account for the variable effects of cDDP treatment on mtDNA
copy number between cell models. It is tempting to speculate that the significantly greater
increase in mtDNA copy number induced by cDDP in A549-CR cells compared to A549-WT
cells may be linked to the significantly reduced rate of ROS production in this cell line, and
further investigation of the ROS dependence of this effect is justified.
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Should increased mtDNA replication prove to be an adaptive response to mtDNA damage
under certain conditions, several clues exist as to the molecular mechanisms driving this
effect. Mitochondrial transcription factor A (TFAM) is a transcription factor essential for
transcription of mitochondrial genes, but also required for the maintenance and, potentially,
replication of mtDNA (Kang, Kim, & Hamasaki, 2007; Larsson et al., 1998). TFAM is a
major component of mtDNA nucleoids, and may further act to regulate the mass of cellular
mtDNA by binding along the entire genome in a manner akin to the histone proteins of
nuclear DNA. In this scenario, mtDNA molecules which do not become associated with
TFAM are degraded, and indeed overexpression and knockdown of TFAM correlated with
increased and decreased mtDNA copy number respectively (Kang et al., 2007). TFAM is a
member of the HMG family of proteins (Parisi & Clayton, 1991), which bind to distorted
regions of DNA such as those caused by cDDP. Binding of TFAM to damaged regions of
mtDNA has been demonstrated, and specifically translocation of a fraction of p53 to the
mitochondrial matrix upon cDDP treatment of colon adenocarcinoma cells enhanced
preferential binding of TFAM to cDDP-mtDNA adducts, accompanied by an increase in
TFAM expression (Yoshida et al., 2002, 2003). Similar signalling events leading to increased
TFAM expression levels in A549 cells following cDDP treatment could account for the
observed increase in mtDNA copy number. Finally, it should be noted that the contribution of
the cDDP-induced increase in mtDNA content of A549 cells to cell fate requires further
investigation, and may equally represent an adaptive response to maintain mtDNA integrity
and mitochondrial function, a secondary effect with no contribution to cell fate or may
promote cytotoxicity since, for example, increased binding of HMG proteins to cDDP
adducts in the nucleus may actually shield these lesions from repair (Siddik, 2003).
4.6 Novel mtDNA Point Mutations Inhibit A549-CR Respiratory Complex I Activity
Mutations of mtDNA, encompassing nucleotide insertion, deletion and substitution, are now
well recognised as correlating with the initiation, progression and drug resistant phenotype of
human cancers (Chatterjee et al., 2006; H.-C. Lee, Chang, & Chi, 2010; J. Lu, Sharma, &
Bai, 2009; S. Mizutani et al., 2009). A review of recent literature estimated that 60% of
cancer cells harbour mtDNA point mutations, with approximately 25% of these affecting
conserved nucleotides likely to alter mitochondrial function (H.-C. Lee et al., 2010). Mutant
mtDNA causing loss of function in ETC components has been shown to correlate with
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resistance to apoptosis through the mitochondrial pathway (Kwong et al., 2007), and HeLa
cell cybrids generated using mtDNA derived from pancreatic cancer samples showed
increased resistance to cDDP-induced apoptosis compared to a cybrid line generated using
mtDNA derived from non-tumour pancreatic tissue (S. Mizutani et al., 2009). Resistance to
cDDP was similarly observed in HeLa cell cybrids generated using mtDNA derived from the
tissue of mitochondrial encephalomyopathy patients, containing point mutations in the
MTATP6 gene (Shidara et al., 2005).
Several previously reported cancer-associated SNPs were found to be present in the mtDNA
of both A549-WT cells and A549-CR cells (Appendix III Table 1). In addition, a previously
unreported point mutation, 225G>T, was identified in the D-loop region of mtDNA in A549-
CR cells, whilst A549-WT mtDNA contained the reference nucleotide (Figure 36, Table 5 &
Table 6). Mutations in the D-loop region are commonly observed in cancer cells (H.-C. Lee
et al., 2010), and have been associated with poor prognosis in late stage lung cancer patients
(Matsuyama et al., 2003). The D-loop has been suggested to act as a binding site for proteins
regulating the structure of mtDNA nucleoids (J. He et al., 2007), and ATAD3, a protein
known to bind in this region, has recently been suggested to be a factor modulating cDDP
sensitivity in lung adenocarcinoma cells (H.-Y. Fang et al., 2010). The potential functional
effects of this mutation on both mtDNA nucleoid structure and cDDP sensitivity were not
investigated during this study, but may form the basis of further work.
A previously unreported mtDNA point mutation in the MTND2 gene (4587T>C) was also
identified as existing in heteroplasmy at a low level in A549-WT cells, and in homoplasmy in
A549-CR cells. The transition from a low level variant in heteroplasmy to homoplasmy
suggested a positive selection for the mutation may have occurred during acquisition of
cDDP resistance by A549-CR cells, thus the functional consequences of this mutation were
further characterised. MTND2 encodes the ND2 subunit of mitochondrial respiratory complex
I, an iron-sulphur protein in the peripheral arm of the complex, from which electrons are
transferred to Ubq (Koopman et al., 2010; Nakamaru-Ogiso et al., 2010). The 4587T>C
mutation occurs within a protein-coding region, and produces a F40L amino acid substitution.
Relative to A549-WT cells, the rotenone-sensitive activity of respiratory complex I of A549-
CR cells, that is, the ability of the isolated complex to reduce NADH with concomitant
transfer of electrons through the complex to Ubq, was reduced by approximately 50% (Figure
38). Measurement of the rotenone-insensitive NADH oxidase activity of complex I
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(diaphorase type activity), independent of electron transfer to Ubq, revealed no difference in
enzyme activity between A549-WT cells and A549-CR cells (Figure 37). These data are
consistent with the role of the ND2 subunit in electron transfer through complex I (Koopman
et al., 2010; Nakamaru-Ogiso et al., 2010), and strongly suggests that the 4587T>C point
mutation present in homoplasmy in A549-CR cells attenuates the function of complex I in
this cell line. Mutation of mtDNA genes encoding complex I components has been linked
with thyroid cancer (Abu-Amero, Alzahrani, Zou, & Shi, 2005), and intriguingly may occur
with greater frequency in cancer cells than mutations in components of other respiratory
complexes (J. Lu et al., 2009).
Thus, A549-CR cells contain a point mutation in the MTND2 mtDNA gene, which is likely
the cause of reduced activity of respiratory complex I in this cell line. The present data do not
indicate whether this mutation may alter cellular sensitivity to cDDP, or indeed induce
general resistance to mitochondria-initiated apoptosis, and generation of cybrid cells using
A549-WT cell mtDNA and A549-CR cell mtDNA is required to investigate any pro-survival
effects of this mutation, independent of changes in the nuclear genetic background of the cell.
Furthermore, homoplasmic mtDNA mutations which alter mitochondrial function have also
been shown to promote tumour growth in vivo, and HeLa cell cybrid xenografts harbouring
mutant mtDNA in nude mice have been shown to have a greater proliferative rate (Shidara et
al., 2005) and improved resistance to cDDP chemotherapy-induced apoptosis (S. Mizutani et
al., 2009; Shidara et al., 2005).
How mtDNA mutations may modulate cDDP sensitivity also requires further study, however
changes in the function of complex I have been linked to the induction of apoptosis (Lemarie
& Grimm, 2011). Increased expression of HIF transcription factors correlates with enhanced
tumour cell cDDP resistance in a range of tumour types, including NSCLC, hepatocarcinoma
and cancers of the head and neck, whilst HIF-1α silencing increased cellular cDDP sensitivity 
(Hao et al., 2008; Lau et al., 2009; Xianrang Song et al., 2006; Weidemann et al., 2008; Z. F.
Yang, Poon, To, Ho, & Fan, 2004; van den Broek et al., 2009). Deficiencies in the ETC
might lead to HIF stabilisation, and promote cell survival under cDDP treatment.
Interestingly, exogenous expression of ND2 mutants in head and neck cancer cells lead to
HIF-1α accumulation and promoted tumour cell growth (S. Zhou et al., 2007). The HIF status 
of A549-WT cells and A549-CR cells, both under normal growth conditions and following
cDDP treatment, should thus form a priority for further investigation. A hypothesis involving
HIF stabilisation may be particularly attractive given the role of this transcription factor in
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shifting cellular metabolism away from oxidative respiration, and the reduced cellular O2
consumption of A549-CR cells compared to A549-WT cells following cDDP treatment
(Section 4.4). However, HIF stabilisation due to mitochondrial dysfunction may require
enhanced ROS production (Majmundar, Wong, & Simon, 2010; S. Zhou et al., 2007), whilst
no difference in ROS generation was observed between the two cell lines under normal
growth conditions and A549-CR cells produced ROS at a significantly reduced rate compared
to A549-WT cells in the presence of cDDP (Figure 11, Figure 12 & Figure 13), thus the true
explanation may not be so straightforward.
4.7 Mitochondrial Function is Impaired in A549-CR Cells Only Under Conditions of
Cellular Stress
The activity of mitochondrial respiratory complex I was reduced by approximately 50% in
A549-CR cells compared to A549-WT cells (Figure 38), likely due to a point mutation in
A549-CR cell mtDNA affecting the MTND2 gene (Figure 36). However, neither ΔΨ (Figure 
31) nor the basal or maximal oxidative activity of the ETC differed between A549-WT and
A549-CR cells under normal growth conditions (Figure 33 & Figure 34). Therefore, A549-
CR cells were able to maintain mitochondrial function comparable to that of A549-WT cells
in spite of complex I dysfunction. The contribution of the individual respiratory complexes to
electron flux along the ETC to O2 varies in a manner that is both cell type and growth stage
specific (Inomoto et al., 1994; Kuznetsov et al., 1997), thus the effect of a change in the
activity of a single complex on the activity of the ETC as a whole cannot be simply predicted
without knowing the relative contribution of that complex. Similarly, the degree of inhibition
of complex activity must surpass a threshold level before functional effects are observed in
the rate of O2 consumption, and again this threshold may vary between complexes and cell
type (Davey, Peuchen, & Clark, 1998). Therefore, one potential explanation for the observed
similarity in basal mitochondrial function may be that the effect of the mtDNA mutation on
complex I activity does not affect the rate of O2 reduction by the ETC, and the relative
contribution of respiratory complexes I-IV in maintaining ΔΨ and O2 reduction may be
assessed to confirm or exclude this possibility.
Alternatively, the ΔΨ and cellular O2 consumption data may be interpreted in terms of
mitochondrial function being maintained, in spite of altered complex I activity, by specific
compensatory mechanisms in A549-CR cells. Indeed, the activity of complex I may prove to
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be a rate limiting factor for the ETC in some models (Moreno-Sánchez et al., 2010; Telford,
Kilbride, & Davey, 2009). Analysis of the abundance of the respiratory complexes
demonstrated that complex I expression is significantly increased in A549-CR cells in
comparison to A549-WT cells, whilst a strong increasing trend was noted in the abundance of
complex III (Figure 35). This observation may support the notion of a compensatory
upregulation of complex I components in A549-CR cells in response to dysfunction and
partial inhibition of the activity of the complex. Increased expression of mitochondrial
proteins in response to mitochondrial dysfunction caused by mtDNA mutations has been
described (A.-M. Joseph, Rungi, Robinson, & Hood, 2004; Wojewoda, Duszyński, & 
Szczepanowska, 2011), and the exact response may vary with the nature of the defect.
Dysfunction of the ETC may also provide further understanding of the disparity in both basal
O2 consumption and maximal oxidative activity between A549-WT cells and A549-CR cells
following incubation with cDDP. It is possible that under normal growth conditions A549-
CR cells are functioning at, or close to, the maximal oxidative capacity of mitochondria in
this cell line. Such a situation may occur through a fundamental shift away from oxidative
metabolism as part of an adaptive response to reduced complex I activity, or may represent
the maximal activity for biosynthesis of mitochondria in this cell type. Thus, cDDP-induced
changes in cell metabolism leading to an oxidative phenotype, or drug-induced proliferation
of mitochondria (Section 4.4) would not alter basal O2 consumption or maximal oxidative
activity of the ETC of A549-CR cells, as observed in this study (Figure 33 & Figure 34).
Should this be the case, A549-CR cells should be more sensitive than A549-WT cells to
conditions which favour an oxidative phenotype, such as treatment with DCA or provision
galactose in place of glucose as the sole sugar in growth medium, the metabolism of which
requires oxidative phosphorylation (Gohil et al., 2010). Alternatively, dysfunction of complex
I might lead to a decreased contribution of this complex to electron flux through the ETC,
thus should cDDP induces changes in the activity of complex I the effect may be less
pronounced. Complex I has been suggested as the major source of increased ROS generation
in renal cells treated with cDDP (Kruidering et al., 1997), thus cellular adaptation to complex
I dysfunction caused by mtDNA mutations may alter cDDP sensitivity.
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4.8 Intracellular Ca2+ Signalling is Reduced in A549-CR Cells
The regulation of Ca2+ homeostasis is crucial in both the life and death of a cell (Section
1.2.6), and indeed the opposing actions of pro-apoptotic and anti-apoptotic BCL-2 family
proteins is in part mediated through changes in cellular Ca2+ handling (Palmer et al., 2004;
Rong & Distelhorst, 2008). Dampening of intracellular Ca2+ release and/ or a reduction in
intracellular Ca2+ store content, as may occur following overexpression of anti-apoptotic
BCL-2 proteins or through the action of pro-survival signalling such as the PI3K/ Akt
pathway (Harr & Distelhorst, 2010; Marchi et al., 2008; Rong & Distelhorst, 2008), increases
cellular tolerance to apoptotic stimuli. Conversely, prolonged, pathological rises in
intracellular Ca2+ and/ or increases in intracellular Ca2+ store content, as may occur in
response to apoptotic stimuli or activation of pro-apoptotic BCL-2 proteins (Harr &
Distelhorst, 2010; R Rizzuto et al., 2003; Rong & Distelhorst, 2008), favours cell death, and
enhances the apoptogenic potential of the cellular Ca2+ store. Rises in intracellular Ca2+ have
been suggested to form part of the cytotoxic mechanism of cDDP, and indeed a phenotype
characterised by reduced intracellular Ca2+ content and a reduced propensity for large Ca2+
responses has been described in cDDP-resistant cells (Al-Bahlani et al., 2011; Del Bello et
al., 2007; Kawai et al., 2006; Liang & Huang, 2000). Further, cDDP-induced ER-stress
signalling has been suggested to lead to apoptosis independent of DNA damage (Mandic et
al., 2003), and release of ER store Ca2+ may be part of this cell death pathway (Chami et al.,
2008; Pinton et al., 2008).
The A549 cell line is known to express a number of plasma membrane Ca2+ channels,
including at least three isoforms of the G-protein linked P2Y receptor, a P2X receptor
channel, the L-type voltage dependent Ca2+ channel and capacitative Ca2+ entry channels, and
respond to stimulation with extracellular ATP with a rise in [Ca2+]cyt (Zhao et al., 2000). ATP
stimulation evoked a rapid increase in [Ca2+]cyt measured by aequorin in A549-WT cells,
however no perceptible changes were measured in A549-CR cells (Figure 17). It is possible
that ATP addition caused low amplitude rises in [Ca2+]cyt which were not detected due to the
relatively low Ca2+ binding affinity of aequorin. Reduced cellular Ca2+ response to ATP has
previously been reported in cDDP resistant NSCLC cell lines (Schrödl, Oelmez, Edelmann,
Huber, & Bergner, 2009). Given the range of plasma membrane Ca2+ channels expressed by
A549 cells, and that both IP3Rs and RYRs are present in the ER membrane, reduced Ca2+
signalling following ATP stimulation might be equally well explained by modifying any one
of a number of signalling pathways, thus the cause of this disparity was further investigated.
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Reduced ER store Ca2+ correlates with apoptosis resistance in some experimental models and
a decrease in the total releasable intracellular Ca2+ pool may explain reduced response to ATP
challenge. No significant difference was observed in change in the Fura-2 fluorescence ratio
upon depletion of ER Ca2+ in nominally ‘Ca2+ free’ buffer (Figure 20), indicating [Ca2+]ER
did not differ between the A549 cell lines. Furthermore, no significant difference was
observed in the ‘FRET-ratio’ of an ER-targeted cameleon probe (Figure 26), a direct
measurement of the ER Ca2+ store content. Thus, inhibition of Ca2+ signals in A549-CR cells
in response to a physiological agonist is not due to reduced [Ca2+]ER.
ATP induces cytosolic Ca2+ signals by stimulating the generation of IP3 through activation of
phospholipase C through P2Y receptors, and reduced activation of IP3Rs upon IP3 binding
could explain the reduced response of A549-CR cells to ATP stimulation. This hypothesis
was tested directly using a cell permeable caged IP3. Uncaging of IP3 in the cytosol induced a
rise in [Ca2+]cyt measured by Fluo-4 in both A549 cell lines, however the peak response was
reduced by approximately 50% in A549-CR cells in comparison to A549-WT cells. This
reduced response was not due to decreased expression of the receptor, since comparable
expression of IP3R-1 was observed in both A549-WT cells and A549-CR cells (Figure 21),
although altered expression of IP3R-2 or IP3R-3 cannot be excluded. Thus, the dissimilarity in
Ca2+ signalling represents a functional difference. Differences in the opening probability of
the IP3R may explain the inhibition of Ca2+ release induced by ATP in A549-CR cells,
although additional differences in signalling induced by extracellular ATP still might also
contribute.
The inhibition of intracellular Ca2+ signalling in A549-CR cells extends beyond that evoked
by IP3 releasing ligands such as ATP. Addition of Ca2+ to the nominally ‘Ca2+ free’
extracellular buffer solution following depletion of ER Ca2+ using Tg caused a rapid rise in
[Ca2+]cyt through the SOCE response in A549-WT cells, measured by both Fura-2 (Figure 20)
and aequorin (Figure 19). In contrast, the SOCE signal measured by Fura-2 in A549-CR cells
was reduced by approximately 50% relative to A549-WT cells (Figure 20), whilst no
significant increase in aequorin bioluminescence was observed upon Ca2+ addition following
ER store depletion (Figure 19). The discrepancy in A549-CR SOCE signalling measured by
Fura-2 and aequorin likely relates to the low affinity of aequorin for Ca2+, thus low amplitude
Ca2+ signals may not be detected using this probe. Such reasoning also explains the lack of
cytosolic Ca2+ signals caused by Tg treatment, as SERCA inhibition produces a prolonged,
low amplitude rise in [Ca2+]cyt due to passive leak of Ca2+ from the ER. The differing SOCE
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response of A549-WT cells and A549-CR cells was not due to incomplete emptying of the
ER Ca2+ store, since no significant difference was observed in the Fura-2 signal measured
following Tg addition (Figure 20), indicating comparable store depletion in both cell lines. A
recent study has linked decreased expression of Orai, the key plasma membrane component
of the SOCE response, to resistance to apoptosis induced by multiple stimuli, including
cDDP, in a prostate cancer cell line (Flourakis et al., 2010), and influx of Ca2+ across the
plasma membrane following cDDP treatment has been suggested to mediate cDDP
cytotoxicity (Splettstoesser et al., 2007). However, cDDP treatment did not cause depletion of
ER Ca2+ in either A549-WT cells or A549-CR cells (Figure 26), and chelation of
extracellular Ca2+ using EGTA failed to alter the percentage of PI positive A549-WT cells
measured following cDDP treatment (Figure 24), indicating SOCE and influx of external
Ca2+ are not modulators of cDDP-sensitivity in this A549 cell model.
4.9 Inhibition of A549-CR IP3R Ca2+ Channel Function Does Not Contribute to cDDP
Resistance
A limited and conflicting body of work exists linking the IP3R to cell fate following exposure
to cDDP. Increased IP3R expression has been reported to correlate with cDDP resistance in
NSCLC cell lines, and was linked to a reduced ER store Ca2+ content (Schrödl et al., 2009).
In contrast, the expression of IP3R-1 decreased in primary tumour samples following cDDP
treatment, and modulation of expression was demonstrated to directly correlate with changes
in the cDDP sensitivity of a bladder cancer cell line. An increased level of expression
sensitised cells to cDDP, whilst knockdown of expression inhibited apoptosis (Tsunoda et al.,
2005). Given the previous data linking IP3R-1 to cDDP sensitivity, this isoform was selected
for further study. Although basal IP3R expression did not differ between A549-WT cells and
A549-CR cells, Ca2+ release in response to IP3 was significantly inhibited in the A549-CR
cell line, thus it was hypothesised that IP3R function rather than absolute expression level
may be the factor impacting upon cellular response to cDDP. Indeed, Tsunoda et al (Tsunoda
et al., 2005) did not provide a mechanism beyond demonstrating that the IP3R expression
level directly correlated with the induction of cell death. Thus, subsequent experimental
approaches were directed towards altering IP3R function by both genetic and
pharmacological means.
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Manipulation of the expression of IP3R-1 through overexpression of an exogenous receptor or
knockdown of gene expression may alter the activity of the channel in cellular signalling. The
transfection efficiency of a siRNA construct targeted towards IP3R-1 mRNA proved too low
for efficient protein silencing during the course of this investigation (data not shown). Further
optimisation of the transfection protocol is thus required to evaluate the effect of IP3R-1
knockdown in A549-WT cells and A549-CR cells. Alternatively, the DT40 chicken
lymphocyte cell line and IP3R triple knockout DT40 cell line provides an appropriate model
to investigate the role of the IP3R in cDDP cytotoxicity, and transfection of individual IP3R
isoforms in knockout cells may provide information on isoform specific contributions. Since
redundancy may exist in the ability of the IP3R isoforms to induce apoptosis (S. K. Joseph &
Hajnóczky, 2007), such an approach may prove most productive.
Overexpression of IP3R-1 A549-WT cells did not alter the percentage of PI positive cells
measured following cDDP exposure, relative to A549-WT cells transfected with a control
ER-GFP construct (Figure 22). It is notable that control transfection of ER-GFP in A549-CR
cells resulted in significant toxicity. The reason for this effect is unknown, since transfection
of the same construct in A549-WT cells did not significantly increase cDDP-induced
cytotoxicity, and transfection using different control constructs should be investigated.
Should similar toxicity specific to A549-CR cells be observed using unrelated control
constructs, differences in the protein translation machinery and ER stress response may be
considered and investigated. For the purposes of the present study, the unacceptable level of
toxicity in control A549-CR cells prevents interpretation of this data. Although both IP3R-1
silencing and overexpression studies in A549 cells encountered significant problems, the fact
that basal IP3R-1 expression is comparable in A549-WT cells and A549-CR cells, and that
overexpression of IP3R-1 in A549-WT cells did not induce a significant increase in cDDP
sensitivity relative to control A549-WT cells, suggests that the expression level of IP3R-1 is
not a modulator of cDDP sensitivity in A549 cells. However, further investigations are
required before a genuine conclusion may be formed. Further extension to include the
expression of IP3R mutants containing a non-functional Ca2+ channel domain or mutations
within the cytosolic protein binding domain would help delineate which function of the IP3R
may be important in determining cell fate.
Since direct modulation of IP3R-1 expression in A549 cells proved problematic, the role of
Ca2+ in cDDP cytotoxicity and the effect of pharmacological inhibition of the IP3R were
assessed to determine whether the inhibition of Ca2+ signalling in A549-CR cells contributed
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to the reduced cDDP sensitivity. Exposure to cDDP over 24 hours did not cause a significant
change in [Ca2+]ER in either A549-WT cells or A549-CR cells, indicating cDDP does not
induce perturbations of intracellular Ca2+ homeostasis in this A549 cell model, although
direct measurement of [Ca2+]cyt at this time point is required for this to be fully determined.
Treatment with cDDP has been reported to induce rises in intracellular Ca2+ within one hour
of drug addition in a range of cell types, including renal cells, colon carcinoma cells and
ovarian carcinoma cells (Berndtsson et al., 2007; Kawai et al., 2006; Mandic et al., 2003;
Splettstoesser et al., 2007). No significant change in Fura-2 fluorescence was observed in
either A549-WT cells or A549-CR cells over a one hour cDDP treatment period (Figure 27),
further suggesting cDDP does not cause Ca2+ perturbations in A549 cells. The difference
from previous reports may suggest that a requirement for rises in [Ca2+]cyt in cDDP-induced
cell death may depend upon the cell type under investigation, whether calpain activation is
required in the induction of apoptosis, and upon the drug concentrations and intrinsic cDDP
sensitivity of the cells to be studied. Indeed, Splettstoesser et al. observed a rise in [Ca2+]cyt in
an ovarian cancer cell line but not an osteocarcinoma cell line following cDDP treatment
(Splettstoesser et al., 2007).
It is notable that a role for cytosolic Ca2+ changes in cDDP cytotoxicity has been inferred
from a disparate selection of experimental models using very different drug concentrations,
ranging from 3 µM to 1 mM (Kawai et al., 2006; Mandic et al., 2003, 2002; Splettstoesser et
al., 2007). Furthermore, the means by which intracellular Ca2+ was measured varies
dramatically, and includes protocols loading cells with non-ratiometric Ca2+ indicators
without measures to account for potential differences in dye loading, population
measurements of Ca2+ likely to include both live and apoptotic cells and manual harvesting of
cells which may itself directly cause cell damage and [Ca2+]cyt changes (Berndtsson et al.,
2007; Del Bello et al., 2007; Kawai et al., 2006; Mandic et al., 2003; Splettstoesser et al.,
2007). Perhaps tellingly, Del Bello et al. observed changes in [Ca2+]cyt following cDDP
treatment only in frankly apoptotic cells (Del Bello et al., 2007). A role for Ca2+ changes in
mediating cell death following cDDP treatment is increasingly becoming accepted, and
indeed may play a role in some models. However, the evidence upon which this hypothesis is
based is surprisingly weak, and the literature would benefit from a systematic study of
changes in intracellular Ca2+ following treatment with a range of cDDP concentrations in
several cell types, in which intracellular Ca2+ signalling pathways are well characterised, to
help clarify the issue.
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The role of Ca2+ in the cDDP sensitivity of A549 cells was further investigated by
pharmacological chelation of Ca2+ during the cDDP treatment period. Chelation of Ca2+ in
the extracellular medium did not alter the percentage of PI positive A549-WT cells measured
following cDDP treatment (Figure 24), suggesting influx of Ca2+ across the plasma
membrane is not required for cDDP-induced cell death in this cell line, consistent with the
lack of observed changes in intracellular Ca2+. Splettstoesser et al. suggest such Ca2+ influx
may be important only in cells in which a fraction of the IP3R is localised to the plasma
membrane; if this is indeed the case it may be predicted that both A549 cell lines in the
present investigation lack such a plasma membrane fraction of the receptor.
Incubation with 10 µM BAPTA-AM during treatment with cDDP provided a modest
protection against cell death to A549-WT cells (Figure 23), indicating a potential contribution
of intracellular Ca2+ to the death process. Several studies have suggested that cDDP may
cause emptying of intracellular Ca2+ stores to induce cell death (Al-Bahlani et al., 2011;
Kawai et al., 2006; Liang & Huang, 2000; Mandic et al., 2002). However, no depletion of the
ER Ca2+ store was observed in A549-WT cells nor in A549-CR cells following cDDP
treatment, and whilst in each of these studies [Ca2+]cyt increased within one hour of drug
exposure, such an increase did not occur in the current experimental model. It is possible that
limited Ca2+ transfer may have occurred directly between the ER and mitochondria to
potentiate apoptosis, and direct measurement of mitochondrial Ca2+ during cDDP treatment
may confirm or disprove this. Likewise, a contribution for other intracellular Ca2+ storage
compartments in cell death, such as the acidic Ca2+ stores, may not be ruled out. Under
certain circumstances the ER stress response has been shown to play a pro-survival role and
abrogate the toxic effects of cDDP (Feng, Zhai, Yang, Jin, & Zhang, 2011; Y. Lin, Wang,
Liu, & Chen, 2011; Pagliacci et al., 1993; Podratz et al., 2011; L.-J. Zhang, Li, Yang, Li, &
Ji, 2009), whilst a delay in caspase-3 activation was observed in enucleated melanoma cells
expressing high levels of Grp78, an ER-stress induced chaperone, following cDDP treatment
(Mandic et al., 2003). Since maintenance of [Ca2+]ER is required for proper function of ER
resident proteins and the ER protein-folding machinery, it is also possible that depletion of
intracellular Ca2+ stores induced an ER stress response in A549-WT cells, providing a degree
of protection against cDDP-induced cell death.
Finally, the role of Ca2+ efflux through the IP3R in cDDP-induced cell death of A549-WT
cells was directly assessed using the pharmacological IP3R channel blocker 2-APB.
Incubation with 2-APB completely inhibited the rise in [Ca2+]cyt observed in A549-WT cells
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in response to stimulation with a supramaximal concentration of extracellular ATP (Figure
28). However, incubation with 2-APB during cDDP treatment did not cause a significant
change in the percentage of PI positive A549-WT cells measured after 24 hours (Figure 29),
indicating that IP3R Ca2+ channel function is not required for the induction of cell death in
response to cDDP. This finding is consistent with the previous observation that cDDP does
not cause perturbations of intracellular Ca2+ in the A549 cell line under the present
experimental conditions.
A549-CR cells showed a marked reduction in intracellular Ca2+ signalling evoked by ATP
stimulation, store Ca2+ depletion and direct stimulation of the IP3R, however this phenotype
was not directly linked to cDDP sensitivity in the present investigation, since cell death in
A549-WT cells showed little requirement for Ca2+ and occurred independently of IP3R Ca2+
channel activity. It is possible that the observed difference in IP3R function is related to
changes in activity independent of its Ca2+ channel function. Anti-apoptotic BCL-2 family
proteins inhibit Ca2+ release from the IP3R (Rong & Distelhorst, 2008), and increased
expression of these proteins may inhibit cell death in response to cDDP in A549-CR cells,
accompanied by decreased intracellular Ca2+ responses. Overexpression of these regulators
however is often associated with a reduction in the [Ca2+]ER (Rong & Distelhorst, 2008),
whilst no difference in ER Ca2+ was observed between A549-WT cells and A549-CR cells,
thus the expression level of these proteins should be determined. Altered protein binding to
the cytosolic domain of the IP3R may also promote cell survival independent of Ca2+
signalling. For example, the IP3R regulates cellular autophagy through interaction with
Beclin-1 (Vicencio et al., 2009), and increased autophagy has been associated with increased
cellular resistance to apoptosis, including that induced by cDDP (Claerhout et al., 2010;
Harhaji-Trajkovic, Vilimanovich, Kravic-Stevovic, Bumbasirevic, & Trajkovic, 2009;
O’Donovan, O’Sullivan, & McKenna, 2011; J.-H. Ren et al., 2010). Whilst the interaction
between the IP3R and Beclin-1 does not alter intracellular Ca2+ signalling (Vicencio et al.,
2009), changes in the population of proteins interacting with the receptor, such as increased
binding of BCL-2, might disrupt Beclin-1 binding and enhance cellular autophagy. As such,
the level of autophagy should be determined in both A549-WT and A549-CR cells under
normal growth conditions and following cDDP treatment, and the effect of pharmacological
enhancers and inhibitors of autophagy on cDDP sensitivity investigated.
Alongside protein binding, the activity of the IP3R is regulated by posttranslational
modification, including phosphorylation. Phosphorylation of the receptor by Akt inhibits
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opening of the Ca2+ channel (Szado et al., 2008), and since Akt overactivation has been
strongly linked with cDDP resistance (Basu & Krishnamurthy, 2010), increased
phosphorylation by Akt could induce decreased response to IP3 in a drug resistant cell line.
However, Akt activation was significantly reduced in A549-CR cells relative to A549-WT
cells (Figure 16) thus regulation of the IP3R by Akt is unlikely to account for the functional
differences observed in the receptor. The IP3R is also a target for regulation by other cellular
kinases. Phosphorylation at serine residues by PKA sensitises the receptor to opening upon
IP3 binding (S. K. Joseph & Hajnóczky, 2007), and reduced PKA activity has been shown to
be linked to the cDDP sensitivity of ovarian carcinoma cells (Cvijic & Chin, 1997). A similar
change in the activity of PKC, or another enzyme capable of modulating IP3R function,
favouring cell survival may account for the changes measured in Ca2+ signalling.
Although the phenotype of reduced intracellular Ca2+ signalling does not contribute to
modulating the sensitivity of A549 cells to acute apoptosis induced by high concentrations of
cDDP, such changes may have been important during the acquisition of cDDP resistance.
Exposure to cDDP induces cellular stress, including increased ROS production, ER stress and
nutrient withdrawal due inhibition of metabolic processes by cDDP, which may induce cell
death with a Ca2+ dependent component. Cells treated with cDDP frequently undergo a
period of senescence before resistant colonies of cells are established (Puig et al., 2008).
Inhibition of large changes in intracellular Ca2+ may favour cell survival under these
conditions, and thus not contribute to cellular response to cDDP directly, but promote cell
survival during the initial stages of acquiring cDDP resistance. If this were to be the case,
A549-CR cells may be predicted to show reduced cell death in response to cellular stress
such as nutrient starvation, agents which induce ER stress such as tunicamycin and drugs
known to induce Ca2+ dependent cell death, such as C2-ceramide (K. Bianchi et al., 2006). An
attempt to model such ROS and Ca2+ induced cell death was made during this investigation
(Section 3.2.5 & Section 4.11). General adaptation to cellular stress during the acquisition of
cDDP resistance may indeed partially explain why some cDDP resistant tumour cells are
cross-resistant to a diverse range of other chemotherapy drugs.
Interestingly, reduced function of the IP3R could be linked to the differences observed in
mitochondrial function between A549-WT cells and A549-CR cells (Section 3.3). The IP3R
forms part of an interorganelle complex with VDAC on the mitochondrial outer membrane,
mediated by chaperone proteins (Szabadkai et al., 2006), which promotes Ca2+ transfer
between the organelles. It was recently reported that basal Ca2+ release from the IP3R may be
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required to maintain mitochondrial function, increasing basal O2 consumption and inhibiting
the induction of autophagy (Cárdenas et al., 2010). Loss of this basal Ca2+ release reduced the
activity of PDH, reduced cellular O2 consumption, and lead to a pro-survival autophagy
response mediated through AMPK activation. Inhibition of Ca2+ release via the IP3R may
form part of cellular adaptation to mitochondrial dysfunction, inhibiting increases in
mitochondrial activity and shifting metabolism away from oxidative phosphorylation.
Although no depletion of [Ca2+]ER was observed in A549 cells following cDDP treatment,
small IP3R signalling events involving only a small number of channels do not lead to
complete store emptying. Thus it is possible that the increase in mitochondrial oxidative
activity measured in A549-WT cells after exposure to cDDP (Figure 32 & Figure 33) may be
due to an increase in the frequency of small IP3R signalling events, whilst inhibition of these
events in A549-CR cells prevents similar changes in mitochondrial function from occurring.
Disruption of complexes coupling the ER and mitochondrial membranes involving the IP3R
may further act to reduce mitochondrial Ca2+ uptake and inhibit increases in mitochondrial
function. This hypothesis further highlights the need to investigate changes in mitochondrial
Ca2+ and autophagic flux following cDDP treatment in both A549 cell lines.
4.10 Oxidative Stress Induced Through TMRM Photoactivation Does Not Model
Pathophysiological ER-Mitochondria Ca2+ Transfer in A549 Cells
Disruption of IP3R function may alter the efficiency of Ca2+ transfer from the ER to
mitochondria, and alter the sensitivity of cells to death induced through mitochondrial Ca2+
overload (Szabadkai et al., 2006). Since IP3R function in A549-CR cells was significantly
inhibited in comparison with A549-WT cells, pathological Ca2+ transfer from the ER to
mitochondria was directly examined using a model of laser-induced oxidative stress.
Photoexcitation of TMRM generates both O2•‾ and OH•‾ free radicals (Zorov, Filburn, Klotz,
Zweier, & Sollott, 2000). In astrocytes (Jacobson & Duchen, 2002) and cardiomyocytes
(Hüser & Blatter, 1999) ROS produced in this way have been hypothesised to act directly at
the ER to induce Ca2+ release and mPT, most likely through oxidising redox-sensitive
residues of the IP3R and/ or RYR. The process leading from mitochondrial ROS to loss of
ΔΨ is however not well understood, and in other cell types the mitochondrial ‘flickering’ 
characteristic of this method seemingly occurs independent of Ca2+ and the mPTP (Falchi,
Isola, Diana, Putzolu, & Diaz, 2005; O’Reilly, Fogarty, Drummond, Tuft, & Walsh, 2004;
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Zorov et al., 2000). The same appears to be true for the A549 cell line, given that
mitochondrial depolarisation induced in A549-WT cells proved insensitive to Ca2+ chelation
using EGTA + BAPTA-AM, EGTA and ER store Ca2+ depletion using Tg prior to
illumination and Cyp D inhibition by CsA (Figure 25 C). Instead, one might infer
depolarisation in A549 cells loaded with TMRM represents Ca2+ independent opening of the
mPTP and/ or non-specific toxicity through oxidative damage to the respiratory chain. In
further support of this scheme, a threshold concentration of TMRM greater than 50 nM is
required for loss of ΔΨ within the experimental time period (Figure 25 E), possibly indicating 
a threshold level of required ROS production, and both depolarisation and ΔΨ ‘flickering’ are 
fully prevented by addition of ascorbic acid to the cell buffer solution (Figure 25 D). TMRM-
induced ROS production is therefore not an appropriate model to measure pathological
interorganelle Ca2+ transfer in A549 cells, which may be more appropriately investigated
using mitochondrial Ca2+ probes to monitor changes in mitochondrial matrix Ca2+
concentration following stimulation of intracellular Ca2+ signalling and the addition of drugs
known to induce mitochondrial Ca2+ overload. It is worth noting that under TMRM
illumination, no significant difference existed between A549-WT cells and A549-CR cells in
the time at which loss of ΔΨ began or the kinetics of depolarisation. Since this process is 
wholly dependent upon ROS production (Figure 25 D & E), the lack of a significant
difference in the sensitivity to depolarisation suggests the ROS sensitivity of the two A549
cell lines is comparable, and that the difference in ROS production measured following cDDP
exposure (Figure 11, Figure 12 & Figure 13) may not be due to differences in the expression
of cellular antioxidant defences.
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5. Summary
5.1 Future Directions
The present study has identified a novel point mutation in the mtDNA encoded MT-ND2 gene
and D-loop region of a cDDP-resistant NSCLC cell line. Whilst the mutation is present as a
low level heteroplasmic variant in the parental, cDDP-sensitive A549-WT cell line, cDDP-
resistant A549-CR mtDNA is homoplasmic for this change. Mutations in mtDNA correlate
both with tumourigenesis and drug resistant phenotypes in cancer cells (A Chatterjee et al.,
2006; H.-C. Lee et al., 2010; S. Mizutani et al., 2009), thus the ND2 mutant here identified
may directly contribute to the cDDP-resistant phenotype of A549-CR cells. The creation of
cybrid cell lines presents the most direct methodology to assess the contribution of mutations
in the mtDNA of the A549-CR cell line to reduced drug sensitivity. To determine the role of
changes in the mtDNA sequence on the same nuclear genetic background, enucleated A549-
WT and A549-CR cells may be used as mtDNA donors to the same mtDNA deficient (ρ0)
cell line, and the ability of cDDP to induce cell death measured in the resulting cybrid cell
lines; differences in drug sensitivity may thus be attributed as resulting from mutant mtDNA.
Further, cybrid cell lines created using A549-WT nuclear donor cells with A549-CR mtDNA
donor cells, and vice versa, may identify the relative importance of novel mtDNA mutations
in governing cDDP-resistance in the A549 cell line, demonstrating whether changes in
mtDNA play and important role in comparison to adaptations of nuclear DNA.
The transition of the non-synonymous mt5487T>C mutation from a low-level heteroplasmic
variant in A549-WT cells to homoplasmy in the non-clonal A549-CR cell population raises
the interesting possibility of positive selection for mtDNA molecules harbouring this
mutation, either as a direct influence upon cDDP-sensitivity or promoting the adaptation of
tumour cells to survival following cDDP treatment. Further evidence for this may be acquired
should a similar apparent selection of mutant mtDNA occur if a second population of cDDP-
resistant A549 cells were independently derived from the parental A549-WT cell line in vitro,
and/ or in an in vivo animal model, which might be predicted to show a similar genetic drift
in mtDNA.
It is unclear at present how changes in mtDNA may influence cellular sensitivity to apoptotic
stimuli, and indeed the effect may depend both upon the nature of the mtDNA mutation and
the nature of the apoptotic stimulus (Kwong et al., 2007). Should cybrid cells containing
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A549-CR mtDNA be found to be resistant to cDDP-induced cell death, it would be of interest
to determine whether this resistance extends to other cellular stresses such as nutrient
starvation, UV irradiation, platinum-based chemotherapy drugs such as carboplatin and
oxaliplatin, ER stress and microtubule destabilising agents. Conversely, homoplasmic
mutations in mtDNA might render A549-CR cells more sensitive to agents which promote
mitochondrial metabolism or inhibit glycolysis, such as DCA and 2-deoxyglucose
respectively.
The homoplasmic mtDNA mutation present in the MT-ND2 gene of A549-CR mtDNA likely
affects the function of the ND2 subunit, since the rotenone-sensitive activity of respiratory
complex-I was reduced in this cell line relative to A549-WT cells. As such, the activity of
complex-I may be a determinant of cellular sensitivity to cDDP in this cell model. As a
pharmacological approach to this question, incubation of A549-WT cells with low, sub-
optimal concentrations of rotenone may mimic the reduced electron transfer from complex I
to ubiquinone observed in A549-CR cells, and thus may reduce the sensitivity of A549-WT
cells to cDDP. Alternatively, creating cybrid cell lines using cells harbouring independent
mutations in MT-ND2 or mtDNA encoded respiratory complex components may determine
whether any pro-survival effect mtDNA mutations following cDDP treatment are specific for
those affecting complex-I, or indeed those affecting ND2 function. A method for the
exogenous expression of wild-type or mutant ND2, by transfecting nuclear-transcribed DNA
constructs converted to the nuclear genetic code along with a mitochondrial targeting
sequence, has previously been reported (S. Zhou et al., 2007). The same methodology may be
employed in the A549 cell line, creating stable clones expressing the Phe40Leu ND2
mutation varying levels, to assess the effect of increasing mutational load on cDDP
sensitivity. Similarly, transfection of wild-type ND2 into A549-CR cells may restore drug
sensitivity. Finally, in silico analysis of mtDNA sequences derived from cDDP-sensitive and
cDDP-resistant tumour samples may reveal whether mutations in MT-ND2 or respiratory
complex-I subunits associate with cDDP resistance in vivo.
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5.2 Summary
The present work used an A549 lung adenocarcinoma cell line model of acquired cDDP
resistance to investigate the potential contribution of the ER and mitochondria to modulation
of cDDP sensitivity. A549-CR cells were derived through prolonged culture in the presence
of a low concentration of cDDP, and show an approximately two-fold level of resistance to
cell death relative to the cDDP-sensitive parental A549-WT cell line following exposure to
cDDP.
Treatment with cDDP induced caspase-dependent apoptosis in A549-WT cells 6-12 hours
post drug exposure, consistent with the known cytotoxic activity of cDDP. Alterations in cell
morphology during this time period were consistent with current definitions of apoptosis,
whilst loss of cell viability was significantly inhibited by a pharmacological pan-caspase
inhibitor. Cell death was not affected by pharmacological inhibition of caspase-8, indicating
that the receptor-mediated pathway of apoptosis is not activated by cDDP in A549 cells. A
strong induction of p53 and arrest of cellular proliferation was also observed following cDDP
exposure, in agreement with cell cycle arrest known to occur in response to cDDP. However,
inhibition of caspases did not completely prevent cell death, indicating that multiple cell
death pathways may be stimulated in A549-WT cells by cDDP. Although cDDP caused a
significant increase in the rate of both mitochondrial and cytosolic ROS production, A549-
WT cell death was not dependent on ROS since antioxidant treatment failed to significantly
protect cells from cDDP-induced death. In contrast to a growing number of reports, including
studies of the A549 cell line, cDDP did not cause perturbations of cellular Ca2+ homeostasis,
and accordingly pharmacological calpain inhibition in A549-WT cells did not modulate
cDDP sensitivity, suggesting these enzymes are not required for cell death in this
experimental model.
The ER may induce cell death through both Ca2+ dependent and Ca2+ independent pathways,
and has been linked in some models to cDDP cytotoxicity. Further, perturbation of
intracellular Ca2+ homeostasis, caused either by emptying of intracellular Ca2+ stores or influx
of Ca2+ across the plasma membrane, and reduced intracellular Ca2+ content has been
measured in cDDP resistant cells. Whilst no difference in [Ca2+]ER existed between A549-WT
cell and A549-CR cells, intracellular Ca2+ a physiological ligand or store depletion was
significantly reduced in A549-CR cells in comparison to A549-WT cells. This reduced Ca2+
signalling phenotype was due in part to inhibition of IP3R function, since direct stimulation of
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the receptor using a caged IP3 compound lead to significantly greater changes in [Ca2+]cyt in
A549-WT cells, and was not caused by a difference in the basal level of expression.
However, pharmacological inhibition of the IP3R in A549-WT cells did not alter cellular
sensitivity to cDDP, indicating that IP3R Ca2+ channel function does not impinge upon
cellular cDDP sensitivity. Furthermore, chelation of intracellular Ca2+ provided only very
modest protection to A549-WT cells treated with cDDP, and removal of external Ca2+ was
without effect, consistent with the lack of changes in intracellular Ca2+ homeostasis induced
by cDDP and that calpain activation is not required for cell death under these conditions.
Thus, changes in intracellular Ca2+ and the Ca2+ channel function of the IP3R do not modulate
cDDP sensitivity of A549 cells, although the marked differences in IP3R function warrant
further investigation of factors known to regulate channel activity and IP3R Ca2+ channel
independent functions as potential extranuclear determinants of cellular response to cDDP.
Exposure to cDDP significantly increased the rate of ROS production in both A549 cell lines,
however this increase was significantly attenuated in A549-CR cells. Similarly, cellular O2
consumption was significantly increased in A549-WT cells but unchanged in A549-CR cells
following cDDP treatment, potentially explaining the difference measured in ROS
production. Although reduced ROS production did not contribute to the cDDP-resistant
phenotype, decreased flux through the electron transport chain may reduce the propensity of
cells to undergo apoptosis, thus the mechanism behind the disparity in O2 consumption was
further investiged. A novel point mutation in the MTND2 gene of mtDNA was identified as
present in heteroplasmy in A549-WT cells and homoplasmy in A549-CR cells, and correlated
with an approximately 50% reduction in the activity of mitochondrial respiratory complex I.
Both mutations in mtDNA and reduced activity of the ETC have been linked to increased
tolerance to apoptosis inducing stimuli, thus the contribution of the changes identified in
A549-CR cell mitochondrial to altered cDDP sensitivity will be addressed in future
investigations through the generation of cybrid cells using A549-WT cells and A549-CR
cells. Although the activity of mitochondrial respiratory complex I was significantly reduced
in A549-CR cells, basal mitochondrial function did not differ between A459-WT cells and
A549-CR cells. Investigation of the ETC revealed a significantly greater abundance of
respiratory complex I in A549-CR cells compared to the A549-WT cell line, possibly a
compensatory response to respiratory complex dysfunction. Such changes may form part of a
mitochondria-nucleus retrograde response, which in turn may promote cell survival and could
alter tumour cell drug sensitivity.
5. Summary
178
In summary, this study has:
 Further clarified the complex pathways by which cDDP may induce cell death in
tumour cells.
 Excluded altered intracellular Ca2+ homeostasis, inhibition of Ca2+ signalling and
reduced IP3R Ca2+ channel function as a determinant of cellular cDDP sensitivity in
this experimental model.
 Identified for further study key differences in mitochondrial function between A549-
WT cells and A549-CR cells. These differences have the potential to directly impact
upon tumour cell fate in response to chemotherapy, and require further investigation
to determine whether such differences may modulate cDDP sensitivity.
The present investigation has further outlined the complex nature of the cytotoxic action of
cDDP. Whilst describing an apoptotic response with kinetics in good correlation with
previously published data, dissimilarities in the contributing factors, notably a lack of Ca2+
and ROS dependence, have been observed. As such, the work highlights the complex, cell-
type specific nature of responses to cDDP, and may help to explain the variation in the
responsiveness of different tumour types to cDDP. In better understanding how such
responses may vary, novel drug targets to modulate cDDP sensitivity relative to tumour type
may be identified.
Finally, two novel point mutations were found in the mtDNA of drug-resistant cells. This is
the first report of the non-synonymous mt5487T>C mutation of MT-ND2, and an original
characterisation of the reduction in complex I activity reduced complex I activity resulting
from mutant ND2. The identification of this novel genetic and functional change in a core
cellular metabolic protein associated with a drug resistant cell line may further knowledge on
the mechanisms of the emerging role of mtDNA variation on cell fate. Changes in
mitochondrial and respiratory complex function related to mtDNA mutations may serve to
alter the threshold apoptotic stimulation (mitochondrial priming) required for mitochondria to
engage the apoptotic pathway (Chonghaile et al., 2011), altering the sensitivity of tumour
cells to chemotherapeutic agents. Research in both in vitro and tumour xenograft models may
reveal the contribution of changes in mitochondrial function to the apoptotic sensitivity of the
organelle.
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The correlation between functional complex I mutations and chemoresistance may provide a
rationale for further investigation of how mutations in respiratory complex I subunits impinge
upon the cDDP-sensitivity of tumour cells. The overall activity of mitochondria in A549-CR
cells was not altered relative to A549-WT cells, due to compensatory upregulation of
complex I subunit expression and assembly. This is likely to represent a novel mitochondria-
nucleus signalling mechanism, and demonstrates the ability of cells to alter metabolism to
restore normal cellular function following genetic perturbations. Further work into the
signalling factors which allow such changes will shed light on the influence of metabolism
and mitochondria on the transcriptional profile of the cell. Targeting such adaptive signalling
components may provide a mechanism to modulate tumour cell drug sensitivity.
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Appendix I: Ascorbic Acid Does Not Inhibit cDDP Cytotoxicity
Appendix I Figure 1: Ascorbic acid does not prevent cDDP-induced cytotoxicity in
A549-WT cells. A549-WT cells were incubated in normal cell culture medium + 200 1 mM
ascorbic acid or in normal cell culture medium + 1 mM ascorbic acid + 75 µM cDDP for 24
hours and cytotoxicity assayed by PI exclusion as outlined in ‘Methods 2.4’. Incubation with
1 mM ascorbic acid was able to fully prevent ROS-induced mitochondrial depolarisation in
A549-WT cells under a model of oxidative stress caused by TMRM photoactivation (Figure
25 C), demonstrating the antioxidant properties of ascorbic acid in this cell model. Data
represent the mean of three independent experiments + S.E.M. * p < 0.05.
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Appendix II: IP3R Stimulation by Caged IP3 Without Fluo-4 Dye
Bleaching Correction
Appendix II Figure 1: IP3R function is reduced in A549-CR cells relative to A549-WT
cells. Cells were loaded with photolabile caged IP3 and 5 µM Fluo-4-AM, and fluorescence
intensity recorded after IP3 uncaging caused by a period of UV illumination, as described in
‘Methods 2.6’. (A) Mean changes in normalised Fluo-4 fluorescence without dye bleaching
correction in A549-WT and A549-CR cells loaded with caged IP3 following UV illumination.
(B) Mean changes in normalised Fluo-4 fluorescence without dye bleaching correction in
A549-WT cells loaded with caged IP3 without the UV illumination period. Traces represent
the mean response of a minimum of five coverslips from four independent experiments ±
S.E.M. * p < 0.05.
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Appendix III: Point Mutations of mtDNA Identified in A549-WT
Cells and A549-CR Cells by Mitochip Sequencing
Appendix III Table 1: Point mutations present in the mtDNA of A549-WT cells and
A549-CR cells identified by Mitochip sequencing. A549-WT cells and A549-CR cells were
incubated in normal cell culture medium for 24 hours. Sequence analysis of the mtDNA
genome was performed using Mitochip V2.0 following PCR amplification of mtDNA as
described in ‘Methods 2.20’. Italics = deviation from revised Cambridge reference sequence.
Point mutations highlighted in red represent novel previously unreported nucleotide
substitutions. Italics = deviation from reference sequence.* Exists in heteroplasmy.
rCRS
Position
Referen
ce
A549-
WT
A549-
CR
Gene
Gene
Product
Amino
Acid
Change
Type
73 A G G D-Loop N/A
Non-
Coding
Reference
Sequence
SNP
225 G G T D-Loop N/A
Non-
Coding
Unreported
Variant
263 A G G D-Loop N/A
Non-
Coding
Reference
Sequence
SNP
750 A G G
MT-
RNR1
12 s
rRNA
Consensus
Reference
Sequence
SNP
1438 A G G
MT-
RNR1
12 s
rRNA
Consensus
Reference
Sequence
SNP
3992 C T T
MT-
ND1
ND1
Thr 229
Met
SNP
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4024 A G G
MT-
ND2
ND2
Thr 240
Ala
SNP
4587 T T / C * C
MT-
ND2
ND2
Phe 40
Leu
Unreported
Variant
4769 A G G
MT-
ND2
ND2
Met 100
Met
Reference
Sequence
SNP
5004 T C C
MT-
ND2
ND2
Leu 179
Leu
SNP
8269 G A A
MT-
CO2
Cox II
Stop 228
Stop
SNP
8860 A G G
MT-
ATP6
ATPase
6
Thr 112
Ala
Reference
Sequence
SNP
9123 G A A
MT-
ATP6
ATPase
6
Leu 199
Leu
SNP
10044 A G G MT-TG
tRNA
Gly
Non-
coding
SNP
12524 T C T
MT-
ND5
ND5
Ile 163
Thr
Unreported
Variant
13105 A G G
MT-
ND5
ND5
Ile 257
Val
SNP
14365 C T T
MT-
ND6
ND6
Val 103
Val
SNP
14582 A G G
MT-
ND6
ND6
Val 31
Ala
SNP
15042 G G A
MT-
CYTB
Cyt b
Gly 99
Glu
Unreported
Variant
15326 A G G
MT-
CYTB
Cyt b
Thr 194
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Appendix IV Figure 1: NAC Inhibits cDDP-Induced H2AX Phosphorylation in A549-
WT Cells. A549-WT cells seeded onto glass coverslips were incubated in normal cell culture
medium + 75 µM cDDP or normal cell culture medium + 5 mM NAC + 75 µM cDDP for 24
hours before immunostaining. Briefly, cells were fixed using 4% paraformaldehyde,
permeabilised using 0.2% Triton X and blocked with 2% BSA. Cells were incubated with
mouse anti-phospho-H2AX primary antibody (Millipore) diluted 1:1000 in PBS + 0.2% BSA
at 4 oC overnight. Coverslips were washed and incubated with goat anti-mouse Alexa 594
conjugated secondary antibody for 45 minutes at room temperature, before three washes with
PBS + 1 µg/ ml Hoecsht. Fixed cells were visualised using a confocal microscope. A
minimum of 100 randomly selected nuclei were counted under each experimental condition
per experiment, and the percentage of phospho-H2AX positive nuclei calculated. (A)
Representative images of A549-WT cells incubated in normal cell culture medium, normal
cell culture medium + 75 µM NAC or normal cell culture medium + 5 mM NAC + 75µM
cDDP for 24 hours before immunostaining. (B) Mean percentage of phosphor-H2AX positive
nuclei in A549-WT cells following incubation in 75 µM cDDP in the presence or absence of
5 mM NAC. Data represent the mean of three independent experiments ± S.E.M. ** p < 0.01.
